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 Thomas Mock Zusammenfassung 
Zusammenfassung  
Der Transkriptionsfaktor nuclear factor-kappa B (NF-κB) ist für die Aktivierung und das 
Überleben von T-Lymphozyten essentiell. NF-κB reguliert die Expression von Zytokinen, 
Wachstumsfaktoren und anti-apoptotischen Genen. Entsprechend ist die physiologische 
NF-κB-Aktivierung von zentraler Bedeutung für eine effiziente Immunantwort. 
Verschiedenste Neoplasien weisen Genmutationen auf, die zu einer aberranten, meist 
konstitutiven NF-κB-Aktivität führen. Diese erlaubt es Tumorzellen, den Zell-intrinsischen 
Kontrollmechanismen zu entgehen und unkontrolliert zu proliferieren.  
Die T-Zell Rezeptor (TZR)-induzierte Signalleitung, die zur Aktivierung von NF-κB führt, 
basiert größtenteils auf Phosphorylierungsreaktionen, die zu Veränderungen in der Funktion 
und Aktivität der phosphorylierten Proteine führen. Diese Phosphorylierung von Proteinen ist 
aber meist transient. Während viele Kinasen und ihre Substrate  charakterisiert wurden, ist 
die Rolle von Phosphatasen in der Modulierung der NF-κB Signalkaskade bisher wenig 
untersucht. 
Um Phosphatasen zu identifizieren, die eine Rolle bei der TZR-induzierten  
NF-κB-Aktivierung spielen, wurde ein RNA Interferenz (RNAi) Screen in Jurkat T Zellen 
durchgeführt. Mit Hilfe dieser Methode konnten verschiedene Phosphatasen und 
Phosphatase-assoziierte Proteine identifiziert werden, welche die NF-κB-Aktivität positiv 
oder negativ regulieren. Entsprechend wurde die protein phosphatase 1, calalytic  
subunit alpha (PP1α) als Positivregulator identifiziert. RNAi-vermittelte Verminderung der 
PP1α-Expression führte zu einer verringerten NF-κB-Aktivität. Umgekehrt führte 
die Überexpression von PP1α zu einer erhöhten NF-κB-Aktivität. Es konnte  
jedoch kein deutlicher Einfluss von PP1α im Hinblick auf  zytoplasmatische 
Phosphorylierungsreaktionen im NF-κB-Signalweg detektiert werden. Allerdings wurde 
festgestellt, dass PP1α, vermutlich Promotor-spezifisch, die Expression einzelner bona fide 
NF-κB-regulierter Gene beeinflusst. Entsprechend führte eine verringerte PP1α-Expression 
zu einer verminderten DNA-Bindeaktivität von NF-κB. Zudem wurde gezeigt, dass PP1α für 
die Proliferation von primären humanen CD4+ T-Lymphozyten benötigt wird. Darüber 
hinaus, induzierte eine verringerte PP1α Expression oder Inhibition der enzymatischen 
Aktivität der Phosphatase Apoptose in NF-κB-abhängigen kutanen T Zell Lymphom (engl.: 
cutaneous T cell lymphoma, CTCL) Zellen.  
In dieser Arbeit konnte ein neuer Regulator der TZR-induzierten NF-κB-Aktivität identifiziert 
werden. Diese Ergebnisse tragen zu einem genaueren Verständnis der NF-κB-Regulation in 
T Lymphozyten bei und sind möglicherweise für die zukünftige therapeutische Behandlung 
von NF-κB-assoziierten Erkrankungen von Bedeutung. 
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Abstract 
The transcription factor nuclear factor-kappa B (NF-κB) is an essential regulator of 
lymphocyte activation and survival mediating expression of cytokines, growth factors and 
pro- and anti-apoptotic genes. Hence, NF-κB activation is essential to mount an efficient 
immune response and to eradicate potential threats. Conversely, several malignancies 
acquire mutations, resulting in constitutive NF-κB activity, allowing them to escape cell-
intrinsic check-point mechanisms.  
Signal transduction to NF-κB, emanating from the T cell receptor (TCR), largely relies on 
phosphorylation of proteins, altering their localisation and activity. However, most 
phosphorylation events are transient. While multiple kinases and their substrates have been 
characterised, the role of phosphatases in modulating NF-κB activity is less well 
understood. 
To systematically identify phosphatases that take part in NF-κB signalling upon TCR 
engagement, a RNA interference (RNAi) genetic screen in Jurkat T cells was performed. 
Using this approach, several phosphatases and phosphatase-associated proteins were 
identified that positively or negatively regulate NF-κB activity. Accordingly, protein 
phosphatase 1, catalytic subunit alpha (PP1α) was identified as a positive regulator of  
NF-κB activity. While PP1α silencing caused decreased NF-κB activity, PP1α 
overexpression augmented NF-κB activity upon TCR engagement. Cytoplasmic signalling 
events, with respect to known phospho-sites in the NF-κB pathway, were not dramatically 
influenced by the phosphatase. However, PP1α was found to selectively regulate 
expression of a subset of bona fide NF-κB target genes, most likely in a promoter-specific 
manner. Accordingly, PP1α-silencing caused a significant reduction of NF-κB DNA binding 
activity. Furthermore, knock down of PP1α or inhibition of its phospholytic activity 
suppressed proliferation of primary human CD4+  T lymphocytes. In addition, PP1α-silencing 
or inhibition sensitised a  malignant NF-κB-addicted cutaneous T cell lymphoma (CTCL) cell 
line towards apoptosis.  
In summary, the present study identified PP1α as a novel regulator of NF-κB activity in 
T lymphocytes and implicates the phosphatase as a factor for lymphoma survival. These 
findings contribute to a more datailed understanding of NF-κB regulation and may have 
implications for the treatment of NF-κB-associated malignancies in the future. 
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 Thomas Mock I Introduction 
1. Introduction 
1.1 The immune system 
The immune system is a complex system, comprising cells, tissues and soluble products 
that ensure the health of an organism by the ability to recognize, attack and eradicate non-
self entities or by the removal of damaged, infected, auto-reactive or transformed cells 
derived from self. The term immunity (latin: “immunitas”, exempt from) describes the normal 
functioning of the immune system in a healthy organism. The concept arose in the 16th 
century, when little was known about the origin of diseases. Individuals that survived the 
first encounter of an otherwise fatal disease and that remained healthy after a second 
exposure were said to be “exempt from” or “immune”. 
The immune system of higher vertebrates (jawed fish and higher) has evolved into two 
general branches that can be distinguished by their nature to recognize invading pathogens 
and mount an immune response. The innate (or natural) immune system recognises foreign 
entities in a totally non-specific or broadly specific and non-selective manner, whereas the 
adaptive (or acquired) immune system mounts an immune response in an uniquely specific 
and selective fashion. Although these features sharply separate the innate and adaptive 
immune systems, the host defence relies on the concerted action of both and their 
interconnection with each other to maintain an individuals health and persistent immunity. 
1.1.1 The innate immune system 
The innate immune system is considered to be the first line of defence against a potential 
pathogenic threat and can be further subdivided into a non-induced and an induced arm 
(Janeway and Medzhitov, 2002). Non-induced mechanisms include anatomical and 
physiological barriers that substantially reduce the likelihood of an infection. The former 
encompassing the skin and mucosae that physically prevent access to the body, the latter 
consisting of actions (e.g. sneezing) and substances produced by tissues (e.g. mucus) 
(Janeway and Medzhitov, 2002).  
The induced mechanisms of the innate immune response are largely dependent on 
specialized cells that arise during haematopoiesis from common myeloid progenitors 
(CMPs). Among the most frequent descendants from CMPs are cells devoted to 
 2 
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phagocytosis and identification of microbial particles. These immune cells possess an 
arsenal of broad-spectrum sensors (pattern recognition receptors, PRRs) that recognize so 
called pathogen-associated molecular patterns (PAMPs). PAMPs are common invariant and 
repetitive molecular structures (e.g. lipopolysaccharide, LPS) shared among a variety of 
microbes that are normally not present in the host (Iwasaki and Medzhitov, 2010). Among 
the best-known PRRs is the family of the extra- and intracellular Toll like receptors (TLRs), 
which were first discovered in Drosophila (Hoffmann, 1999; Kawai and Akira, 2010). Upon 
binding to their ligands, PRRs initiate an intracellular signalling cascade, which induces a 
transcriptional program leading to a clearance response that takes the form of 
phagocytosis, target cell lysis and/or induction of inflammation (Akira and Takeda, 2004). In 
addition to the cellular component of the innate immune system, the humoral constituents 
of the complement system are an essential part of an innate immune response. The 
complement system is activated by a series of proteolytic cleavages leading to three 
principle outcomes: (i) lysis of pathogens, (ii) opsonisation of pathogens, (iii) clearance of 
immune complexes (Ricklin et al., 2010). 
The combination of the humoral and cellular parts of innate immunity will either eliminate a 
foreign entity or will keep it in check until the slower, but potentially more effective, adaptive 
immune response can develop.  
1.1.2 The adaptive immune system 
The class of cells that mediate the adaptive immune response is called lymphocytes. 
Lymphocytes are further subdivided into B lymphocytes (B cells, B referring to the avian 
bursa of Fabricius) and T lymphocytes (T cells, T referring to thymus). They originate from so 
called common lymphoid progenitors (CLPs), which are generated in the bone marrow from 
multipotent hematopoietic stem cells (HSCs) earlier during haematopoiesis. While B cell 
precursors mature in the bone marrow, T cell precursors migrate to the thymus, where they 
eventually differentiate into mature T cells and enter the periphery. Whereas the innate 
immune system mounts a response in a broad and unspecific fashion, the adaptive immune 
system employs highly specific, selective and unique recognition receptors, called B or T 
cell antigen receptors (BCRs or TCRs, respectively). Each lymphocyte expresses thousands 
of identical copies of a unique given antigen receptor. In contrast to the genetically fixed 
recognition receptors of the innate immune system, antigen receptors are generated from a 
large collection of gene fragments, giving rise to an almost limitless repertoire of unique 
specificity by means of somatic recombination (Tonegawa, 1993). During this process, 
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potential auto-reactive antigen receptors are generated. To circumvent lymphocyte attacks 
to an auto-antigen, self-reactive lymphocytes are negatively selected, leading to central 
tolerance (Starr et al., 2003).  Binding of an antigen to a specific antigen receptor on a 
mature lymphocyte can trigger its clonal expansion and differentiation into daughter effector 
cells.  
B lymphocytes are able to recognize antigen in its intact form. Engagement of the BCR will 
lead to the activation of the B cell, causing it to proliferate and differentiate into an antibody 
secreting plasma cell. An antibody is the modified soluble form of the BCR that can enter 
the circulation to neutralize or mark antigens for clearance from the body. It therefore 
constitutes the humoral part of the adaptive immune system. T cells can be further 
subdivided into two subsets: CD8+ cytotoxic T cells (CTLs), which can lyse target cells 
directly, and CD4+ helper T cells (TH), which can further differentiate into TH1, TH2, TH17 and 
Treg cells to assist CTL or B cell mediated responses, depending on the context and type of 
antigen they encounter (Zhou et al., 2009). Unlike B cells, T cells are not able to recognize a 
native antigen. The TCR recognizes a bipartite structure on the surface of a host cell, made 
up of the major histocompatibility complex (MHC) and a short peptide derived from a 
protein antigen, which is referred to as peptide-MHC complex (p:MHC) (Trombetta and 
Mellman, 2005).  
Clonal expansion of lymphocytes results in short lived daughter effector cells and long-lived 
memory cells. The antigen-experienced memory cells persist in a resting state after a 
pathogen is eliminated. During a second encounter with the same pathogen, memory cells 
undergo more rapid proliferation and differentiation into effector cells. The result is a 
stronger and faster secondary immune response. The phenomenon of immunological 
memory is the fourth hallmark of the adaptive immune system besides the concepts of 
specificity, diversity and tolerance that distinguishes it from the innate immune system. 
1.1.3 The interconnection between innate and adaptive immunity  
The course of an immune response can be divided into three phases. The first phase 
includes the non-induced innate immune system. Anatomical and physiological barriers 
protect against invading pathogens. When a pathogen manages to breach this first passive 
line of defence, the second phase will start to develop. Tissue-resident phagocytes, like 
macrophages or dendritic cells (DCs) sense common microbial structures by their PRRs, 
leading to the production of pro-inflammatory cytokines and chemokines. Cytokines are low 
molecular weight peptides or glycoproteins that mediate intercellular communication within 
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the immune system. In the context of the second phase of an immune response cytokines 
either intensify (e.g. TNFα) or dampen (e.g. IL-10) an immune response. Chemokines are 
chemoattractant cytokines (e.g. IL-8) that are secreted to recruit more innate immune cells, 
like neutrophils and monocytes, to the site of infection and thereby amplify the initial cell-
mediated response. In addition, activation of complement contributes to pathogen 
clearance during this phase. In many cases pathogen invasion can be controlled by the 
innate immune system within the first 4 to 96 hours. However, the innate immune system is 
limited in cell numbers and its potential to mount a sufficient immune response. If a 
pathogen surpasses innate immunity, the third phase with the induction of adaptive 
immunity will be provoked. At the interface of innate and adaptive immunity are so called 
professional antigen presenting cells (APCs), like macrophages, B cells and most 
importantly DCs. They are endowed with high rates of antigen processing and their 
presentation in p:MHC complexes.  DCs are activated at sites of inflammation from where 
they migrate to the lymphoid organs to present p:MHC to T cells and activate them. 
Recognition of p:MHC by the TCR only is not sufficient to induce T cell activation. To ensure 
that activation is restricted to an immune response, activated DCs express co-stimulatory 
ligands.  Only recognition of p:MHC and binding of co-stimulatory ligands on DCs to co-
receptors on T cells will lead to full activation of T cells.  T cells start to proliferate and 
differentiate into large numbers of daughter effector cells that eliminate the pathogen by 
cell-mediated mechanisms and in addition, T cells aid the humoral response by helping B 
cells. Innate and adaptive immune responses are not separate events, but are deeply 
interconnected by the interface of professional APCs. Lymphocytes require the cells and 
cytokines of the innate immune system to be activated. Vice versa, T and B cells secrete 
cytokines that improve the effectivity of the innate immune system. 
1.2 Antigen recognition by the TCR and signal transduction 
The TCR recognises antigen in complex with MHC molecules. Two classes of MHC 
molecules exist in the body. Whereas MHC class I molecules are expressed on all nucleated 
cells, the expression of MHC class II molecules is confined to cells of the immune system. 
MHC I molecules display intracellular peptides, either processed from self or from non-self 
(e.g. viral antigens) antigens. Infected cells, which present pathogenic peptides on MHC I 
are directly lysed by CD8+ CTLs (Germain, 1994). The CD8 co-receptor binds to MHC class I 
molecules, thereby stabilizing the interaction between the TCR and enabling it to recognize 
the MHC bound peptide. Similarly, the CD4 co-receptor on TH cells binds MHC class II 
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molecules to stabilize the interaction between the TCR and p:MHC class II on the 
presenting APC (e.g. DC) (Rudolph et al., 2006). Once the TCR binds its specific p:MHC, the 
supramolecular immunological synapse  (IS) forms (Bromley et al., 2001) and the externally 
sensed signal induces an array of intracellular signalling cascades, which will ultimately 
activate the T cell to proliferate and differentiate, thereby translating environmental clues 
into cellular behaviour.   
 
1.2.1 The T cell receptor complex 
The TCR is not a single chain receptor, but a multi-component signalling complex. Two 
types of TCRs exist, which are defined by their component chains: TCRαβ and TCRγδ. In 
humans, most mature T cells are αβT cells and only 5 to 10% are γδT cells. The N termini of 
the paired immunoglobulin (Ig)-like polypeptide chains contain the variable regions (V 
region), which shape the antigen recognition site. The V regions are followed by the 
constant and the connecting domains, harbouring a disulphide bond covalently connecting 
the α and β or the γ and δ chains, respectively. Each chain contains a transmembrane 
domain followed by a short cytoplasmic tail. The cytosolic portion of the TCR chains are not 
capable of signal transduction (Bentley, 1997). Instead, the non-polymorphic CD3 γ, δ, ε and 
ζ  chains non-covalently associate in different configurations with the TCR polypeptides to 
build platforms for signal transduction (Meuer et al., 1983a; 1983b; Smith-Garvin et al., 
2009). The CD3 complex consists of heterodimers of CD3εδ and CD3εγ and a homodimer of 
CD3ζζ. CD3 molecules contain long cytoplasmic tails that comprise various copies of 
immunoreceptor tyrosine based activation-motifs (ITAMs). ITAMs are found in other immune 
receptors as well and serve as recruiting platforms for signalling molecules (Reth, 1989). The 
signature of this motif is two tyrosine residues flanked by a series of amino acids with 
stereotypic spacing (D/Ex7D/ExxYxxI/Lx7YxxI/L; single letter code, x is for any amino acid). 
Using mutants that lack the key tyrosine residues as well as chimeric proteins, several 
laboratories have identified the ITAMs to be the minimal requirement to couple the 
TCR/CD3 complex to the intracellular signalling machinery (Irving and Weiss, 1991; Romeo 
et al., 1992; Wegener et al., 1992; Letourneur and Klausner, 1992).  
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1.2.2 TCR proximal signalosome  
One of the first events following ligation of the TCR/CD3 complex is thought to be a 
conformational change within the cytoplasmic tails of CD3 that renders the ITAMs 
accessible to phosphorylation in a stimulus dependent manner (Xu et al., 2008). 
Subsequently, Src-family kinases (SFKs), including lymphocyte-specific protein tyrosine 
kinase (Lck) and FYN oncogene related to SRC (Fyn), are recruited to the TCR complex via 
the co-receptors CD4 and CD8. In the absence of TCR signals, Lck is maintained in an 
inactive state by the combined action of the tyrosine kinase Csk and the tyrosine 
phosphatase PEP. Csk phosphorylates an inhibitory tyrosine residue in the C-terminus while 
PEP dephosphorylates the activation loop tyrosine of Lck. Upon TCR ligation the receptor-
like protein tyrosine phosphatase CD45 dephosphorylates Lck in the C-terminus thereby 
facilitating its activation (Hermiston, 2002). Once activated, Lck and Fyn are able to 
phosphorylate critical tyrosine residues within the ITAM motifs. Subsequently the Syk-family 
kinase ζ chain-associated protein kinase of 70 kDa (ZAP-70) is recruited to the doubly 
phosphorylated ITAMs via interaction with its tandem src-homology 2 (SH2) domains. This 
increases the local concentration of ZAP-70 at activated TCRs. The kinase is fully activated 
by Lck-mediated phosphorylation of tyrosine residues in the activation loop of its kinase 
domain (Au-Yeung et al., 2009). The most important substrates of ZAP-70 are the 
transmembrane adaptor protein linker of activated T cells (LAT) and the cytosolic adaptor 
protein SH2-domain-containing leukocyte protein of 76 kDa (SLP-76) (Zhang et al., 1998; 
Wardenburg et al., 1996; Koretzky et al.).  LAT and SLP-76 build the framework, also 
referred to as the TCR proximal signalosome, for further signal propagation and 
diversification (Lindquist et al., 2003; Fuller et al., 2003) (Fig. 1.1). LAT contains several 
tyrosine residues, that when phosphorylated serve as interaction sites for phospholipase 
Cγ1 (PLCγ1), the p85 subunit of phosphoinositide 3-kinase  (PI3K) and the adaptor proteins 
growth factor receptor bound 2 (GRB2) and GRB2-related adaptor downstream of shc 
(Gads) (Sommers et al., 2004). SLP-76 is recruited by its mutual binding partner Gads (Liu et 
al., 1999). SLP-76 harbours several phosphorylation-induced interaction sites in its N-
terminal domain, which are required to recruit IL-2 inducible kinase (Itk), guanine-
nucleotide-exchange factor (GEF) Vav1 and adapter non-catalytic region of tyrosine kinase 
(Nck) to the complex. In addition, SLP-76 binds PLCγ1 and adhesion and degranulation-
promoting protein (ADAP) in a constitutive manner and can inducibly interact with 
hematopoietic progenitor kinase 1 (HPK1) (Koretzky et al.). Once PI3K gets recruited to the 
complex it converts phosphatidylinositol 4,5-bisphosphate (PIP2) into 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), which is important for local enrichment of Itk  
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and Protein Kinase B (PKB/Akt). The binding of PLCγ1 to SLP-76, LAT and Vav1 as well as 
to its activating kinase Itk, indicates a complicated organization within the complex that is in 
part also independent of its participant’s enzymatic activities. Several laboratories have 
generated mutant mouse strains and cell lines that support the role of a higher order 
organization as a prerequisite for sufficient signal propagation from the LAT:Gads:SLP-76  
complex  (Qi and August, 2007; Miletic et al., 2006; Sommers et al., 2005; Jordan et al., 
2008). Formation of the LAT:Gads:SLP-76 complex ultimately leads to the activation of 
PLCγ1 and subsequent downstream effector pathways as well as to cytoskeletal 
rearrangements and integrin signalling (Smith-Garvin et al., 2009). 
1.2.3 PLCγ1 mediated generation of second messengers 
LAT:Gads:SLP-76 complex-mediated activation of PLCγ1 catalyses the generation of the 
second messengers diacylglycerol (DAG) and inositol-1,4,5-trisphospahte (IP3) by 
hydrolysing PIP2 (Fig. 1.1). While production of DAG initiates two pathways that result in 
activation of the transcription factors nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) and activator protein-1 (AP-1), IP3 mediates the induction of calcium ion-
dependent pathways leading to activation of nuclear factor of activated T cells (NFAT). Both 
will be further discussed in the following paragraphs.  
i. DAG-mediated signalling pathways 
Generation of the membrane integral second messenger DAG leads to activation of two 
distinct pathways. One involves activation of the lymphocyte-specific Protein Kinase C 
(PKC) isoform  PKCθ, which is essential to trigger NF-κB activation and will be discussed in 
detail in paragraph 1.3.3. The second DAG-induced pathway depends on the small guanine 
nucleotide binding protein Ras, which is necessary for downstream activation of mitogen 
activated protein kinases (MAPK). While activation of Ras is mediated by GEFs that facilitate 
binding of GTP, it is suppressed by GTPase activating proteins (GAPs) that hydrolyse Ras-
bound GTP. T cells possess two GEF proteins: Ras guanyl nucleotide releasing protein 
(RasGRP) and son of sevenless (SOS) (Dower et al., 2000; Ebinu et al., 2000; Egan et al., 
1993). RasGRP is recruited to the plasma membrane by binding to DAG, where it is 
phosphorylated by PKCθ (Ebinu et al., 1998; Roose et al., 2005). In contrast, SOS is 
constitutively bound to the adaptor protein GRB2, which is inducibly recruited to the 
LAT:Gads:SLP-76 signalosome, where it locally augments Ras activity. The GEF activity of 
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SOS is limited by initial RasGRP-dependent RasGTP production, implying a positive 
feedback loop. Ras activation leads to downstream phosphorylation of the MAPKs 
extracellular signal-regulated kinase 1 and 2 (Erk1/2). Like the other two major MAPK 
pathways (the p38 MAPKs and the c-Jun NH2-terminal kinases (JNK) pathways), Erk1/2 
activation is part of a hierarchical phosphorylation cascade that involves upstream MAPK 
kinase kinases (MAPKKKs) and MAPK kinases (MAPKKs) (Dong et al., 2002). Ras activates 
the MAPKKK Raf1, which in turn phosphorylates the MAPKKs MEK1 and MEK2, leading to 
Erk1/2 phosphorylation and activation. Erk activity induces the transcription factor Elk1, 
which regulates c-Fos expression and, thereby, AP-1 (c-Jun:c-Fos) activation (Smith-Garvin 
et al., 2009).   
ii. Ca2+ ion-mediated signalling  
Calcium-ions (Ca2+) serve as universal second messengers in eukaryotic cells. The 
concentration of calcium is low in unstimulated T cells. Once the TCR is triggered, highly 
mobile IP3 is generated and acts as a ligand for heterotetrameric IP3-receptors (IP3Rs) in the 
membrane of the endoplasmic reticulum (ER). Binding of IP3 to IP3Rs causes the release of 
Ca2+ from ER stores into the cytosol. This leads to a transient increase in the local, cytosolic 
Ca2+ concentration. ER store depletion is one prerequisite for a sustained strong Ca2+ influx 
from the extracellular space. In a process, referred to as store-operated Ca2+ entry (SOCE), 
stromal interaction molecules (STIMs) sense ER store depletion and Ca2+-release-activated 
Ca2+ (CRAC) channels are activated, mediating influx of extracellular calcium (Oh-hora and 
Rao, 2008). Cytosolic Ca2+-ions bind to and modulate the conformation and biochemical 
property of the protein calmodulin (CaM). In context of TCR induced signalling, Ca2+:CaM 
acts on the serine/threonine phosphatase calcineurin (CN) and the Ca2+:CaM-dependent 
kinases (CaMK) (Soderling, 1999; Savignac et al., 2007). CaMKs have diverse functions in 
different signalling pathways. Whereas CaMKII was identified as a negative regulator during 
TCR-induced signalling, CaMKIV was found to have a positive regulatory role (Liu, 2009). 
The Ca2+:CaM-activated CN is able to dephosphorylate proteins of the NFAT family, which 
comprise three calcium-regulated members in T cells (NFAT1,2,4) (Fig. 1.1). NFAT 
transcription factors are rendered inactive by hyperphosphorylation, which masks their 
nuclear localisation sequence (NLS) and exposes their nuclear export sequence (NES). 
Once CN is activated, it binds NFAT and dephosphorylates critical serine residues. This 
reveals a NLS and enables NFAT to shuttle to the nucleus where it can bind to promoters 
and induce gene transcription (Macian, 2005). Although NFAT proteins can bind as  
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Figure 1.1 TCR-induced signaling pathways. Stimulation of the TCR and engagement of co-
receptors lead to activation of src-fmaily kinases, like Lck, which in turn phosphorylate the ITAM 
motifs in the cytoplasmic tails of the CD3 chains. Subsequently ZAP-70 is recruited and activated 
via binding to the double-phosphorylated ITAMs. In turn, ZAP-70 phosphorylates LAT and SLP-
76, leading to the assembly of the proximal TCR signalosome. Phosphorylated LAT is able to 
interact with SLP-76 via the adaptor Gads, inducing recruitment and activation of PLCγ1. 
Activated PLCγ1 generates the second messengers DAG and IP3, which in turn activate several 
pathways. First, IP3 induces release of Ca2+ from the ER leading to activation of NFAT. Second, 
DAG-mediated activation of PKCθ induces assembly of the CBM complex, leading to NF-κB 
activation and initiates ERK signalling via Ras. In addition, the GEF SOS, recruited to LAT, via the 
adaptor GRB2, facilitates activation of p38 through Rac1. Alternatively, p38 can be activated 
alternatively via ZAP-70 (dashed line). JNK is activated in a TAK1-dependent manner downstream 
of PKCθ. Activation of Erk, JNK and p38 culminates in AP-1 activity.  
 10 
 Thomas Mock I Introduction 
 
homodimers to target gene sequences, there are several examples for cooperative binding 
with other transcription factors (activators or repressors). The most prominent example is 
described for the IL-2 promoter, where cooperative binding of NFAT:AP-1 complexes is 
mandatory for normal induction of IL-2 expression (Macián et al., 2001; Serfling et al., 2007). 
Once calcium levels decline, CN is inactivated and different kinases phosphorylate NFAT, 
thereby masking the NLS and exposing a NES. Among those negative regulatory kinases 
are the glycogen-synthase-kinase 3β (GSK3β), Casein Kinase 1α (CK1α), DYRK1 and 2 and 
protein kinase A (PKA). These either act in the cytoplasm maintaining NFAT 
hyperphosphorylated in unstimulated cells or in the nucleus by rephosphorylation of 
promoter-bound NFAT in stimulated cells.   
1.2.4 Activation of the JNK and p38 pathways 
In addition to Erk, two other MAPKs, belonging to the family of stress-activated protein 
kinases (SAPKs), are activated upon TCR engagement: the group of JNKs and the group of 
p38 MAPKs (Dong et al., 2002). 
i. JNK activation 
Three members of the JNK family (JNK1-3) have been identified in mammals. Whereas 
JNK3 is not expressed in T cells, JNK1 and JNK2 expression is low in resting T cells. 
However expression is strongly induced upon T cell activation. (Rincon and Davis, 2009). 
JNK1/2 are activated by dual phosphorylation of threonine 180 and tyrosine 182 in the 
activation loop of the kinase domain by the upstream MAPKKs MKK4 and MKK7. The 
MAPKKs are also regulated by dual phosphorylation by upstream MAPKKKs. These include 
the TGFβ-activated kinase (TAK1) (Huang et al., 2009), the mixed lineage kinase (MLK) 
group and members of the Erk family (Manning and Davis, 2003). Several studies have also 
identified PKCθ to contribute to JNK activation. The phorbolester 12-myristate 13-acetate 
(PMA), which activates PKCs, was shown to induce JNK phosphorylation. This is in line with 
results from PKCθ deficient mice that exhibit reduced c-Jun phosphorylation and 
concomitantly decreased AP-1 activity (Isakov and Altman, 2002). Moreover, TAK1 activity 
seems to be required for activation of JNKs (Huang et al., 2009). Downstream substrates of 
JNK include the transcription factor c-Jun. Phosphorylation of c-Jun by JNKs induces its 
dimerization with c-Fos, leading to the formation of transcriptionally active AP-1 complexes. 
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Although some studies associate JNKs with T cell activation, their actual contribution 
remains controversial. Studies from knockout mice suggest that JNKs are dispensable for 
IL-2 production and T cell activation (Dong et al., 2002), but seem to play non-redundant 
roles during T helper differentiation. Whereas JNK1 deficient mice exhibit enhanced TH2 
differentiation (Dong et al., 1998), JNK2 deficiency leads to an impairment of TH1 
polarisation (Yang et al., 1998). The existence of several isoforms of JNK1 and JNK2 adds 
another layer of complexity, complicating to attribute their relative impact on T cell function. 
ii. p38 activation 
The p38 pathway is the third MAPK pathway initiated upon TCR triggering. There are four 
known p38 isoforms (p38α, p38β, p38γ and p38δ), each encoded by a separate gene. All, 
except p38γ, are expressed in T cells (Hale et al., 1999). p38 proteins can be activated in a 
classical MAPK signalling cascade manner. In T cells, the formation of the proximal 
LAT:Gads:SLP-76 signalosome leads to the recruitment and activation of the small Rho-
GTPase family members Ras-related C3 botulinum toxin substrate (Rac1) and cell division 
cycle 42 (CDC42) via the GEF Vav1, inducing MAPKKK activity. Several studies, using 
knockout mice suggest that MKK3, MKK4 and MKK6 act as p38 MAPKKs during classical 
MAPK activation (Brancho et al., 2003). Similar to JNK, p38 is activated by dual 
phosphorylation of threonine and tyrosine residues in the activation loop of the kinase 
domain. Using p38-specific inhibitors, different groups established that p38 needs to 
autophosphorylate itself in a TAK1-binding protein 1  (TAB1) –dependent manner, to be fully 
activated (Ge et al., 2002). The requirement for autophosphorylation-dependent activation 
seems to be cell type specific and can be observed in T cells. Notably, it has become 
evident that T cells also use an alternative activation pathway, involving ZAP-70 and 
growth-arrest and DNA damage-inducible 45α (GADD45α).  GADD45α seems to have a dual 
role during TCR-induced MAPK activation. On the one hand, it positively regulates JNK and 
p38 by facilitating activation of the MAPKKK MTK1, which in turn activates MKK4 and 
thereby JNK and p38. On the other hand, it was identified as a negative regulator of  
ZAP-70-mediated phosphorylation of tyrosine 323 of p38, which is required to induce its 
autophosphorylation on threonine 180 (Lu et al., 2001; Salvador et al., 2005b; 2005a). 
Prominent downstream targets of p38 include the tumor suppressor p53 and the 
transcription factors activating-transcription factor 2 (ATF2) and c-Fos. In that way 
activation of JNK and p38 converge by inducing transcriptional activation of the AP-1 
complex. Surprisingly, isoform-specific knockout mice of p38 have shown few abnormalities  
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despite the body of indirect evidence from studies using inhibitors, transgenic mouse 
models or protein mutants (Ashwell, 2006).  
1.2.5 Co-stimulation by CD28 
Several early studies have suggested that binding of p:MHC to the TCR alone is not 
sufficient for full activation of T cells. This led to the formulation of the two signal 
hypothesis, which postulates that additional binding of ligands from the surface of APCs to 
co-stimulatory receptors on the surface of the T cells, are required for T cell activation (Quill 
and Schwartz, 1987). The best characterised co-stimulatory ligand/receptor complex is the 
B7/CD28 interaction. CD28 belongs to the Ig-like family of co-stimulatory receptors 
(Boomer and Green, 2010; Rudd and Schneider, 2003; Rudd et al., 2009). Engagement of 
CD28 by the B7-family members B7-1 (CD80) and B7-2 (CD86) that are expressed on the 
surface of activated APCs leads to increased sensitivity to TCR triggering. In addition, co-
stimulation strongly enhances IL-2 production and is necessary for full T cell activation via 
amplification of the three major TCR-induced transcription factors NFAT, AP-1 and NF-κB. 
Consequently, cell survival is increased by elevated expression of anti-apoptotic genes and 
effector molecules (Thompson et al., 1989; Radvanyi et al., 1996). CD28 is expressed as a 
disulphide linked homodimer. Its short cytoplasmic tail contains several motifs that are 
important to facilitate recruitment of signalling molecules upon binding of its ligands. Lck 
and Fyn can phosphorylate the tyrosine residue in the membrane proximal motif YMNM, 
which is able to recruit the SH2-domain containing p85 subunit of PI3K and the adaptor 
proteins GRB2 and Gads (Cai et al., 1995; Schneider et al., 1995; Ellis et al., 2000). The 
adjacent proline-rich-region was shown to recruit Itk2 via its SH3-domain (Marengere et al., 
1997), whereas the more distal PYAP motif binds Lck, Grb2 and Filamin-A (Tavano et al., 
2006). Although binding and activation of PI3K has been shown, one study using knockin 
mice suggests that the membrane proximal YMNM-mediated recruitment of PI3K is 
dispensable for proper IL-2 secretion and T cell activation (Dodson et al., 2009). After CD28 
co-stimulation Lck is able to phosphorylate the tyrosine residue in the membrane proximal 
motif. This enables recruitment of the p85 subunit of PI3K and subsequently, docking and 
activation of the larger kinase domain-containing subunit p110. PI3K, once activated, 
induces the production of the D3-lipid PIP3. D3-lipids serve as docking sites for pleckstrin-
homology-domain (PHD)-containing proteins, including phosphoinositide-dependent kinase 
1 (PDK1) or Akt. Binding of Akt to PIP3 induces conformational changes that render Akt 
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accessible to phosphorylation and activation by PDK1 (Vanhaesebroeck and Alessi, 2000). 
Upon activation, Akt is released from the membrane into the cytosol, where it can influence 
different signalling pathways. Accordingly, Akt is able to phosphorylate an inhibitory 
threonine residue on GSK3β, thus sustaining NFAT activity. In addition, it was shown to 
phosphorylate activating residues of I-kappa-B-kinase α (IKKα), mammalian target of 
rapamycin (mTOR) and cAMP-response-element binding protein (CREB), thereby 
influencing gene expression. PDK1 was proposed to be the crucial component that 
connects TCR- and CD28-induced NF-κB activation by directly activating I-kappa-B kinase 
β (Vanhaesebroeck and Alessi, 2000) (discussed in detail in paragraph 1.3.4). Engagement 
of CD28 also leads to PI3K-independent pathways by binding of the adaptor molecules 
GRB2 and Gads. GRB2 links CD28 to JNK and p38 activation, possibly through activation 
of Ras and Rac1 in a Vav1-dependent manner (Bustelo, 2000; Zhang et al., 1999; Su et al., 
1994). CD28-initiated signalling is negatively regulated by phosphatase and tensin homolog 
(PTEN) and inositol-5-phosphate-phosphatase (INPP5D/SHIP1) that function to inactivate 
the products of PI3K activity. (Shan et al., 2000; Freeburn et al., 2002). Knockout mice of 
either protein display fatal autoimmune pathologies due to T cell hyper-responsiveness. 
CD28 co-stimulation provides the means to amplify TCR-induced signalling pathways and 
to prevent apoptosis by regulating the activity of pro-apoptotic proteins like Bad and BclXL. 
It is still controversial whether CD28 signalling is initiated independent of TCR engagement 
in vivo (Lühder et al., 2003; Tacke et al., 1997). Although anti-CD28 superagonistic 
antibodies exist that are able activate T cells independently of TCR signals, this effect 
seems to be rather short-lived and non-physiological (Tacke et al., 1997).  
1.3 The transcription factor NF-κB 
The identification of the transcription factor NF-κB was a breakthrough discovery in the 
early 1980s. It was first described as a factor that binds the enhancer sequence 5´-
GGGACTTTCC-3 in the κ-light gene locus of B cells, promoting the expression of the κ-light 
chain during B cell development (Sen and Baltimore, 1986). However, it soon became clear 
that NF-κB expression is not exclusive to B cells and that the influence on κ-light chain 
expression is of quantitative and not of qualitative nature. One of the most important early 
findings was that NF-κB is an inducible factor (Sen and Baltimore, 1986). In the absence of 
any stimuli, it is sequestered in an inactive form in the cytosol, complexed with an inhibitory 
protein (Baeuerle and Baltimore, 1988). Activation takes place in response to certain stimuli 
(e.g. LPS) that induce the release of the inhibitor from the transcription factor, thus enabling 
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it to migrate to the nucleus where it can bind its target sequences and activate gene 
transcription. Today, it is known that NF-κB is functional in virtually all cell types and can be 
activated by various stimuli. Since its initial description, the importance of NF-κB has been 
demonstrated in thousands of publications, especially manifesting its role in immunology 
and cancer biology. In context of immune-receptor signalling NF-κB activates transcription 
of several effector molecules that are necessary for activation, proliferation and 
differentiation (for instance IL-2, INFγ or TNFα). Many cancer cells abduct NF-κB to increase 
expression of anti-apoptotic genes leading to enhanced proliferation and survival as well as 
resistance to classical theraouetic treatment. The following paragraphs will discuss the most 
important aspects of NF-κB signalling, particularly focussing on its impact on T cell biology. 
1.3.1 The family of NF-κB transcription factors 
The family of NF-κB transcription factors consists of five members: RelA (p65), c-Rel, RelB, 
p50 and p52, which are able to homo- or heterodimerize to form the NF-κB complex 
(Hayden and Ghosh, 2008). Of note, p50 and p52 are generated through proteolytic 
cleavage of their precursor proteins p105 and p100, respectively. All family members 
possess a conserved 300 amino acid long Rel-homology-domain (RHD) at their N-terminus, 
which is necessary for homo- and heterodimerization, interaction with inhibitory proteins 
and mediates DNA binding. The RHD consists of an amino-terminal domain (NTD) and the 
dimerization domain (DimD), which is followed by a NLS. RelA, c-Rel and RelB are 
additionally characterised by the C-terminal transcription activation domain (TAD), which is 
not present in p50 and p52 (Huxford and Ghosh, 2009). p50 and p52, therefore, rely on 
forming dimers with RelA, c-Rel or RelB to activate gene transcription. In fact, homodimers 
of p50 or p52 are found to act as transcriptional repressors. RelB additionally possesses a 
leucine-zipper-motif (LZ) at its N-terminal region (Vallabhapurapu and Karin, 2009). It was 
found to preferentially heterodimerize with p100/p52, whereas RelA and c-Rel 
predominantly dimerize with p50. Whether the LZ of RelB confers specificity for dimerization 
is not known. A number of posttranslational modifications among the NF-κB proteins 
including phosphorylation, methylation, acetylation and ubiquitinylation further fine-tune the 
ability of individual dimers to activate gene transcription (Oeckinghaus and Ghosh, 2009; Liu 
and Chen, 2011; Harhaj and Dixit, 2011) (Figure 1.2). Furthermore, modifications enable the 
subunits to recruit and interact with co-factors that are required to access DNA. The 
combinatorial possibility of 15 individual NF-κB dimers as well as a variety of 
posttranslational modifications culminates in a multitude of regulatory mechanisms to 
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control NF-κB activity.  By far the most important regulators of NF-κB are the family of 
inhibitor of kappa B proteins (IκBs) 
1.3.2 The IκB family 
The best-studied regulators of NF-κB are the IκB proteins. In unstimulated cells IκBs retain 
the NF-κB dimer in the cytoplasm by masking its NLS. Although the IκBs have been mainly 
described as potent negative regulators, it has become evident that they can serve different 
functions (Hayden and Ghosh, 2008). The family of IκBs consists of seven members that 
can be further subdivided. The group of canonical IκBs consists of IκBα, IκBβ and IκBε, the 
so called precursor IκBs comprise p105 and p100 and the group of atypical IκB proteins 
contains Bcl-3 as well as IκBζ .  All IκBs are characterised by multiple ankyrin repeats, which 
enable them to bind to the RHD of NF-κB dimers and interfere with the exposure of the NLS 
Figure 1.2 The NF-κB family of transcription factors. The NF-κB family consists of five 
members, which are characterised by the presence of a N-terminal Rel homology domain (RHD). 
The RHD confers homo- and heterodimerization, interaction with inhibitory proteins and DNA-
binding. RelA, RelB and c-Rel also possess a transcription activation domain (TAD), which 
mediates transcription initiation at κB-site-containing promoters. RelB is additionally 
characterised by a leucine-zipper (LZ) motif in its N-terminus. p50 and p52 are generated from 
their precursor proteins p105 and p100, respectively. The N-terminus harbors the RHD of p50 
and p52, which is followed by a glycine-rich region (GRR) and multiple ankyrin repeats (violet 
ovals) and a death domain (DD).  
Red circles indicate known phosphorylation sites that alter the function of the respective protein. 
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sequence. It is believed that individual IκBs bind prefentially to a particular subset of NF-κB 
dimers, but surprisingly few details are known (Oeckinghaus and Ghosh, 2009; 
Vallabhapurapu and Karin, 2009). The canonical members of the IκB family possess an 
amino-terminal signal responsive region (SRR), which contains conserved serine residues 
that are phosphorylated by I-kappa-B kinase beta (IKKβ) (see paragraph 1.3.3) (Fig. 1.3). 
Phosphorylation initiates K48-linked ubiquitinylation und subsequent degradation via the 
proteasomal pathway. IκBα is the best-studied and prototypic member of the canonical 
family members and primarily associates with the canonical RelA:p50 dimer. 
Crystallographic analysis of the IκBα:RelA:p50 complex revealed that IκBα only masks the 
NLS of RelA, but not p50. In addition, IκBα contains a NES, which mediates immediate 
export of NF-κB from the nucleus. Hence, under basal conditions, IκBα:NF-κB complexes 
constantly shuttle between the cytosol and the nucleus. Once IκBα is degraded, this 
equilibrium shifts and NF-κB will be mainly located in the nucleus. IκBα is resynthesized in a 
NF-κB-dependent manner, constituting a negative feedback mechanism to block prolonged 
NF-κB activity.  
In contrast to IκBα, the role of IκBβ is less well understood. It shows similar binding to  
NF-κB dimers and, like IκBα, is also degraded and resynthesized in a stimulus- and NF-κB-
dependent manner. In addition to its inhibitory function, IκBβ was reported to augment 
transcription of a subset of genes (e.g. TNFα) by binding and stabilizing DNA-bound  
RelA:c-Rel complexes (Rao et al., 2010). IκBε is also degraded and resynthesized under NF-
κB-inducing conditions. It is predominantly expressed in cells of the hematopoietic system, 
indicating that IκBs may have unique roles in different cell types (Basak et al., 2007; Kearns 
et al., 2006). Surprisingly, cells from mice with triple knockout of the canonical IκB family 
members exhibit a normal nuclear/cytoplasmic RelA distribution, but a significantly higher 
basal expression of NF-κB target genes, indicating that modulation of NF-κB transcriptional 
activity is partly independent of IκB-dependent cytoplasmic sequestration (Tergaonkar et 
al., 2005).  
Under steady state conditions, the IκB/NF-κB–like precursor protein p105 is processed to 
p50 in a co- and posttranslational fashion (Moorthy et al., 2006; Lin et al., 1998). However,  
when p105 is bound to NF-κB dimers, it is protected from processing and acta as an IκB 
protein (Hayden and Ghosh, 2008). A complete IκBα-like degradation is induced by IKKβ-
mediated phosphorylation of serine residues in the C-terminal region of p105 (Perkins, 
2006).  The processing of the IκB-like p100 precursor protein is largely stimulus-dependent 
and requires the activity of IKKα (Senftleben et al., 2001). IKKα is mainly operative during 
non-canonical activation of NF-κB (paragraph 1.3.4). Similar to p105, the p100 protein is 
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constantly processed at a low rate to p52, and in its precursor form it acts as an IκB protein. 
Regulation of RelB by p100 is especially crucial, since it is the only IκB protein that binds 
RelB (Solan et al., 2002). Whereas RelB is exclusively controlled by p100, p100 can act 
more broadly, since it was shown to associate with RelA-containing dimers as well. In this 
respect, it was described to limit RelA-activity in an induced negative feedback following T 
cell activation (Ishimaru et al., 2006).  
The two atypical IκB family members Bcl-3 and IκBζ regulate NF-κB by a distinct 
mechanism that is not understood yet. Bcl-3 is special in that it contains a TAD. It is found 
in the nucleus, where it associates with p50 and p52 homo- and heterodimers (Bours et al., 
1993). This interaction was suggested to induce release of transcriptionally repressive NF-
κB dimers, thereby facilitating recruitment of transcriptionally active RelA-containing 
complexes (Wulczyn et al., 1992). In contrast, it was shown that induced expression of  
Bcl-3 inhibits NF-κB activity. These opposing properties may be partially explained by 
different posttranslational modifications of Bcl-3 (Nolan et al., 1993; Massoumi et al., 2006a; 
Bundy and McKeithan, 1997). The second atypical IκB protein IκBζ is not constitutively 
expressed, but its expression is induced after triggering the IL1- or TLR4 receptor 
(Motoyama et al., 2005). IκBζ is localized to the nucleus where it associates with p50 
homodimers as a co-activator for a subset of genes after LPS or IL-1 treatment. In addition 
IκBζ has been shown to inhibit RelA-containing NF-κB complexes. This is in line with an 
Figure 1.3 The IκB family. IκB proteins are characterised by multiple ankyrin (violet ovals) 
repeats, which mediate binding to the RHD of NF-κB dimers. Therefore, p105 and p100 can 
function as an NF-κB protein, when processed to p50 and p52 or as IκB proteins in there full-
length form. At their C-terminus IκBα and IκBβ have a proline-, glutamic acid-, serine-, threonine- 
(PEST) motif, indicative for proteins with a short half life.  
Red circles indicate known phosphorylation sites that alter the function of the respective protein. 
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observed mild elevation of NF-κB target gene expression in IκBζ knockout mice (Motoyama 
et al., 2005; Yamamoto et al., 2004).  
1.3.3 The IKKs 
The induced degradation of IκB proteins by phosphorylation is a prerequisite for NF-κB 
activation. IκB phosphorylation is mediated by two kinases that either function 
independently or assembled in a complex with a scaffold protein - the so-called IKK 
complex. The IKK complex mediates activation of the canonical NF-κB pathway, whereas 
IKK complex-independent activation leads to non-canonical NF-κB activation (see 1.3.4) 
(Hayden and Ghosh, 2008; Oeckinghaus and Ghosh, 2009; Huxford and Ghosh, 2009). The 
IKK complex was initially purified as a high molecular weight complex of 700 to 900 kDa. It 
was found to contain the two kinases IKK1 and IKK2, IKKα and IKKβ respectively, and an 
adaptor/scaffold protein termed IKKγ or NEMO (Zandi, 1997; Woronicz et al., 1997; 
DiDonato et al., 1997; Mercurio et al., 1999). The two kinases display about 50% sequence 
homology and exhibit molecular weights of 85 and 87 kDa. The 48 kDa sized NEMO is not 
related to IKKα or IKKβ and does not possess any intrinsic catalytic activity. The exact 
stoichiometry of the complex is still not resolved, but several studies, suggest a 2:1:1 
(IKKγ:IKKα:IKKβ) ratio (Huxford and Ghosh, 2009). Since this cannot account for the high 
apparent molecular weight of the purified endogenous complex, it was suggested that 
single complexes oligomerize into higher order structures, consisting of dimers or tetramers 
of IKK complexes. So far, no in vitro reconstitution with purified proteins resulted in a 700 to 
900 kDa structure exhibiting catalytic activity. Accordingly, it was recently suggested that 
the high apparent molecular weight from gel filtration might be due to the elongated 
structure of NEMO, leaving this issue highly controversial (Xu et al., 2011). The two kinases 
have a similar domain organization that was predicted to encompass an amino-terminal 
kinase domain, followed by a ubiquitin-like (UBL) domain, a central leucine zipper and a 
helix-loop-helix (HLH) motif (Huxford and Ghosh, 2009). The C-terminus was predicted to 
contain a serine rich region and the NEMO-binding-domain (NBD), which mediates 
interaction with NEMO (Figure 1.4). In addition, and in contrast to IKKβ, IKKα was predicted 
to possess a NLS sequence in the kinase domain. This is consistent with a described role of 
IKKα in the nucleus (Yamamoto et al., 2003). A recently published crystal structure, using 
Xenopus laevis IKKβ, which shares about 74% sequence homology with human IKKβ, 
describes a domain organization that differs from the previously made predictions. The 
structure revealed a tretramodular domain organization, encompassing the kinase domain, 
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the UBL-domain and a helical-scaffold/dimerization domain (SDD) and the NBD. 
Unexpectedly, the predicted LZ and HLH do not form but appear to be part of the SDD 
(Figure 1.2). The UBL domain and SDD seem to mediate and restrict the interaction with 
IκBα. In addition the UBL domain is required for the catalytic activity of the kinase. The SDD 
was shown to be important for dimerization, which is required during activation, but not to 
maintain catalytic activity. The study proposes a similar structure and domain organization 
for related kinases, including IKKα, IKKε and the TANK-binding kinase 1 (TBK1) (Xu et al., 
2011).  
Phosphorylation of conserved activation loop serine residues in IKKα and IKKβ is mandatory 
for kinase activity. The phosphorylation sites (S176/S180 in IKKα and S177/S181 in IKKβ 
(Fig. 1.4)) are reminiscent of the MAPKK consensus motif SXXXS (X can be any amino acid), 
which is also consistent with the observation that the MAPKKKs TAK1 and NIK are able to 
phosphorylate IKKs (Hayden and Ghosh, 2008). In addition, it was shown that IKKs can be 
activated through transautophosphorylation, but the exact mechanism remains elusive. 
Although IKKα and IKKβ are structurally similar, they exhibit different substrate specificities. 
Whereas IKKβ can phosphorylate most NF-κB bound IκBs, IKKα preferably displays 
specificity for p100. This is also reflected in knockout mice. IKKβ is sufficient and necessary 
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Figure 1.4 The IKK family. IKKα is shown with its predicted domain organization, containing an 
N-terminal kinase domain, followed by a LZ, a helix-loop-helix (HLH) motif, and the C-terminal 
NEMO binding domain (NBD). The domain organization of IKKβ is represented according to the 
crystal structure of Xenopus laevis IKKβ. The N-terminal kinase domain is followed by an ubiquitin 
like domain (UBL), the helical-scaffold/dimerization domain (SDD) and a NBD. Previously 
predicted motifs for human IKKβ are indicated in brackets. NEMO possesses two coiled-coil 
(CC1 and CC2) domains, which mediate the interaction with IKKα and IKKβ via  their respective 
NBD. The CC2 domain is followed by a LZ and a C-terminal zinc finger (Z) motif. The CC2-LZ 
region mediates binding to poly-ubiquitin chains and is necessary for NEMO function. 
Red circles indicate known phosphorylation sites that alter the function of the respective protein. 
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to confer phosphorylation of IκBα and IκBβ in IKKα knockout mice. In contrast, IKKα cannot 
compensate IKKβ deficiency, although residual IKK activity is observed (Hacker and Karin, 
2006). NEMO acts as a scaffold protein with regulatory function within the IKK complex. It 
was predicted to contain two coiled-coil domains – designated CC1 and CC2 – a helical 
dimerization domain near the amino-terminal end, a central LZ motif and a Zinc-finger 
domain (ZF) at its C-terminus (Figure I.2). The N-terminal helical coiled-coil domain interacts 
with both IKKα and IKKβ via their C-terminal NBD. Two NEMO proteins pair through 
extended coiled coil interactions to form the docking site for a pair of kinase subunits at the 
N-terminus (Huxford and Ghosh, 2009). Interestingly, the CC2-LZ region of NEMO was 
shown to bind to free linear ubiquitin chains that act as signalling mediators upon TNF 
receptor triggering (Rahighi et al., 2009). While IKKα, IKKβ and NEMO are considered to be 
the essential core components of the IKK complex, other proteins were co-purified with 
endogenous IKK complex. These include the chaperones Hsp90 and Cdc37 as well as the 
ELK protein. It is known that Hsp90 stabilizes protein folding of several protein kinases, 
indicating that Hsp90 might have a non-specific function in IKK-mediated signalling. RNAi-
mediated knockdown of ELK was described to interfere with TNFα and IL-1-induced IκB 
phosphorylation (Ducut Sigala et al., 2004; Chen et al., 2002). While these interactions are 
stable there may be a multitude of other interacting regulatory proteins, but their binding to 
the IKK complex may be rather transient and instable. 
1.3.4 Induction of canonical and non-canonical NF-κB signalling 
Signalling to and activation of NF-κB can be divided into the canonical or classical pathway, 
which is NEMO-dependent, and the non-canonical or alternative pathway, which is 
activated in a NEMO-independent fashion. The IKKs and the IκBs are the generic key 
components for both pathways, but activation of IKKs as well as the composition of NF-κB 
dimers differ, resulting in initiation of distinct transcriptional programs and functional 
outcomes. The classical and alternative pathway is initiated by different receptor subsets 
and requires a different set of signalling molecules upstream of their IKKs (Hayden and 
Ghosh, 2008). 
i. The canonical NF-κB pathway 
The key step in the canonical NF-κB pathway is activation of the IKK complex, leading to 
phosphorylation and degradation of NF-κB-bound IκBs. The canonical pathway is activated 
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in response to a multitude of stimuli, including cytokines (e.g. TNFα), PAMPs (e.g. LPS) and 
engagement of antigen receptors (e.g. TCR). Although all stimuli will lead to activation of the 
IKK complex, the different receptor systems employ specific signalling mediators to do so.  
Most of our knowledge concerning canonical IKK activation has been gathered by studying 
TNF-induced signalling. However, some principles like the use of scaffold and adaptor 
proteins as well as K63-linked ubiquitination can be transferred to other receptor systems, 
including PRRs and antigen receptors and seem to be a prerequisite for canonical NF-κB 
signalling (Ruland, 2011). Phosphorylation of serine residues in the activation loop of IKKs is 
mandatory to induce kinase activity (Hacker and Karin, 2006). However, it has been a long-
standing question whether this is facilitated by transautophosphorylation or by upstream 
IKK kinases (IKK-Ks) (Hayden and Ghosh, 2008; Oeckinghaus et al., 2011). Indeed, 
evidence for both exists and both might be necessary to induce IKK activity. TAK1 and 
MEKK3 have been described to act as IKK-Ks. Accordingly, MEKK3 deficient fibroblasts 
exhibit impaired NF-κB activation after TNFα or IL-1 stimulation. MEKK3 overexpression 
alone is able to induce IKK activity, indicating that the kinase acts directly proximal of or on 
the IKK complex (Yang et al., 2001b). In addition, MEKK3 catalytic activity is needed to 
rescue impaired IKK activity in MEKK3-deficient cells (Blonska et al., 2004). Although this 
supports an important function for MEKK3, no study has shown that MEKK3 directly 
phosphorylates the activation loop serine residues of IKKβ under physiological conditions. 
Therefore, MEKK3 might also serve another function during IKK activation. In contrast to 
MEKK3, TAK1 overexpression alone does not induce IKK activity, but is dependent on co-
overexpression of the TAK1 binding proteins TAB1, TAB2 or TAB3 (Wang et al., 2001; 
Kanayama et al., 2004; Ishitani et al., 2003; Kishida et al., 2005). Interestingly, single 
knockouts of TAB1 or TAB2 fail to show a NF-κB defect in response to IL-1 or TNFα (Shim 
et al., 2005). However, simultaneous RNAi-mediated silencing of TAB1 and TAB2 resulted in 
impaired NF-κB signalling (Ishitani et al., 2003). Moreover, silencing of TAK1 in Jurkat T cells 
resulted in impaired IκBα phosphorylation and decreased IL-2 production upon TCR-
triggering (Sun et al., 2004). However, the analysis of TAK1-deficent mice did not support a 
general role for TAK1 in  antigen receptor-dependent IKK activation. BCR-triggering 
resulted in normal IKK activity and TAK1 specifically impinges on TCR-induced NF-κB 
activation in thymocytes, but not during activation of mature T cells (Liu et al., 2006; Sato et 
al., 2005; Wan et al., 2006). In conclusion, MEKK3 and TAK1 may act in a cell type specific 
manner and are possibly required to amplify an initial transautophosphorylation-mediated 
IKK activation. Transautophosphorylation may occur through recruitment of IKK complexes 
to macromolecular signalling platforms that may facilitate oligomerization and, thus, 
proximity-induced transautophosphorylation of IKKs.  
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Additionally, among different pathways, conserved signalling intermediates involved in 
activation of the IKK complex are the family of TNFR-associated factors (TRAFs) and 
receptor-interacting proteins (RIPs). The family of TRAFs consists of seven members. All 
members are characterised by the presence of the TRAF domain, enabling interaction with 
signalling mediators. With exception of TRAF1, all TRAFs possess a RING domain, which 
can function as a ubiquitin ligase (Hacker and Karin; 2006). However, ubiquitin-conjugating 
activity has only been proven for TRAF2 and TRAF6 (Chen, 2005). Among the best-studied 
TRAFs are TRAF2, 5 and 6. They have been extensively characterised in context of TNFα/IL-
1/Toll-induced NF-κB activation (Tada et al., 2001). Upon TNFα stimulation, TRAF2 or, in its 
absence, TRAF5 is recruited via the adaptor molecule TNFR-associated via death domain 
(TRADD) to the TNFR-complex. Knockout mice from either TRAF do not exhibit any 
alteration of IKK activation (Tada et al., 2001; Nakano et al., 1999; Yeh et al., 1997). 
However, cells from double knockout mice are unable to mount a TNFα-dependent NF-κB 
response. Although it is now established that ubiquitination is necessary for proper IKK 
activation, the E3-ligase activity of either TRAF2 or TRAF5 is not needed (Devin et al., 2001; 
Tada et al., 2001). Therefore, it was proposed that TRAF proteins serve as adaptors that 
recruit E3-ligase activity through recruitment of the cellular inhibitor of apoptosis proteins 1 
and 2 (cIAP1 and cIAP2). The TRAF:cIAP1/2 signalosome is able co-recruit RIP1 (Devin et 
al., 2000), which was shown to be essential for TNFα induced NF-κB activation (Meylan et 
al., 2004; Ting and Pimentel-Muinos, 1996). Although RIP1 possesses a kinase domain, its 
kinase activity is dispensable in this context (Lee et al., 2004). Similar to the TRAFs, RIP1 
serves as an adaptor that is modified by K63-linked polyubiquitination, most probably by 
the cIAPs (Oeckinghaus et al., 2011). The polyubiquitin chains on RIP1 were shown to 
interact with the ubiquitin-binding site of NEMO, thereby recruiting the IKK complex to the 
receptor, which is thought to induce conformational changes and/or its oligomerization (Ea 
et al., 2006; Li et al., 2006a; Wu et al., 2006) Interestingly, RIP1-anchored polyubiquitin 
chains  co-recruit and activate TAK1 (via TAB2), bringing the IKK complex in close proximity 
to the proposed IKK-K (Kanayama et al., 2004). Of note, several groups recently 
characterised a novel E3-ligase complex, called linear ubiquitin chain assembly complex 
(LUBAC), which was shown to associate with the TNFR (Ikeda et al., 2011; Tokunaga et al., 
2011; Gerlach et al., 2011; Haas et al., 2009). LUBAC induces the addition of linear ubiquitin 
chains to NEMO and RIP1, which was suggested to augment the recruitment of the IKK 
complex to the receptor. However, none of the studies provide genetic evidence, that this 
type of ubiquitination is essential for IKK activation.  
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ii. The non-canonical NF-κB pathway 
Whereas receptor-mediated activation of the canonical NF-κB pathway occurs within 
minutes and is independent of protein synthesis, non-canonical NF-κB signalling requires 
de novo protein synthesis and takes several hours. The non-canonical activation is NEMO- 
and IKKβ-autonomous, but involves IKKα. It is initiated by a distinct set of receptors 
belonging to the TNFR-superfamily. These include lymphotoxin β-recepter (LTβR), CD40, 
receptor activator for NF-κB (RANK) and B cell activating factor receptor (BAFF-R). Non-
canonical NF-κB signalling has been implicated in lymphoid organogenesis, B cell 
development and survival as well as DC maturation and bone metabolism. In addition to 
IKKα, NF-κB inducing kinase (NIK), which mediates IKKα activation is absolutely required ro 
initiate non-canoncial NF-κB activation (Xiao et al., 2001; Sun, 2010a). In the absence of any 
stimuli, NIK exhibits a short half-life and is constantly degraded via the proteasome. Upon 
receptor engagement, NIK is stabilized and activates IKKα. IKKα in turn phosphorylates 
RelB-bound p100, which induces its limited proteolysis to p52 and enables the RelB/p52 
dimer to travel into the nucleus (Derudder et al., 2003; Coope et al., 2002). The control of 
NIK stability is crucial for positive and negative regulation of the non-canonical NF-κB 
pathway. A complex consisting of TRA2 and TRAF3, which recruits the E3 Ligase activity of 
cIAP1 and cIAP2, mediates NIK turnover under basal conditions. Upon receptor 
engagement, the complex is translocated to the activating receptor, probably followed by 
conformational changes. As a consequence, the complex is destabilized through 
degradation of TRAF2 and TRAF3, resulting in liberation and stabilisation of NIK. NIK 
accumulates in the cytoplasm, where it activates IKKα, leading to non-canonical NF-κB 
activation (Vallabhapurapu et al., 2008; Sun, 2011). In contrast signal activation, little is 
known about negative regulation of non-canonical NF-κB. A recent publication suggests 
that IKKα regulates over-accumulation of NIK in addition to its activating function (Razani et 
al., 2010). This is likely to control the magnitude of NIK accumulation, but may not be 
sufficient to shut off non-canonical NF-κB signalling completely. 
1.3.5 TCR-induced NF-κB signalling 
Activation of NF-κB upon antigen receptor triggering, is essential for proper lymphocyte 
activation, survival and differentiation. Lack of NF-κB-mediated gene transcription can result 
in immunodeficiency, whereas an over-activation is associated with autoimmune 
pathologies and can be causative for development of lymphoid malignancies (Li, 2002). TCR 
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and CD28 co-receptor stimulation results in activation of the canonical NF-κB pathway. 
Although some of the characteristics described in paragraph 1.3.4 also apply to TCR-
induced signalling, recent studies have established that T cells use a distinct set of 
signalling molecules to activate the IKK complex. These include the PKC isoform PKCθ and 
an inducible trimodular complex, composed of caspase recruitment domain (CARD) and 
membrane-associated guanylatekinase (MAGUK)-containing scaffold protein 1 (CARMA1), 
CARD-containing adapotor protein B cell CLL/Lymphoma 10 (Bcl10) and the paracaspase 
mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1). The complex 
is also referred to as the CBM complex (Vallabhapurapu and Karin, 2009; Thome et al., 
2010; Blonska and Lin, 2010) (Fig. 1.3). PKCθ is predominantly expressed in T lymphocytes 
and is the only PKC isoform that was shown to be recruited to the IS upon T cell activation 
(Monks et al., 1998; Isakov and Altman, 2002). Recruitment and activation of PKCθ is 
mediated by direct binding to DAG (see paragraph 1.2.3) and phosphorylation by PDK1, 
whichis activated upon CD28 co-stimulation. Under basal conditions PKCθ is thought to 
adopt a closed conformation, which is opened upon binding to DAG and subsequent 
phosphorylation by Lck as well as PDK1 (Villalba et al., 2002). Several studies have 
established PKCθ as an essential component of TCR-induced NF-κB activation (Schulze-
Luehrmann and Ghosh, 2006). However, the connection between PKCθ and IKK complex 
activation has not been clear until recently. Several studies have now established that the 
kinase is required for recruitment and assembly of the lymphocyte-specific CBM complex 
into the IS (Fig. 1.5). The requirement for the CBM complex to induce proper NF-κB 
signalling and, thus, lymphocyte activation is supported by impaired NF-κB activation in 
CARMA1, Bcl10 and MALT1 knockout mice (Thome et al., 2010; Blonska and Lin, 2010).  
CARMA1 acts as a scaffold protein and is characterised by a N-terminal CARD domain, 
followed by a coiled-coil domain and an extended linker region. The C-terminus comprises 
the MAGUK domain, which contains several motifs for protein-protein interactions, typical 
for scaffold proteins at sites of cell-cell contact. It consists of a PDZ  
domain (named after the domain-containing PSD-95, Dlg and ZO-1 proteins), followed by a 
SH3 domain and a GUK domain (Dimitratos et al., 1999). The CARD, the SH3 domain and 
the coiled-coil domain as well as the linker region are all essential for NF-κB activation, 
whereas the PDZ domain is dispensable (Gaide et al., 2002). While the CARD was shown to 
be necessary for the inducible interaction with Bcl10, the exact contribution of the GUK- 
and the SH3 domain to CARMA1 function is not yet understood (Gaide et al., 2002). For 
other MAGUK proteins it has been proposed that the SH3-GUK domain mediates 
intramolecular interactions that keep the protein in an auto-repressive conformation (Yaffe,  
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Figure 1.5 T cell receptor induced NF-κB signalling. Stimulation of the TCR leads to the 
assembly of the proximal TCR signalosome, resulting in the activation of PLCγ1. PLCγ1 mediates 
generation of the second messenger DAG, leading to recruitment of PKCθ to the plasma 
membrane. Co-stimulation of CD28 induces the recruitment and activation of PDK1, which 
activates PKCθ and inducibly associates with CARMA1. PKCθ is now able to phosphorylate 
CARMA1 in its linker region, possibly provoking a conformational change that induces interaction 
with preformed Bcl10:MALT1 dimers, which results in the assembly of a macromolecular 
signalling platform, known as the CBM complex. CBM complex formation in turn leads to 
recruitment and oligomerization of the E3-ligase TRAF6, stimulating its E3-ligase activity. TRAF6 
mediates K63-linked polyubiquitination of NEMO, and Bcl10, inducing the recruitment of the IKK 
complex to the signalling platform. The IKK complex in turn is activated, presumably through 
proximity-induced transautophosphorylation. In addition, TRAF6 ubiquitinates itself, leading to the 
recruitment of TAK1, which may act as an IKK-K to amplify IKK activation. Activated IKKβ 
phosphorylates IκBα, marking it for degradation via the proteasome. The RelA:p50 NF-κB 
heterodimer is liberated and can shuttle to the nucleus, where it binds to κB-sites and drives gene 
transcription. 
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2002; Feng and Zhang, 2009). However, a similar mechanism has not yet been formally 
shown for CARMA1. CARMA1 function is controlled by phosphorylation of several kinase-
specific serine residues in its linker region (Wang et al., 2002; Sommer et al., 2005; 
Matsumoto et al., 2005)(Matsumoto et al., 2005; Sommer et al., 2005; Wang et al., 
2002)(Matsumoto et al., 2005; Sommer et al., 2005; Wang et al., 2002). Upon TCR 
stimulation, CARMA1 is enriched in lipid rafts, where it is able to interact with PKCθ. PKCθ 
in turn mediates phosphorylation of the linker region, which evokes a conformational 
change within CARMA1, enabling it to bind Bcl10. Following TCR triggering, preformed 
Bcl10:MALT1 complexes are recruited by CARMA1 (Gaide et al., 2002). CBM complex-
dependent NF-κB activation is thought to occur through facilitating IKK complex recruitment 
to and oligomerization at the plasma membrane. IKK activation was shown to be dependent 
on K63-linked ubiquitination of NEMO. In addition, NEMO possesses an ubiquitin-binding 
domain, which is thought enable the IKK complex to bind to upstream formed polyubiquitin 
chains, enabling the IKK complex to be ordered into higher macromolecular structures 
(Vallabhapurapu and Karin, 2009). The CBM complex may act as a molecular platform that 
recruits signalling intermediates responsible for NEMO ubiquitination and activation 
(Blonska and Lin, 2010). K63-linked ubiquitination of NEMO was shown to occur in a 
CARMA1 dependent manner. Interestingly, phosphorylation of IKK activation loop serine 
residues in CARMA1- and Bcl10-deficient cells is normal, but kinase activity is completely 
abolished, indicating that phosphorylation alone is not sufficient (Shambharkar et al., 2007). 
TRAF2 and TRAF6, which were thought to predominantly act within TNFR/IL-1R-mediated 
NF-κB activation, were also shown to be involved in TCR-mediated IKK activation (Sun et 
al., 2004). The study describes an interaction between MALT1 and TRAF6, stimulating its 
ligase activity towards NEMO and possibly Bcl10. Moreover, TRAF6 autoubiquitination 
stimulates the recruitment and activation of TAB:TAK1 complexes, which may also 
participate in the activation of the IKK complex (Sun et al., 2004). The complexity of the 
CBM-signalosome is even further increased by the finding that caspase-8 is necessary for 
recruitment of the IKK complex (Misra et al., 2007).  
Co-stimulation by CD28 is a prerequisite for full NF-κB activation in T cells. PDK1 appears 
to be the long missing link between CD28 and IKK complex activation. CD28 stimulation 
leads to the activation of PI3K, which induces production of PIP3 to serve as a docking site 
for PDK1. Binding of PDK1 to PIP3 induces its activation, possibly through 
autophosphorylation of a critical threonine residue. This mediates binding of PDK1 to 
CARMA1 as well as to PKCθ, which in turn is phosphorylated in its activation loop by the 
former. PDK1-activated PKCθ is now able to phosphorylate CARMA1 in its linker region 
resulting in CBM complex assembly and NF-κB activation.  Thus, PDK1 has a dual function, 
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by activating and bridging PKCθ towards its substrate (Park et al., 2009; Blonska and Lin, 
2010). Of note, CK1α, HPK1 and IKKβ have been shown to phosphorylate non-PKCθ target 
serine residues in the linker region of CARMA1 that are essential to mediate NF-κB 
activation (Bidère et al., 2009; Lee et al., 2005; Brenner et al., 2009; Wegener et al., 2006). In 
summary, lymphocytes activate canonical NF-κB signalling, using lymphocyte-specific 
kinases and scaffold proteins. An overview of TCR-induced NF-kB activation is shown in 
Fig. 1.5. 
1.3.6 Termination of NF-κB signalling 
Although tremendous efforts have been made to understand how NF-κB is activated in 
various scenarios and contexts, a lot less is known about negative regulation of NF-κB. 
Immediate activation of NF-κB is required for a successful immune response. However,  
NF-κB activity has to be tightly controlled to prevent excessive production of inflammatory 
cytokines that may lead to tissue damage or even death through septic shock. Uncontrolled 
continuous inflammation enhances the risk for autoimmunity and can promote cancer 
formation (Karin and Greten, 2005; Ben-Neriah and Karin, 2011). Therefore several negative-
regulatory mechanisms have evolved to terminate or modulate the magnitude of NF-κB 
activity. IκB proteins are the best-characterised negative regulators of NF-κB. Their function 
has been reviewed in paragraph 1.3.2. Hence, this paragraph will concentrate on the 
negative regulatory function of ubiquitin-editing enzymes. The role of phosphatases will be 
discussed separately.  
i. Negative regulation of NF-κB by ubiquitin-editing enzymes 
The role of ubiquitin-mediated signalling during NF-κB activation upon various inducing 
conditions is a field of intense investigation. As described in paragraphs 1.3.4 and 1.3.5 
addition of K63-linked polyubiquitin chains to signalling molecules is necessary for induction 
of canonical NF-κB signalling upon various stimuli. K63-linked ubiquitin chains mediate 
recruitment to and stabilization of downstream signalling proteins into signalling complexes. 
In addition, they can alter the function and activity of their substrates. Accordingly, 
counterregulation of ubiquitin signalling is of special interest in this context. Indeed, several 
deubiquitinases (DUBs) have been found to act as negative regulators (Harhaj and Dixit, 
2011). A20 is the best-studied DUB and possesses an E3 ubiquitin ligase domain that 
surprisingly allows for dual ubiquitin editing function. A20 is expressed in a NF-κB-
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dependent manner and can therefore be considered as an induced negative feedback 
regulator. It was shown to remove K63-linked polyubiquitin chains from RIP1 (see 
paragraph 1.3.4), NEMO, TRAF6 and MALT1 (Boone et al., 2004; Duwel et al., 2009; 
Coornaert et al., 2009). Thus, A20 can act in the TNFR-induced as well as in the PRR- and 
antigen receptor-induced NF-κB pathway. Its activity is controlled by Tax binding protein 1 
(TAXBP1), which facilitates interaction with RIP1 or TRAF6.  Within the TNFR-pathway, A20 
removes K63-linked ubiquitin chains from RIP1. Additionally, A20 functions as an adaptor 
that recruits the HECT ubiquitin ligase Itch, which promotes K48-linked ubiquitination and 
degradation of RIP1 (Shembade et al., 2008; Scharschmidt et al., 2004; Wagner et al., 
2008). Interestingly, the removal of K63-linked ubiquitin from RIP1 seems to be a 
prerequisite for its’ K48-linked polyubiquitination (Wertz et al., 2004). Consistent with A20s 
function within different NF-κB pathways, A20-deficient T cells were shown to have 
prolonged IKK activity and IκBα phosphorylation upon stimulation. Accordingly, T cells from 
A20-deficient mice exhibit a hyperactivated phenotype and, consequently, A20-deficient 
mice die early due to hyperinflammation (Lee et al., 2000).  
Another important negative regulator of ubiquitin-mediated NF-κB activation is the 
tumorsuppressor CYLD (cylindromatosis). Unlike A20, CYLD is not expressed in a NF-κB-
dependent manner. However its activity is controlled in a stimulus-dependent fashion by 
phosphorylation and localization (Massoumi et al., 2006b; Reiley et al., 2005). CYLD was 
shown to deubiquitinate several activators, including TRAF2, TRAF6, TAK1 and NEMO 
(Trompouki et al., 2003; Sun, 2010b).  Whereas A20 and CYLD negatively regulate receptor 
proximal events, by targeting K63-linked ubiquitination, other E3-ligases mediate inhibition 
of NF-κB activity by degradative K48-linked ubiquitination of nuclear RelA. Copper 
metabolism (Murr1) domain containing 1 (COMMD1) was shown to inhibit NF-κB, as an 
important component of an E3-ligase complex, including elongin b or c and cullin-2 or -5 as 
well as suppressor of cytokine secretion 1 (SOCS1) (Maine et al., 2007; Natoli and Chiocca, 
2008). Another E3-ligase that inhibits NF-κB acitivity in the nucleus is PDLIM2 (PDZ and LIM 
domain 2). PDLIM2 facilitates incorporation and ubiquitination of RelA in insoluble 
promyelocytic leukemia nuclear bodies, which are enriched with proteasome activity 
(Tanaka et al., 2007; Natoli and Chiocca, 2008). 
1.3.7 The role of phosphatases in T cell activation and NF-κB  
 signalling 
Phosphorylation is a key posttranslational modification, involved in intracellular signal 
transduction. It can mediate conformational changes (e.g. phosphorylation of CARMA1), 
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alter the biochemical activity of signalling intermediates (e.g. phosphorylation of IKKs) or 
can function to establish interaction surfaces for other molecules (e.g. ITAM motifs). The 
human genome encodes 518 kinases, including 90 protein tyrosine kinases (PTKs) and 428 
protein serine/threonine kinases (PSKs). In contrast, there are 107 protein tyrosine 
phosphatases (PTP) and only a few protein serine/threonine phosphatases (PSPs) (about 
30) present. The PSPs are further subdivided into 3 families: the phosphoprotein 
phosphatases (PPPs), the metal-dependent phosphatases (PPMs) and the aspartate-based 
phosphatases. The vast majority of phosphorylation reactions occur on serine and threonine 
residues. Although there are more than 400 known serine/threonine kinases, only 30 PSPs, 
including seven catalytically active PPPs, are encoded in the human genome (Manning et 
al., 2002; Shi, 2009). This discrepancy may imply that PPPs act in a broadly unspecific 
manner to counter-regulate kinase function. However, PPPs are tightly controlled by 
regulatory subunits that interact with the catalytic cores to modulate substrate specificity, 
localisation and enzymatic activity. PPPs function, therefore, in multimeric holoenzyme 
complexes that consist of a catalytic core subunit that associates with one or more 
regulatory subunits (Virshup and Shenolikar, 2010). Hundreds of regulatory subunits were 
shown to exist. Accordingly, a plethora of distinct holoenzyme complexes can form that 
possess the same catalytic core, but exert distinct functions. This concept has been 
established for protein phosphatase 1 (PP1) and 2A (PP2A), which were shown to account 
for nearly 90% of phosphatase activity in eukaryotic cells (Moorhead et al., 2007; Virshup 
and Shenolikar, 2010).  
The following paragraphs will briefly discuss the role of PTPs during the initial phase of T 
cell activation and further review the known PPPs involved in NF-κB signalling in different 
pathways. 
i. The role of phosphatases during T cell activation  
The initial steps during T cell activation, leading to the formation of the proximal TCR 
signalosome, primarily rely on the action of PTKs. Accordingly, most phosphatases involved 
in these early events belong to the PTP family. About 40 PTPs, are involved in a variety of 
signalling pathways in T cells. The most important PTPs will be shortly discussed in the 
following.  
The most prominent PTP involved in T cell activation is the transmembrane protein CD45. In 
resting cells, Lck is kept in an inactive state via Csk-mediated mediated phosphorylation of 
an inhibitory tyrosine residue. Upon T cell activation, CD45 is recruited to the IS and 
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dephosphorylates the inhibitory site. Although this function as a positive regulator is well 
established, it was also reported that CD45 could negatively regulate Lck by 
dephosphorylating the kinase in its activation loop (Hermiston et al., 2003; Maksumova et 
al., 2005). However, the positive regulatory role seems to dominate since Csk inhibition 
alone leads to T cell activation (Zikherman et al., 2010). In addition, protein tyrosine 
phosphatase, non-receptor type 22 (PTPN22) was shown to negatively regulate Lck 
(Hasegawa et al., 2004). The currently best-understood PTP in lymphocytes is SH2-domain 
containing phosphatase 1 (SHP1), which mainly acts as a negative regulator of TCR 
signalling. SHP1 dephosphorylates Lck and ITAM-bound ZAP-70. In addition, SHP1 was 
reported to dephosphorylate the downstream signalling mediators Vav1 and SLP-76 
(Stebbins et al., 2003; Binstadt et al., 1998). In contrast to SHP1, the closely related SHP2 
phosphatase positively regulates the Ras-Raf-MEKK-ERK-pathway, through 
dephosphorylation of an unknown substrate (Frearson and Alexander, 1998). Furthermore, 
the suppressor of TCR signalling 1 and 2 (Sts1 and 2) phosphatases were shown to 
negatively regulate proximal TCR signalling events. T cells derived from Sts1- and Sts2 
double-deficient knockout mice exhibit hyperphosphorylation of Zap-70, LAT and SLP-76 
causing hyperproliferation. Accordingly, double deficient mice have an increased risk of 
autoimmunity (Carpino et al., 2004; Mikhailik et al., 2007).  
ii. The role of protein serine/threonine phosphatases in NF-κB 
 signalling 
The best-studied PPP with respect to NF-κB signalling is the serine/threonine 
phosphatase 2, catalytic subunit A (PP2CA). PP2CA has previously been implicated as a 
negative regulator of RelA (Yang et al., 2001a; Fu et al., 2003; DiDonato et al., 1997), but 
these studies lacked evidence for distinct holoenzyme complexes. One study systemically 
delineated the action of three different PP2CA holoenzymes within the TNFα-induced NF-κB 
pathway in mouse astrocytes (Li et al., 2006b). First, a holoenzyme consisting of PP2CA and 
the regulatory subunit PP2R1B was found to associate and dephosphorylate serine 536 in 
the TAD of RelA, phosphorylation of which is necessary for transcription activation. Second, 
the authors identified a novel phosphorylation site in the zinc finger domain of TRAF2 
(threonine 117), which was shown to be important for NF-κB activation in response to  
TNFα. Phosphorylation was counteracted by a PP2CA holoenzyme that contains the 
regulatory subunits PP2R1A and PP2R5C. Accordingly, knock down of either subunit led to 
a marked increase in NF-κB activity. Third, the authors showed that a PP2CB/PP2R1A 
holoenzyme was able to interact and dephosphorylate the activation loop serine residues of  
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IKKα and IKKβ (Li et al., 2006b). In addition, PP2CA was more recently reported to 
dephosphorylate the IKK-K MEKK3, thereby limiting IKK activity (Sun et al., 2010). Indeed, 
the same authors provided evidence that the metal-ion-dependent phosphatases PPM1A 
and PPM1B interact with IKKβ and dephosphorylate it in a stimulus-dependent manner 
upon TNFR engagement (Sun et al., 2009). Interestingly, PP2CA was also implicated to 
positively regulate NF-κB activity, presumably by removing inhibitory phosphate groups 
from NEMO (Kray et al., 2005). Another study recently provided evidence that a 
PP2CA:PP2R1A phosphatase complex is necessary to dephosphorylate a critical serine 
residue in the linker region of CARMA1 in T cells. Knock down of PP2R1A or chemical 
inhibition of PP2CA with okadaic acid enhanced CBM complex formation and NF-κB 
activation (Eitelhuber et al., 2011). 
Another study has shown that the PPP PP1c may negatively regulate IKK complex activity.  
The authors provided evidence that PP1c is recruited to the IKK complex via the adaptor 
protein CUE domain containing 2 (CUEDC2) and the regulatory subunit growth arrest and 
DNA damage-inducible gene 34 (GADD34). Consistently, knock down of CUEDC2 
enhanced IKK activity and IL-6 production in macrophages upon TNFα treatment (Li et al., 
2008).  
Only few other phosphatases have been linked to the regulation of NF-κB activity. Two 
publications have implicated a role for the PPP PP6 in regulation of IκBε, but failed to show 
a functional relevance (Stefansson and Brautigan, 2006; Bouwmeester et al., 2004). A more 
recent publication has identified the phosphatase WIP1 as a negative regulator of RelA 
activity (Chew et al., 2009). However, another study, investigating the phenotype of WIP1 
knockout mice, reported decreased proliferating capacity of T and B cells, arguing against a 
general, non-redundant role of WIP1 in regulating NF-κB.  
Interestingly, two groups independently reported that the calcium-dependent phosphatase 
calcineurin (see paragraph 1.2.3) is involved in the positive regulation of NF-κB in T cells by 
controlling the phosphorylation of an inhibitory serine residue in Bcl-10 (Frischbutter et al., 
2011; Palkowitsch et al., 2011). 
Recently, we identified a novel NF-κB-regulating PPP phosphatase holoenzyme, containing 
the catalytic subunit PP4c and the regulatory subunit PP4R1, that regulates IKK complex 
activity in T cells. We were able to show that PP4R1 acts as an adaptor that directs PP4c 
phosphatase activity specifically towards the IKK complex in a stimulus-dependent manner. 
PP4c:PP4R1 is able to dephosphorylate the IKK complex, thereby limiting IKK activity. 
Notably, this holoenzyme is only functional in expanded T cells, since expression of PP4R1 
is absent in resting cells, indicating that the PP4c:PP4R1 holoenzyme is involved in  
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termination of an immune response. (Brechmann, 2010; Brechmann and Mock et al., 
manuscript in preparation).  
A comprehensive overview of the here discussed NF-κB-modulating phosphatases is given 
in Table 1.1. Although some of the mentioned studies provide conflicting data concerning 
redundant roles of different phosphatases in regulating IKK- as well as RelA-activity, these 
discrepancies may be explained by different experimental setups and redundant roles of 
different phosphatases in different cell types and signalling contexts. 
1.4 Human lymphoid pathologies associated with NF-κB 
Given the crucial role of NF-κB, especially in context of an immune response, it is not 
surprising that deregulation of NF-κB is associated with several lymphoid pathologies. 
Deregulated NF-κB activity serves mainly pro-oncogenic functions since NF-κB target 
genes include factors, which promote the hallmarks of cancer, including apoptosis 
resistance-, migration-, invasion-, and pro-angiogenic factors (Hanahan and Weinberg, 
2011). In addition, NF-κB controls the vast majority of pro-inflammatory cytokines, which 
were shown to favour cancer development under special circumstances (Staudt, 2010; Ben-
Neriah and Karin, 2011). Several molecular lesions were identified that drive aberrant NF-κB 
activity, enabling a malignant cell to evade apoptosis and allow growth independent of 
paracrine mitogenic factors. In addition, over-activation of NF-κB was associated with 
increased metastatic capacity, probably through expression of NF-κB-dependent matrix-
metalloproteinases (MMPs) (Bond et al., 1998; Levine et al., 2003). This paragraph will focus 
on the most prominent examples of oncogenic NF-κB activation (for a comprehensive 
overview see (Lenz and Staudt, 2010; Karin, 2009; Staudt, 2010)). 
Several T and B cell malignancies rely on the constitutive activation of NF-κB. The 
preferential utilisation of the pathway within this cellular compartment may be caused by its 
crucial role during lymphocyte development and homeostasis (Vallabhapurapu and Karin, 
2009). About 90% of human lymphomas arise from the B cell compartment during various 
stages of B cell development. The most relevant subtype of non-Hodgkin’s lymphoma is the 
diffuse large B cell lymphoma (DLBCL). Recent studies have defined distinct subtypes of 
DLBCL, according to their gene expression profile and their origin from different stages of B 
cell development. These include the germinal center-like (GCB) DLBCL, the activated B cell-
like (ABC) DLBCL and the primary mediastinal B cell lymphoma (PMBL) (Rosenwald, 2003). 
Constitutive activation of NF-κB is now considered as a hallmark of the ABC-DLBCL (Lenz 
and Staudt, 2010; Staudt and Dave, 2005). ABC-DLBCL cells exhibit rapid phosphorylation 
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and degradation of IκBα and accumulation of RelA:p50 and c-Rel:p50 dimers in the nucleus. 
Overexpression of an IκBα super-suppressor or treatment with an IKKβ inhibitor sensitize 
ABC-DLBCL cells towards apoptosis, but have no impact on GCB-DLBCL cells (Davis et al., 
2001; Lam et al., 2005). This aberrant NF-κB activation causes increased expression of the 
transcription factors IRF4 and XBP-1, which normally mediate plasma cell differentiation. 
Interestingly, accompanying inactivating mutations of the factor Blimp-1, another master 
regulator that mediates cell cycle arrest in terminally differentiated plasma cells, are 
frequently observed. As a consequence, malignant cells do not terminally differentiate into 
plasma cells and escape cell cycle arrest (Shaffer et al., 2009; Staudt, 2010). Another 
hallmark of the ABC-DLBCL subtype is the NF-κB-dependent expression of IL-6 and IL-10. 
Both cytokines are secreted in large amounts and signal in an autocrine fashion, inducing 
STAT3 signalling and thereby favouring cell survival (Yang et al., 2007; Lam et al., 2008). 
Several mutations within the components of the BCR-driven NF-κB pathway have been 
identified to cause the constitutive activation of NF-κB in ABC-DLBCL cells. Recently, so-
called “Achilles heel” RNAi screens, identified several components of the pathway, including 
CARMA1, A20, CK1α, CD79A and CD79B and MYD88. These were shown to be critical for 
constitutive NF-κB activation and survival of ABC-DLBCL cells (Davis et al., 2010; Ngo et 
al., 2011; Staudt, 2010; Bidère et al., 2009; Lenz et al., 2008). Knock down of either of those 
signalling intermediates sensitized cells towards apoptosis. In fact, several activating and 
inactivating mutations have now been identified in these proteins. For instance, ~10% of 
ABC-DLBCL biopsies were shown to contain activating mutations within the coiled-coil 
domain of CARMA1 (Lenz et al., 2008). These mutated CARMA1 proteins were shown to 
form signalling-active, cytoplasmic aggregates with several NF-κB pathway components, 
including Bcl10, MALT1 and the IKK complex. Although the exact mechanism remains 
elusive, it was proposed that these mutations cause release of CARMA1 from a normally 
auto-inhibiting conformation, thus allowing its oligomerization with CBM complex 
components to signalling lattices that activate the IKK complex (Ben-Neriah and Karin, 
2011; Staudt, 2010). Nevertheless, these mutations were only found in a small fraction of 
patients. More recently, somatic mutations in the ITAM containing components of the BCR 
complex, CD79A (Igα) and CD79B (Igβ), were found in more than 20% of ABC-DLBCL 
specimens. These mutations mediated increased surface expression of the BCR, leading to 
auto-clustering and chronic active BCR signalling and, thus, NF-κB activation (Davis et al., 
2010). An additional study established a role for the adaptor protein MYD88. MYD88 
normally links TLR and IL-1/IL-18 receptor signals to the NF-κB pathways. The authors 
found recurrent mutations within MYD88 in ABC-DLBCL cell lines as well as in 29% of 
primary tumor samples. Accordingly, knock down sensitised cells towards apoptosis. In 
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contrast, overexpression of mutant MYD88 confers survival advantages in NF-κB-
independent GCB-DLBCL cell lines. The mutant MYD88 protein promotes survival by 
spontaneously assembling a complex, containing and activating the kinases IRAK1 and 
IRAK4, enhanced IL-10, IL-6 and Interferon-β production as well as JAK-STAT signalling. 
Hence, the found mutations can be considered driver mutations of lymphomagenesis (Ngo 
et al., 2011).  In contrast to these activating mutations, the NF-κB negative regulator A20 
was found to be bi-allelicaly inactivated as a frequent pathogenetic event in ABC-DLBCL 
(Compagno et al., 2009).  
Mucosa-associated-lymphoid-tissue (MALT) lymphoma, a form of marginal zone lymphoma, 
is another tumor entity associated with dysregulated NF-κB activity. Approximately 25% of 
gastric MALT lymphomas harbor a chromosomal translocation that generates a fusion 
protein, comprising parts of cIAP2 and MALT1 (Akagi et al., 1999; Dierlamm et al., 1999; 
Morgan et al., 1999). The cIAP2-MALT1 fusion protein activates NF-κB when overexpressed 
(Lucas et al., 2001; Uren et al., 2000; Jost and Ruland, 2007). Less frequently, MALT1 and 
Bcl10 are overexpressed due to a translocation linking them to the immunoglobulin heavy 
chain locus. At present, the exact mechanism of NF-κB activation through the fusion protein 
is not known, but it seems to involve the recruitment and activity of TRAF2 via the BIR 
domains of cIAP2 and the MALT1 protease activity. A current model suggests that cIAP2-
MALT1 protein oligomerizes, providing a multivalent platform for recruitment of the ubiquitin 
ligases TRAF2 and TRAF6. The IKK complex gets recruited and subsequently ubiquitinated, 
possibly helping to retain it in the complex and facilitating its activation by IKK-Ks like TAK1. 
In addition, cIAP2-MALT1 oligomers might exhibit MALT1 protease activity towards A20, 
thereby amplifying NF-κB activation (Staudt, 2010).  
Multiple myeloma is another prominent example of a neoplastic disorder for which 
constitutive NF-κB activation has been described, both in cell lines and in patient samples 
(Ni et al., 2001). In many myeloma cases a diverse array of genetic aberrations target NF-κB 
regulators. At varying frequencies, multiple myeloma cells harbor gene amplifications or 
translocations of components of the non-canonical NF-κB pathway, including LTβR, CD40, 
or NIK as well as deletions or inactivating mutations of components of the canonical NF-κB 
pathways, including TRAF2, TRAF3 and CYLD. However, all genetic lesions target the 
activity and/or stabilization of NIK, which leads to activation of non-canonical and canonical 
NF-κB signalling (Malinin et al., 1997; O'Mahony et al., 2000; Demchenko and Glebov, 2010) 
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1.4.1 NF-κB and the Sézary syndrome 
Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of skin-associated 
neoplasms and unlike some B cell lymphomas, CTCLs are rarely curable. Mycosis 
fungoides (MF) and Sézary syndrome (SS) are the most common variants of CTCL. MF is 
confined to the skin and is characterised by erythematous patches, plaques, and less 
frequently, tumors. MF is a slow-progressing disease, defined by indolent clinical behaviour. 
In contrast, the more aggressive and systemic SS, considered the leukemic subtype of 
CTCL, is clinically characterised by a triad of generalized erythroderma (defined as affecting  
<80% of the body surface area), lymphadenopathy and the presence of 5% or more 
malignant clonal T cells with cerebriform nuclei (known as Sézary cells) (Booken et al., 2008; 
Diamandidou and Cohen, 1996; Dippel et al., 2003; Klemke et al., 2005; Hwang et al.). 
Interestingly, malignant MF and Sézary cells exhibit a TH2 cytokine pattern. Clinical 
treatment of patients with TH1 or TH1-inducing cytokines (IL-12 and IL-2) as well as 
interferon-α and –β was shown to be beneficial (Kaplan et al., 1990; Rook et al., 1999). SS 
ultimately results in immunosuppression, due to the clonal expansion of Sézary cells and 
the collapse of the normal T cell repertoire (Yawalkar et al., 2003). The breakdown of the T 
cell compartment results in high susceptibility to pathogens that will ultimately result in 
lethal infections (sepsis). Accordingly, SS patients have an overall low median survival rate 
of two to four years. 
Several publications have established a direct link between aberrant NF-κB activation and 
the pathogenesis of SS. One report describes a chromosomal rearrangement that results in 
a truncated version of the NFKB2 gene (encoding p100) in the CTCL cell line Hut78. The 
truncated p100 protein was shown to be devoid of its C-terminus and to accumulate in the 
nucleus in the absence of any stimuli (Zhang et al., 1994). These findings were further 
substantiated by the discovery that p65 in the CTCL cell lines Hut78, MyLa, SeAx and HH 
exhibited constitutive DNA-binding activity (Izban et al., 2000). DNA binding could be 
counteracted by chemical inhibition of NF-κB. A more recent study extends this observation 
to primary Sézary cells and conclusively shows that inhibition of IKKβ is sufficient to drive 
CTCL cells into apoptosis (Sors et al., 2008; ) . Moreover, overexpression of an IκBα super-
suppressor led to apoptosis in several CTCL cell lines (Sors et al., 2006), indicating that 
Sézary cells are oncogenically addicted to constitutive NF-κB activity. A publication from 
our laboratory uncovered one possible molecular explanation for the selective death 
response of CTCL cells upon treatment with IKK inhibitors. Targeting of NF-κB with different 
compounds lead to a marked decrease of ferritin-heavy-chain (FHC) expression (Kiessling 
et al., 2009). FHC is an iron storage protein whose expression depends on NF-κB. 
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Downregulation of FHC induced an increase of free intracellular Fe2+-ions, resulting in 
massive production of reactive oxygen species (ROS) and ROS-dependent cell death in 
vitro and in vivo. 
Recently we uncovered a role for the PP4c:PP4R1 phosphatase holoenzyme (see paragraph 
1.3.6) that controls IKK activity in activated human T cells (Brechmann, 2010; Brechmann 
and Mock et al., manuscript in preparation). Interestingly, we found PP4R1 expression to be 
significantly reduced or absent in two CTCL cell lines (Hut78 and HH) as well as in a small 
cohort of SS patients. Ectopic re-expression of PP4R1 in those deficient cell lines sensitised 
cells towards apoptosis. Concomitantly, re-expression of PP4R1 suppressed constitutive 
IKK activity in HH cells. This effect was specific for PP4R1, since control overexpression of 
PP2CA was not sufficient to induce apoptosis. Therefore, absence of PP4R1 may be one 
causative factor that drives NF-κB-dependent lymphomagenesis in a subgroup of CTCLs 
(Brechmann and Mock et al., manuscript in preparation). However, the exact molecular 
lesions leading to persistent IKK and NF-κB activation in CTCL remain to be uncovered. 
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Aim of the study 
 
TCR-induced signalling to NF-κB relies on the concerted action of kinases and their 
phosphorylated substrates, including receptor proximal protein complexes and the  
NF-κB core components themselves. Hence, phosphorylation events cover every step of 
NF-κB activation. Although most phosphorylations on target proteins are of transient nature, 
implying the involvement of phosphatases, the role of phosphatases in NF-κB activation or 
signal termination has not been thoroughly studied in T lymphocytes to date.  
Therefore, a RNAi screening approach, using a NF-κB reporter Jurkat T cell line, was 
performed to identify NF-κB-modulating phosphatases. Using this approach, we have 
previously identified and characterised the PP4c:PP4R1 phosphatase holoenzyme. We have 
shown that PP4c:PP4R1 negatively regulates IKK activity in activated human T cells and 
that loss of PP4R1 may contribute to survival of a subset of human CTCL cells (Brechmann, 
2010; Brechmann and Mock et al., manuscript in preparation). These findings underscored 
the validity of our screening approach and prompted us to investigate other putative 
candidate hits, among which PP1α was found as a putative positive regulator of NF-κB. 
PP1α gained special interest, since it is predominantly expressed in cells of the 
hematopoietic system, suggesting an important function in this cellular compartment. The 
present study was therefore conducted to validate PP1α as a positive regulator of NF-κB in 
T cells with the following objectives: (i) validation of the primary RNAi screen, using different 
and independent experimental readouts; (ii) biochemical characterisation of the NF-κB 
pathway in the presence or absence of PP1α; (iii) identification and characterisation of PP1α 
substrates; (iv) characterisation of the physiological function of PP1α in T cells;  
(v) evaluation of PP1α as a potential therapeutic target in malignant CTCL cells. 
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2. Materials 
2.1 Chemicals, reagents & consumables  
All chemicals and reagents were purchased from Serva (Heidelberg), Fluka (Neu-Ulm), 
Sigma (München), Roth (Karlsruhe) and Merck (Darmstadt), unless otherwise indicated. 
2.1.1 Consumables  
Name Company 
96-well plates for qRT-PCR Applied Biosystems 
Amersham HyperfilmTM ECL GE Healthcare 
AmershamTM HybiondTM-N nylon membrane GE Healthcare 
AmershamTM HybiondTM-ECL nitrocellulose membrane GE Healthcare 
Cell culture plates and flasks TPP/Greiner 
Electropuration cuvettes (4 mm) BioRad 
ELISA 96-well plates costar® 
Gaussia-Glow Juice p.j.k. 
Gene RulerTM 1 kb DNA ladder Fermentas 
High Sensitivity” ECL substrate solution: Immobilon 
Western chemiluminescent HRP substrate Millipore 
LS columns Miltenyi Biotec 
Pipette tips TipOne 
Reaction tubes (1.5, 2 ml) Eppendorf 
Reaction tubes (5, 15, 50 ml) BectonDickinson/Nunc/TPP 
Reaction tubes for PCR TipOne 
Sealing strips Applied Biosystems 
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2.1.2 Commercial kits and reagents 
All kits and reagents were used according to the manufacturers instructions, unless 
otherwise described.  
 
Serological pipettes Becton Dickinson/Greiner 
Sterile filters (0.22 µm, 0.45 µm) Millipore 
Trypan blue Sigma 
Whatman Blotting paper Biorad/Schleicher & Schuell 
Name Company 
Cell Line Nucleofector® Kit V Lonza 
Cell Lysis Buffer (10x) Cell Signalling Technology 
CellTiter-Glo® Luminescent Cell Viability Assay Promega 
Dual-Light® System Applied Biosystems 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Human IFNg, IL-2, TNFa ELISA BD Bioscience 
Human IL-8 ELISA  Immunotools 
Human T Cell Nucleofector® Kit  Lonza 
KOD Hot Star Polymerase Kit Novagen 
Lightshift® Chemiluminescent EMSA Kit Thermo Scientific 
NE-PER Nuclear and Cytoplasmic Extraction Reagents Thermo Scientific 
o-Phenylenediamine dihydrochloride tablets for ELISA Sigma 
PhosSTOP, Phosphatase inhibitor tablet Roche 
Power SYBR® Green PCR Master Mix Applied Biosystems 
Protein A Sepharose beads Sigma 
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2.1.3 Reagents and kits for T cell isolation 
   
Protein molecular weight standard New England Biolabs (NEB 
Proteinase Inhibitor Cocktail Roche 
QIAEX II Gel extraction Kit Qiagen 
Qiagen® Plasmid Maxi Kit Qiagen 
Qiagen® Plasmid Mini Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
RNAqueous®-Micro Kit Applied Biosystems 
Roti®-Quant Bradford assay Roth 
SensoLyte® pNPP Protein Phosphatase Assay AnaSpec 
Signal Boost immunoreaction enhancer kit Calbiochem (Merck) 
Streptavidin-HRP Jackson ImmunoResearch 
Transcriptor High Fidelity cDNA Synthesis Kit Roche 
TRIzol® Reagent Invitrogen 
Western LightningTM Plus-ECL reagent PerkinElmer 
Name Company 
CD4 MicroBeads Miltenyi Biotec 
CD4+ T cell isolation kit II, human Miltenyi Biotec 
CD25 MicroBeads Miltenyi Biotec 
Ficoll  Biochrom 
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2.1.4 Reagents for treatment of cells 
 
2.2 Buffers and solutions 
Buffers and solutions were prepared in sterile double distilled water (ddH2O). Lysis buffer for 
lysis of eukaryotic cells were freshly supplemented with Proteinase Inhibitor Cocktail Tablets 
(Roche) with 1 tablet per 50 ml  and 1 tablet of PhosSTOP phosphatase inhibitor cocktail 
(Roche) per 15 ml of 1x lysis buffer. 
 
Name Composition 
ACK buffer (10x) 
41.45 g NH4Cl  
5.0 g KHCO3  
0.186 g EDTA 
pH 7.27 
ad 500 ml ddH2O 
Name Company 
Chloroquine Sigma 
5(6)-Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) Sigma 
Doxycycline Sigma 
Ionomycin Sigma 
Phorbol 12-myristate 13-acetate (PMA) Sigma 
Phytohemagglutinin (PHA) Sigma 
Polybrene Millipore 
Recombinant IL-2 Cell	  line	  LBRM-­‐33	  5A4;	  (Gillis	  et	  al.,	  1980)	  
Recombinant TNFα BASF 
Tautomycetin Tocris Bioscience 
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Cell Lysis Buffer (10x) 
20 mM Tris-HCl (pH 7.5) 
150 mM NaCl 
1 mM Na2EDTA 
1 mM EGTA 
1% Triton X100 
2.5 mM sodium pyrophosphate 
1 mM β-glycerophosphate 
1 mM Na3VO4 
1 µg/ml leupeptin 
Citrate buffer (ELISA) 
6.9 g Citric acid  
20.95 g Sodium citrate dihydrate  
pH 5.0 
ad 1 l ddH2O 
Coating Buffer (ELISA) 
8.4 g NaHCO3 
3.56 g Na2CO3 
pH 9.6 
ad 1 l ddH2O 
DNA sample buffer()6x) 30 % (v/v) glycerine 0.36 % (w/v) bromophenol blue (BPB) 
FACS Buffer 
5% FCS  
0.1% NaN3  
in PBS 
HBS (10x) 
1.4 M NaCl 
100 mM KCl  
500 mM HEPES  
20 mM Na2HPO4  
22.2 mM Glucose pH 6.5 
KCM buffer (5x) 
500 mM KCl  
150 mM CaCl2  
250 mM MgCl2 
Kinase buffer 
50 mM Tris/HCl pH 8.0  
5 mM MgCl2  
2 mM MnCl2  
0.5 mM DTT 
MACS buffer 
0.5% BSA  
2 mM EDTA  
in PBS 
Nicoletti lysis buffer 
0.1% (w/v) sodium citrate pH 7.4 
0.1% (v/v) Triton X-100 
50 µg/ml propidium iodide 
PBS  
137 mM NaCl  
8.1 mM Na2HPO4  
2.7 mM KCl  
1.5 mM KH2PO4 pH 7.4 
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PBS-T PBS 0.05% (v/v) Tween 
Reducing sample buffer (2x) 
4% SDS (w/v) 
10% 2-mercaptoethanol 
20% glycerol 
0,004% bromphenol blue 
100 mM Tris-HCl 
Reducing sample buffer (5x) 
10% SDS (w/v) 
25% 2-mercaptoethanol 
50% glycerol 
0.01% bromphenol blue 
250 mM Tris-HCl 
RIPA buffer 
120 mM NaCl  
50 mM Tris/HCl pH 7.5  
0.5% (w/v) Desoxycholate  
1 mM Dithiothreitol 
SDS PAGE runnung bufer 
25 mM Tris  
0.19 M Glycin  
1% (w/v) SDS 
SDS seperating gel buffer 
37.5 mM Tris-HCl pH = 8.8 
8-12% (w/v) Acrylamid/Bisacrylamid 37,5:1  
0.1% (w/v) SDS  
0.03% (w/v) Ammonium persulfate (APS) 
0.1% (w/v) Tetramethylethylendiamin (TEMED) 
SDS stacking gel buffer 
24 mM Tris-HCl pH 6,8  
5 % (w/v) Acrylamid/Bisacrylamid 37,5:1  
0.1% (w/v) SDS  
0.1% (w/v) APS  
0.1% (w/v) TEMED 
Stripping buffer 
15 g glycine 
1g SDS 
10ml Tween20 
pH 2,2 
ad 1 l ddH2O 
TAE buffer (1x) 
40 mM Tris/HCl  
20 mM Acetic acid  
1 mM EDTA 
pH 8.3 
TBE buffer (10x) 
890 mM Tris base 
890 mM Boric acid 
20mM EDTA pH 8.0 
TBS  20 mM Tris/Cl pH 7.2  150 mM NaCl 
TBS-T 1x TBS  0,1% (w/v) Tween-20 
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Transfer buffer (wet blot transfer) 
25 mM Tris  
192 mM Glycine 
 20% (v/v) Methanol 
TSB solution 
10 mM MgCl2  
10 mM MgSO4  
5% (v/v) DMSO  
10% (v/v) PEG 6000 in LB medium 
 
2.3 Culture Reagents 
Unless otherwise indicated, all media for culture of eukaryotic cells were supplemented with 
10% heat-inactivated FCS (v/v) and 1% (v/v) penicillin/streptomycin. For selection of stably 
transduced Jurkat, Hut78 or HH cells, respective media were supplemented with 1 µg/ml 
puromycin. All media were stored at 4°C and prewarmed to 37°C before use: 
2.3.1 Reagents for bacterial culture 
Media for E. coli were autoclaved and stored at 4°C. Autoclavation of liquids was carried out 
at 125°C for 30 min. To ensure plasmid propagation LB medium and LB agar plates were 
supplemented with 50-100 μg/ml ampicillin or 30 μg /ml kanamycin. 
 
 
 
Medium Constituents 
Luria Broth (LB) Medium 
10g tryptone 
5 g yeast extract 
10 g NaCl 
pH 7.0 
ad 1 l ddH2O 
LB Agar 20g Agar in 1 l LB Medium 
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2.3.2 Reagents for eukaryotic cell culture 
Culture media 
 
 
 
Cell culture supplements 
 
2.4 Biological material 
2.4.1 Bacteria 
For plasmid propagation the E. coli strain DH5α was utilised. 
 
Name Company 
Dulbecco's Modified Eagle Medium (DMEM) Sigma 
Iscove's Modified Eagle Medium (IMDM) Gibco 
Roswell Park Memorial Institute (RPMI) 1640 
medium Sigma 
X-Vivo 15 Medium Lonza 
Reagent Company 
Fetal Calf Serum (FCS) Biochrom/Gibco 
Penicillin/Streptomycin Sigma 
Puromycin Sigma 
Trypsin/EDTA Sigma/Gibco 
Name Company 
DH5α Invitrogen 
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2.4.2 Eukaryotic cell lines 
 
Name Description 
Gluc-J16 
Reporter T cell line derived from J16-145 with stable genomic 
integration of a NF-kB-dependent Gaussia luciferase. cassette 
(Brechmann and Mock et al., 2011) 
HEK293T (CRL-11268) Human embryonic kidney cell line (Pear et al., 1993). 
HEK293FT subclone of HEK293T.  
HH (CRL-2105) Human CTCL derived from a patient with Sézary syndrome (Starkebaum et al., 1991) 
Hut78 (TIB-161) Human CTCL cell line derived from a patient with Sézary syndrome (Gootenberg et al., 1981). 
JE6.1 (TB-152) Human lymphoblastoid cell line derived from acute T cell leukemia cell line (Schneider et al., 1977). 
J16-145 Subclone of the human lymphoblastoid cell line J16. 
JE6.1 shContr. Jurkat T cell line stably transduced with a Doxycycline-inducible non-targeting shRNA expression cassette.  
JE6.1 shPP1α #47 Jurkat T cell line stably transduced with a Doxycycline-inducible PP1α-targeting shRNA expression cassette.  
JE6.1 shPP1α #34 Jurkat T cell line stably transduced with a Doxycycline-inducible PP1α-targeting shRNA expression cassette.  
JE6.1 shPP1α #50 Jurkat T cell line stably transduced with a Doxycycline-inducible PP1α-targeting shRNA expression cassette.  
 
 
48 2. Materials Thomas Mock 
2.5 Materials for molecular biology 
2.5.1 qRT-PCR primers 
Primers for SYBR Green qRT-PCR were designed using the online  primer designing tool 
Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). In General all primers were 
designed to span exon-exon junctions with primer efficiencies between at least 1.7 and 2.0. 
All primers for qRT-PCR were synthesized by MWG Biotech or Sigma. 
  
 
 
Gene Primer Sequence (5' -> 3') 
A20 
forward TGCGGCACCCTTGGAAGCAC   
reverse TGCGCTGGCTCGATCTCAGTT   
CD25 
forward CACTCGGAACACAACGAAACA 
reverse TGTGGCTTCATTTTCCCATG 
CD69 
forward GCTCTTTGCATCCGGAGAGTGGA 
reverse ACAGCACACAGGACAGGAACTTGG 
HPRT1 
forward TGACACTGGCAAAACAATGCA 
reverse GGTCCTTTTCACCAGCAAGCT 
IL-2 
forward AAGTTTTACATGCCCAAGAAGG 
reverse AAGTGAAAGTTTTTGCTTTGAGCTA 
IL-8 
forward GAATGGGTTTGCTAGAATGTGATA 
reverse CAGACTAGGGTTGCCAGATTTAAC 
IFNG 
forward TTCAGCTCTGCATCGTTTTGG 
reverse TCCGCTACATCTGAATGACCTG 
NFKBIA 
forward CGCCCAAGCACCCGGATACA 
reverse AGGGCAGCTCGTCCTCTGTGA 
PP1CA 
forward TGGCCAAGTTCCTCCACAA 
reverse GCCGCTTGGCAAAGAACTC 
RelA forward CGGGATGGCTTCTATGAGG reverse CTCCAGGTCCCGCTTCTT 
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2.5.2 PCR primers for gene cloning 
For cloning of HA-tagged human PP1CA as well as FLAG-tagged PP1CA, the primers listed 
below were used. Amplicons were BamHI/NotI-digested and ligated into derivatives of the 
pEF4 expression vector (Invitrogen) containing 5’-HA or 5’-FLAG-epitope tags 
(pEF4:HA/pEF4:FLAG) (see 2.5.7). PCR primers were synthesized by MWG Biotech or 
Sigma. 
 
 
2.5.3 DNA oligonucleotides for electromobility shift assay 
Electromobility shift assays (EMSAs) were performed using the following DNA 
oligonucleotides, which were biotinylated at their 5’ – ends. To retrieve double stranded 
DNA, sense and antisense DNA oligonucleotides were mixed in equal amounts and 
incubated for 5 minutes at 95°C in a heat block. After incubation, the heat block was turned 
off and the oligonucleotide mixture was cooled down to room temperature. DNA oligos were 
purchased from Sigma. Biotinylation of 5’-ends was performed by Sigma.  
 
Binding 
transcription factor strand Sequence (5' -> 3') 
NF-κB 
sense GGATCCTCAACAGAGGGGACTTTCCGAGGCCA 
antisense TGGCCTCGGAAAGTCCCCTCTGTTGAGGATCC 
NF-Y 
sense TTTTCTGATTGGTTAAAA 
antisense TTTTAACCAATCAGAAA 
 
Primer Sequence (5' -> 3') Target vector 
PP1CA_BamHI 
forward CGCGGATCCGCGGGCTCCGACAGCGAGAAGCTCAA pEF4:HA / pEF4:Flag 
PPP1CA_NotI 
reverse 
ATAGTTTAGCGGCCGCCTATTTCTTGGCTTTGGCGGAA
TTG pEF4:HA / pEF4:Flag 
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2.5.4 siRNA for gene transcript silencing 
siRNAs were dissolved in RNase-free H2O with a final concentration of 20 µM and 10 µl 
aliquots were  stored at -80°C until use. 
 
siRNA targeted gene Sequqnece (5' -> 3') Company 
siContr. non-targeting UUCUCCGAACGUGUCACGUTT Qiagen 
siCYLD CYLD GAUUGUUACUUCUAUCAAATT Applied Biosystems 
siCARMA1#1 CARMA1 ACUCGAGAUCGAUCAGCUATT Qiagen 
siPP1CA #1 PPP1CA CAUCUAUGGUUUCUACGAUTT Applied Biosystems 
siPP1CA #2 PPP1CA CGAGAGCAACUACCUCUUUTT Applied Biosystems 
siPP1CA #3 PPP1CA CGACCUUCUGCGACUAUUUTT Applied Biosystems 
siRelA RelA CCAUCAACUAUGAUGAGUUTT Applied Biosystems 
 
2.5.5 shRNAs for gene transcript silencing 
All shRNA sequence clones targeting PP1CA were obtained as glycerol stocks from Open 
Biosystems. As a negative control a non-targeting shRNA control vector was used. All 
shRNA sequence clones were used from pGIPZ shRNAmir lentiviral vectors. shRNA 
cassettes were cloned into the pTRIPZ inducible shRNAmir vector from Open Biosystems 
according to the manufacturers instructions. 
 
 
 
Clone ID target gene shRNA sequence (5' -> 3') 
V2LHS_26
2414 (#14) PP1CA 
TGCTGTTGACAGTGAGCGACGCATCTATGGTTTCTACGATTAGTGAAGCCA
CAGATGTAATCGTAGAAACCATAGATGCGGTGCCTACTGCCTCGGA 
V3LHS_63
5636 (#36) PP1CA 
TGCTGTTGACAGTGAGCGATACGACCTTCTGCGACTATTTTAGTGAAGCCA
CAGATGTAAAATAGTCGCAGAAGGTCGTAGTGCCTACTGCCTCGGA 
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V3LHS_63
5635 (#35) PP1CA 
TGCTGTTGACAGTGAGCGACAGCGAGAAGCTCAACCTGGATAGTGAAGCC
ACAGATGTATCCAGGTTGAGCTTCTCGCTGTTGCCTACTGCCTCGGA 
V3LHS_63
5634 (#34) PP1CA 
TGCTGTTGACAGTGAGCGACGCGGCCATAGTGGACGAAAATAGTGAAGCC
ACAGATGTATTTTCGTCCACTATGGCCGCGATGCCTACTGCCTCGGA 
 
V3LHS_63
5633 (#33) 
PP1CA TGCTGTTGACAGTGAGCGACGGCTACGAGTTCTTTGCCAATAGTGAAGCCACAGATGTATTGGCAAAGAACTCGTAGCCGTTGCCTACTGCCTCGGA 
V3LHS_31
8050 (#50) PP1CA 
TGCTGTTGACAGTGAGCGACTCAAGATCTGCGGTGACATATAGTGAAGCCA
CAGATGTATATGTCACCGCAGATCTTGAGGTGCCTACTGCCTCGGA 
V3LHS_31
8046 (#46) PP1CA 
TGCTGTTGACAGTGAGCGCCGGCTACGAGTTCTTTGCCAATAGTGAAGCCA
CAGATGTATTGGCAAAGAACTCGTAGCCGTTGCCTACTGCCTCGGA 
V3LHS_31
8047 (#47) PP1CA 
TGCTGTTGACAGTGAGCGCCGCGGCCATAGTGGACGAAAATAGTGAAGCC
ACAGATGTATTTTCGTCCACTATGGCCGCGATGCCTACTGCCTCGGA 
V3LHS_31
8051 (#51) PP1CA 
TGCTGTTGACAGTGAGCGCCCAGGTGGTAGAAGACGGCTATAGTGAAGCC
ACAGATGTATAGCCGTCTTCTACCACCTGGTTGCCTACTGCCTCGGA 
  
non-
targetin
g 
not available 
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2.5.6 Enzymes 
All restriction endonucleases were purchased from Fermentas or New England Biolabs 
(NEB). KOD DNA polymerase was purchased from Novagen®. T4 DNA ligase as well as calf 
intestinal phosphatase (CIP) were obtained from Fermentas. All enzymes were used 
according to the manufacturer’s instructions. 
2.5.7 Vectors 
Vector Description Origin/Reference 
pEF4:HA Derivative of the pEF4 eukaryotic expression vector with a 5’ single HA tag 
Invitrogen/ J. Hoffmann, 
DKFZ 
pEF4:HA-PP1CA pEF4:HA derivative encoding for HA-tagged human PP1CA full-length protein This study 
pEF4:Flag Derivative of the pEF4 eukaryotic expression vector with a 5’ single FLAG tag 
Invitrogen/ J. Hoffmann, 
DKFZ 
pEF4:Flag-PP1CA pEF4:Flag derivative encoding for Flag-tagged human PP1CA full-length protein This study 
8xNF-κB-pGluc 
pGluc basic derivative with a Gaussia 
reporter cassette under control of the 
mouse c-fos promoter and eight kB sites 
Brechmann, 2010 /  
Arnold et al., 2001 
8xNF-κB-pGL 
pGL derivative with a firefly reporter 
cassette under control of the mouse c-fos 
promoter and eight kB sites 
Arnold et al., 2001 
pfosLacZ 
pSDK derivative encoding for b-
galactosidase under control of the mouse 
c-fos promoter 
Arnold et al., 2001 
pTRIPZ inducible 
shRNAmir (empty vector) 
Lentiviral inducible shRNAmir expression 
vector Open Biosystems 
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2.6 Antibodies 
2.6.1 Antibodies for immunoblot analysis 
Primary antibodies for immunoblot analysis were diluted, as indicated in the table, in  
TBS-T, containing 5% BSA and 0,02% NaN3. Secondary, horseradish peroxidase (HRP)-
conjugated, antibodies were diluted 1:10000 in TBS-T, containing 1% non-fat, dry milk. 
pTRIPZ shPP1CA #14 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V2LHS_262414) 
Open Biosystems / This 
study 
pTRIPZ shPP1CA #36 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V3LHS_635636) 
Open Biosystems / This 
study 
pTRIPZshPP1CA  #35 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V3LHS_635635) 
Open Biosystems / This 
study 
pTRIPZ shPP1CA #34 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V3LHS_635634) 
Open Biosystems / This 
study 
pTRIPZ shPP1CA #33 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID:  
V3LHS_635633) 
Open Biosystems / This 
study 
pTRIPZ shPP1CA #50 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V3LHS_318050) 
Open Biosystems / This 
study 
pTRIPZ shPP1CA #46 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V3LHS_318046) 
Open Biosystems / This 
study 
pTRIPZ shPP1CA #47 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V3LHS_318047) 
Open Biosystems / This 
study 
pTRIPZ shPP1CA #51 
Derivative of pTRIPZ inducible shRNAmir 
with shRNA cassette targeting PP1CA 
retrieved from pGIPZ vector (Clone ID: 
V3LHS_318051) 
Open Biosystems / This 
study 
 
54 2. Materials Thomas Mock 
Alternatively, for detection of phospho-proteins, secondary antibodies were diluted 1:10000 
in Signal Boost enhancer solution for secondary antibodies (Calbiochem). 
 
(i)  primary antibodies for immune-blotting (IB) and immune-precipitation (IP) 
 
Name Species and Isotype Antigen Dilution Company 
Anti-β-Actin Rabbit, polyclonal β-actin 1:8000 (IB) Sigma 
Anti-cRel Rabbit, polyclonal  c-Rel 1:1000 (IB)  SCBT 
Anti-ERK1 
(MK12) Mouse, IgG1 Erk1 1:1000 (IB)  
BD  
Bioscience 
Anti-FLAG (M2) Mouse, IgG1 Flag epitope 1:1000 (IB),  2 µl (IP)  Sigma 
Anti-HA (12CA5) Mouse, IgG2b HA epitope 
100 µl  
hybridoma  
supernatant  
(IP) 
selfmade 
Anti-HA (3F10) Rat, polyclonal HA epitope 1:1000 (IB) Roche 
Anti-IkBα  Mouse, IgG1 β-actin 1:1000 (IB)  CST 
Anti-IkBβ Mouse, IgG2a IkBβ 1:1000 (IB)  SCBT 
Anti-IkBε Rabbit, polyclonal IkBε 1:1000 (IB)  CST 
Anti-IKKα  Rabbit, polyclonal IKKα  1:1000 (IB) CST 
Anti-IKKβ 
(10A9B6) Mouse, IgG1 IKKβ 1:500 (IB) Imgenex 
Anti-IKKγ (FL-
419) Rabbit, polyclonal IKKγ 
1:1000 (IB),  
5 µl (IP) SCBT 
Anti-p-ERK1/2 Mouse, IgG2a 
phospho-Erk1 
(T202/Y204) 
and  phospho-
Erk2 
(T180/Y182) 
1:2000 (IB) SCBT 
Anti-p-IkBα (5A5) Mouse, IgG1 phospho-IkBα (S32/S36) 1:1000 (IB) CST 
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(ii) secondary HRP-conjugated antibodies for immune-blot analysis 
 
Anti-p-IKKα/β 
(S180/S181) Rabbit, polyclonal 
phospho-IKKα 
(S180) and 
phospho-IKKβ 
(S181) 
1:1000 (IB) CST 
Anti-p-IKKα/β 
(S176/S177) Rabbit, polyclonal 
phospho-IKKα 
(S176) and 
phospho-IKKβ 
(S177) 
1:1000 (IB) CST 
Anti-p-P65 (s536) Rabbit, polyclonal phospho-P65 (S536) 1:1000 (IB) CST 
Anti-p-P38 
(T180/Y182) Rabbit, polyclonal 
phospho-P38 
(T180/Y182) 1:2000 (IB) CST 
Anti-PP1α Mouse, IgG1 PP1α 1:2000 (IB) Invitrogen 
Anti-p105/p50 Goat, polyclonal p105/p50 1:1000 (IB) CST 
Anti-p38 Rabbit, polyclonal p38 1:1000 (IB) CST 
Anti-p65 Rabbit, polyclonal p65 1:1000 (IB) CST 
Anti-Tubulin (B-
5-1-2) Mouse, IgG1 Tubulin 1:10000 (IB) Sigma 
Name Species and Isotype Antigen Dilution Company 
Anti-IgG1-HRP Goat, polyclonal Mouse-IgG1 1:10000  (IB) SCBT 
Anti-IgG2a-HRP Goat, polyclonal Mouse-IgG2a 1:10000  (IB) SCBT 
Anti-IgG2b-HRP Goat, polyclonal Mouse-IgG2b 1:10000  (IB) SCBT 
Anti-Goat-IgG-HRP Sheep polyclonal Goat-IgG 1:10000  (IB) SCBT 
Anti-Rabbit-IgG-HRP Goat, polyclonal Rabbit-IgG 1:10000  (IB) SCBT 
Anti-Rat-IgG Goat, polyclonal Rat-IgG 1:10000  (IB) SCBT 
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2.6.2 Antibodies for T cell stimulation 
Name Species and Isotype Antigen Company 
Anti-CD3 (OKT3) Mouse-IgG2a CD3 SCBT 
Anti-CD28 (CD28.2) Mouse-IgG1 CD28 Beckton Dickinson 
Anti-Mouse goat-polyclonal Mouse-IgG Southern Biotechnology 
2.7 Instruments 
Instrument Company 
ABI 7500 Standard qPCR Applied Biosystems 
Agarose gel electrophoresis apparatus GIBCO BRL 
Analytical and precision balances Mettler 
Bacteria culture incubator/shaker CH-403 Infors AG 
Centrifuges 
- Biofuge Fresco 17 
- Biofuge A 
- Megafuge 3.0R 
Sorvall Evolution RC 
Heraeus 
Chemiluminesence detector Chemi-Smart 5100 Vilber Lourmat 
CO2-cell culture incubator Stericult Forma Scientific 
Developing system for Roentgen films Curix 160 Agfa-Gevaert 
Electrophoresis power suply PS500 Renner 
Electroporation System Gene Pulser II Bio-Rad 
FACS Canto II Beckton Dickinson 
Freezer 
- -20°C 
- -80°C 
Liebherr 
Forma Scientific 
Gel documentation system Bio-Rad 
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2.8 Software 
GeneAmp PCR-System 9700 Applied Biosystems 
Laminar chambers Baker Company 
Orion L Microplate Luminometer Berthold Detection Systems 
Microplate reader 680 Bio-Rad 
Microscopes: 
- Fluorescence microscope Labovert FS 
- Light microscope ID 02 
Leica 
Zeiss 
Microwave oven HMG 730G Bosch 
Mini-PROTEAN Tetra Electrophoresis System Bio-Rad 
Mini Trans-Blot Cell Bio-Rad 
Neubauer counting chamber Brand 
NanoDrop ND-1000 Peqlab 
pH-meter Calimatic LHD Labortechnik 
Spectrophotometer BioPhotometer Eppendorf 
Thermocycler DNA Engine DYAD MJ Research 
Thermal Cycler C1000 Bio-Rad 
Thermostated hot block 5320 Eppendorf 
Waterbaths Köttermann 
Instrument Company 
7500 Software (Version 2.0.1) Applied Biosystems 
4Peaks (Version 1.7) Mekentosj 
 
58 2. Materials Thomas Mock 
 
 
 
Bio-1D Vilber Lourmat 
Chemi-Capt  Vilber Lourmat 
EnzymeX 3 Mekentosj 
FACSDIVA Beckton Dickinson 
Microsoft office:mac 2008 (Version 12.3.1)  Microsoft 
Microsoft office:mac 2011 (Version 14.1.3) Microsoft 
Papers2 (Version 2.0.9) Mekentosj 
Photoshop CS4 Extended (Version 11.0) Adobe 
Simplicity 4.10 Berthold Detection Systems 
Mac OS X 10.6.8 Apple Inc. 
7500 Software (Version 2.0.1) Applied Biosystems 
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3.  Methods 
3.1  Methods in Molecular Biology 
3.1.1 Cultivation and storage of bacteria 
 
Bacteria were cultured under aerobic conditions at 37°C in a rotary shaker at 180 rpm. For 
propagation of plasmids, LB media were supplemented with ampicillin (100 µg/ml), 
kanamycin (30 µg/ml) or zeocin (25 µg/ml) and inoculated with cells of a single colony of 
transformed bacteria. For long term bacteria strain storage, 1 ml freshly saturated bacterial 
culture was pelleted at 3000 g for 5 minutes. The supernatant was discarded and the 
bacterial pellet was resuspended in 1⁄4 volume of LB. Then 1⁄4 volume of 100% glycerol 
was added and the cell suspension mixed. Bacteria were stored at -80°C 
 
3.1.2 Generation of KCM-competent bacteria  
 
For the generation of transformation competent E. coli cells, 100 ml LB medium without 
antibiotics were inoculated with 1 ml overnight culture of E. coli. The culture was grown until 
an OD600 value of 0.5-0.6 was reached. The bacterial suspension was incubated on ice for 
10 minutes and then harvested at 1,500 g and 4°C for 15 minutes. The supernatant was 
removed and the bacterial pellet was resuspended in 7.5 ml TSB solution. After incubation 
on ice for 1 h the bacteria were shock-frozen with liquid nitrogen, and aliquots of 100 µl 
were stored at -80 °C until use. 
 
3.1.3 Transformation of KCM-competent bacteria 
 
100 µl aliquots of KCM-competent bacteria were thawed on ice. Subsequently 100 µl of 1x 
KCM, containing a suitable amount of plasmid DNA (100 – 500 ng) or 20 µl of a ligation 
sample were added to the bacterial suspension.  The transformation sample was incubated 
on ice for 20 minutes, followed by 10 minutes of incubation at room temperature (RT). For 
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regeneration, 800 µl of pre-warmed LB medium without antibiotics was added and cells 
were incubated at 37°C for 45 minutes in a rotary shaker. After regeneration, bacteria were 
centrifuged at 2000 g for 2 minutes. The supernatant was discarded and the bacterial pellet 
was resuspended in 200 µl of LB Medium. The suspension was spread onto LB-Agar plates, 
containing appropriate antibiotics and were incubated at 37°C overnight. 
3.1.4 Plasmid preparation on analytical scale (miniprep) 
For analytical plasmid isolation 5 ml of LB medium, supplemented with an appropriate 
antibiotic, were inoculated with a single bacterial colony and the culture was grown at 37°C 
in a shaker overnight. The next day the plasmid DNA was isolated using the Qiagen® 
Plasmid Mini Kit according to the manufacturer’s instructions. 
3.1.5 Plasmid preparation on preparative scale (maxiprep) 
For the production of larger amounts of plasmid DNA, 100-250 ml of LB medium, containing 
appropriate antibiotics, were inoculated and the cultures were grown at 37°C in a shaker 
overnight. The preparation of plasmid DNA was carried out with the Qiagen® Plasmid Maxi 
Kit according to the manufacturer’s instructions. 
3.1.6 Photometric determination of DNA concentrations 
DNA concentrations were determined using a Biophotometer (Eppendorf) or a NanoDrop	  
ND-­‐1000. DNA concentrations can be approximately calculated by the following formula: 
OD260 = 1 refers to 50 µg/ml DNA (layer thickness of the cuvette: 1 cm). The ratio 
OD260/OD280 characterises the purity of DNA with values between 1.7 and 2.0 for pure DNA.	  
3.1.7 Isolation of total cellular RNA 
For the isolation of total cellular RNA from small amount of cells (1 to 5x105 cells), the 
RNAqueous®-Micro Kit (Applied Biosystems) was used according to he manufacturer’s 
protocol. For isolation of total cellular RNA from larger amounts of cells (0.1 to 1x107 cells) 
phenol-chloroform extraction was performed using TRIZOL© reagent. Cells were centrifuged 
at 2000 rpm for 5 minutes. Afterwards, the supernatant was discarded and up to 1x107 cells 
were lysed with 750 µl of TRIZOL reagent at RT for 5 minutes. Subsequently 150 µl of 
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chloroform was added and the mixture was inverted for 15 seconds, followed by a 2 
minutes incubation at room temperature. For phase separation, the TRIZOL/chloroform 
mixture was centrifuged at 12000 g for 15 minutes. The mixture separates into a lower red 
phenol-chloroform phase, an interphase and a colourless upper aqueous phase. The RNA 
remains exclusively in the upper phase. The aqueous phase was transferred into a fresh 
Eppendorf tube and mixed with an equal amount of 100% isopropanol, followed by 10 
minutes incubation at RT. Subsequently, the mixture was centrifuged at 12000 g for 10 
minutes to precipitate the RNA. After centrifugation, the supernatant was discarded and the 
RNA pellet was washed with 75% ethanol. After washing, the RNA pellet was air-dryed and 
subsequently resuspended in DEPC-treated water. RNA concentrations were 
photometrically determined using Nanodrop ND-1000. RNA was stored at -80°C. 
3.1.8 Reverse transcription of RNA into cDNA 
To produce cDNA from total RNA, the High Capacity Reverse Transcription Kit (Applied 
Biosystems) was used according to the manufacturer’s protocol. For one reverse 
transcription reaction  , 2 µg total RNA were used. One reaction mix contained the following 
components: 
 
Components volume / amount 
10x RT Buffer 2.0 µl 
25x dNTP (100mM) 0.8 µl 
10x RT Random Primers 2.0 µl 
Reverse Transcriptase 1.0 µl 
Rnase Inhibitor 1.0 µl 
Nuclease free H2O 3.2 µl 
total cellular RNA 2.0 µg/10 µl 
Nuclease free H2O x µl 
total 20 µl 
 
 
Reverse transcription reactions were performed using the conditions below. Synthesized 
cDNA was diluted 1:20 in sterile ddH2O and stored at –20°C. cDNA was used for 
quantification of gene expression by SYBR-based qRT-PCR. 
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Step Time; Temperature  
Annelaing 25°C 10 min 
Elongation 37°C 120 min 
Denaturation 85°C 5 min 
   
 
For cloning of individual genes, total RNA was extracted from Jurkat T cells and reverse 
transcribed using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche). The 
recombinant Transcriptor High Fidelity Transcriptase possesses enhanced proof-reading 
capability for high accuracy of  reverse transcription of RNA. 2 µg of total RNA  in a volume 
of 10 µl were mixed with 1 µl anchored oligo(dT)18 primers (50 pmol/µl) and filled up with  
0.4 µl ddH2O. To denature the template-primer mixture, samples were heated for 10 minutes 
at 65°C. Subsequently samples were stored on ice and the following components were 
added to a final volume of 20 µl. 
 
 
Components volume 
Transcriptor High Fidelity 
Reverse Transcriptase, 5x 
Reaction Buffer 
4.0 µl 
Protector RNase Inhibitor 0.5 µl 
dNTP mix /10mM) 2.0 µl 
DTT (100mM) 1.0 µl 
Transcriptor High Fidelity 
Transcriptase (10U) 1.1 µl 
Template-primer mix 11.4 µl 
total 20 µl 
 
 
All reagents were mixed and reverse transcription was performed under the following 
conditions 
 
 
 
 
Step Temperature; Time 
Elongation 50°C 30 min 
Denaturation 85°C 5 min 
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3.1.9 Polymerase chain reaction (PCR)  
The polymerase chain reaction (PCR) enables amplification of DNA fragments in vitro (Mullis 
et al., 1986). Short oligonucleotide fragments which anneal to the complementary strands of 
the DNA template in an inverse orientation determine the ends of the amplified DNA 
fragment. In the presence of dNTPs thermo stable DNA polymerases extend these forward- 
and reverse-primers along the denatured single stranded DNA generating a complementary 
DNA strand. 
Cloning and mutagenesis of tagged human PP1α was performed, using the KOD Hot Start 
Polymerase Kit (Novagen). KOD Hot Start DNA Polymerase is a pre-mixed complex of the 
high fidelity KOD DNA Polymerase and two monoclonal antibodies that inhibit the DNA 
polymerase at ambient temperatures (Mizuguchi et al., 1999). The KOD DNA polymerase 
possess a 3’→5’ proofreading capacity, which replaces mismatched 3’- terminal 
nucleotides from primer-template complexes. Primers were designed with 40% to 60% GC 
content, no internal secondary structure and complementarities at the 3’-end. PCR 
reactions were prepared on ice. PCR was performed according to the manufacturer’s 
recommendations under the following conditions.  
 
Component Volume/Amount Final concentration 
KOD buffer (10x) 5.0 µl 1x 
25 mM MgSO4 3.0 µl 1.5 mM 
dNTPs (2mM) 5.0 µl 0.2 µM (each) 
KOD Hot Start NA 
Polymerase (1 U/ml) 1.0 µl 0.02 U/µl 
Forward primer (100 µM) 0.25 µl 0.75 µM 
Reverse primer (100 µM) 0.25 µl 0.75 µM 
ddH2O 34.5 µl x µl 
Template DNA 1 µl (30-50 ng) 30-50 ng/50µl 
total volume 20 µl 
  
 
 
The following cycle conditions were applied. 
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3.1.10 Quantitative Real Time-PCR (qRT-PCR) 
Quantitative real-time PCR (qRT-PCT) relies on the quantification of incorporated 
fluorescent DNA-intercalating reporter dyes, like SYBR Green, which can be detected by a 
CCD camera during conventional PCR. Thereby DNA amplification products are already 
detected during synthesis, allowing relative and absolute quantification of transcripts 
without the danger of measuring saturated signals, which often limits analysis of semi-
quantitative RT-PCR. Incorporation of SYBR Green was detected using the ABI Prism 7500 
standard (Software: 7500 2.0.3) qRT-PCR cycler, which allows for measurements in a 96-
well format. Master mixes for triplicate measurements were prepared according to the 
following table. 
 
Component Volume 
Template cDNA 1 µl  
Forward primer (5 µM) 5.1 µl 
Reverse primer (5 µM) 5.1 µl 
Power SYBR© Green Master 
Mix (2x) 42.5 µl 
ddH2O 30.3 µl 
total volume 85 µl 
 
Reactions were carried out in triplicates with a final volume of 25 µl per reaction in a 96 well 
plate. The Power SYBR® Green PCR Master Mix contains 300 µl 110x SYBR Green buffer, 
360 µl 25 mM MgCl2, 240 µl dNTP(10  mM each), 15 µl U/µl Hot Gold Star Taq 
polymerase and 30 µl U/µl uracil-N-glycosylase. 
Relative gene expression levels were determined through cycle theshold values (Ct) by 
normalisation to the house-keeping genes hypoxanthine phosphoribosyltransferase 1 
(HPRT1) or glyceraldehyde-3-phosphate as reference genes. Results are presented as fold 
Step Temperature; Time Cycles 
Polymerase 
activation 95°C 2 min 1 
Denaturation 95°C 20 s 
35 Annealing Lowest primer Tm °C  10 s 
Elongation 70°C 20s/kb 
Storage 4°C ∞   
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expression compared to transcript levels of unstimulated control cells, which were set to 1. 
Fold expression was calculated using the ∆∆Ct method (Pfaffl, 2001) according to the 
following formula:   
 
relative mRNA expression = 2-(Ct of gene of interest – Ct of HPRT1/GAPDH) 
 
To accurately evaluate results, two control samples were used on every plate. The „no-
template“ control serves to exclude unspecific primer-dimer-amplification products and is 
prepared like a normal triplicate master mix, but without template. The no-RT-control uses 
purified RNA, instead of cDNA to control for genomic DNA-contamination during RNA 
isolation. 
3.1.11 Enzymatic manipulation of DNA 
(i) Digestion of DNA with restriction endonucleases 
For the sequence-specific cleavage of DNA molecules the samples were incubated with 
restriction endonucleases under appropriate reaction conditions. The amount of enzyme 
and DNA, the choice of buffer, temperature and duration of the reaction were adjusted 
according to the manufacturer’s instructions. 
 
(ii) Dephosphorylation of linearized vector DNA 
Restriction of vector DNA with a single enzyme may lead to subsequent religation. 
Therefore, 5’ termini of vector DNA were dephosphorylated using Antarctic PhosphataseTM 
(NEB) according the manufacturers recommendations. 
 
(iii) Ligation of DNA fragments 
For the ligation of linearised vectors with DNA-fragments the T4 DNA ligase was used. This 
enzyme catalyses the formation of phosphodiester bonds between adjacent 3’-OH and 5’-P 
ends in double-stranded DNA. For ligations of cohesive ends a molar ratio between 1:5 and 
1:10 (vector vs. insert DNA) was chosen. 
 
3.1.12 Agarose gel electrophoresis 
DNA samples were separated, characterised and purified by agarose gel electrophoresis. 
For preparation of agarose gels 1% agarose (w/v) was dissolved in 1x TAE buffer by boiling 
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and supplemented with 6 µl ethidium bromide/100 ml solution. Prior to loading DNA 
samples were mixed with 6x DNA loading buffer. Additionally, 5-10 µl of a DNA molecular 
weight standard (Gene RulerTM 1 kB DNA ladder, Fermentas) was loaded. The voltage was 
set to 5 V/cm electrode distance and electrophoresis was performed in a horizontal gel 
chamber filled with TAE buffer. DNA fragments stained with ethidium bromide were 
visualized by UV-excitation at l = 312 nm. 
3.1.13 Extraction of DNA from agarose gels 
DNA fragments and linearized vectors were isolated from agarose gels and purified using 
the QIAEX II Gel extraction Kit (Qiagen). Alternatively, double-stranded DNA fragments from 
PCR or other enzymatic reactions were purified using the QIAquick PCR Purification Kit 
(Qiagen). 
3.1.14 DNA sequencing 
DNA sequencing was conducted by GATC Biotech according to the dideoxy method 
(Sanger et al., 1977). 
3.2 Methods in mammalian cell culture 
3.2.1 General culture conditions 
All used cell lines were cultured at 37°C in an atmosphere with a relative humidity of 90% 
and a CO2 content of 5%. FCS was heat-inactivated at 56°C for 30 minutes before use. 
Unless otherwise stated, all used media were supplemented with 10% heat inactivated FCS 
and 1% penicillin/streptomycin. Cell lines were harvested at 1500 rpm for 5 minutes at 4°C. 
Primary human T cells were harvested at 1500 rpm for 10 minutes at $°C. All cell culture 
work was carried out under sterile conditions using a laminar flow hood. 
3.2.2 Culture of adherent cells 
The epithelial cell lines HEK293FT and HEK293T were maintained in DMEM medium 
allowing them to grow at a confluence of up to 80%.  Cells were split in ratios of 1:3 to 1:12 
depending on further use. Therefore, culture medium was removed, cells were carefully 
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washed with 10 ml of sterile PBS. Subsequently, the supernatant was discarded and 2 - 5 
ml Trypsin/EDTA, depending on the flask size were added for 5 minute at 37°C. Detached 
cells were resuspended in fresh DMEM medium and seeded with a confluence of 15 – 25 % 
into fresh culture flasks or plates. 
3.2.3 Culture of suspension cell lines 
For the culture of suspension cell lines or primary human T lymphocytes the following media 
were used. 
 
Cell line Cell culture medium 
JE6.1; J16-145; Gluc-J16; JE6.1 shContr.; 
JE6.1 shPP1α; JE6.1 shPP1α  #34; JE6.1 
shPP1α #47;  
JE6.1 shPP1α #50 
IMDM 
HUT78; Hut78 shPP1α #47; HH;  
HH shPP1α #47 RPMI	  
Primary	  human	  CD4+	  T	  cells	   X-­‐vivo	  15	  medium	  (supplemented	  with	  25	  U/ml	  IL-­‐2,	  when	  T	  cells	  were	  activated)	  
 
 
Culture media were replaced every three days. All suspension cells were cultured up to a 
density of 4 – 5 x 105/ml before they were split.  
3.2.4 Thawing and freezing of eukaryotic cells 
1–1.5 x 107 cells were harvested by centrifugation and resuspended in 1ml freezing medium, 
containing 90% (v/v) FCS and 10% (v/v) DMSO. 1 ml of cell suspension was transferred into 
a cryo-tube and immediately stored at -80°C or -140°C for long-term storage. For thawing, 
cryo-tubes were incubated at 37°C in a water bath until the suspension was completely 
thawed. Subsequently, cells were transferred into 10 ml of sterile 1x PBS to dilute the 
DMSO. Cells were centrifuged at 1500 rpm for 5 minutes and afterwards resuspended in  
10 to 15 ml prewarmed RPMI, IMDM or DMEM, depending on the cell line. 
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3.2.5 Determination of the cell density and viability 
The cell density was determined using a Neubauer chamber slide. If necessary, cells were 
diluted prior counting. To assess viability, cell suspensions were diluted with trypan blue 
solution to 0.05% (w/v) trypan blue and counted in a Neubauer chamber. Cell density was 
calculated according to the following formula: 
 
cell number/ml = mean cell number per square x dilution factor x 104 
3.2.6 Ficoll gradient isolation of lymphocytes from human blood 
Primary human mononuclear cells were isolated from 500 ml total blood or buffy coats 
according to the following protocol. 1 ml heparin was added to 500 ml whole blood to 
inhibit coagulation. Buffy coats were adjusted to 200 ml with PBS. 15 ml Ficoll were filled in 
50 ml Falcon tubes and slowly overlaid with 35 ml blood, followed by centrifugation (650 x 
g, 20 min, 20°C, with slow acceleration and without break). Peripheral blood mononuclear 
cells (PBMCs) were collected from the interphase and washed once with 1x PBS, followed 
by centrifugation (460 x g, 10 min, 20°C). The cell pellet was resuspended in 50 ml RPMI 
medium supplemented with 10% (v/v) FCS. PBMCs were transferred into cell culture flask 
and cultured for up to 60 minutes (37°C/5% CO2) to deplete adherent monocytes and 
macrophages. Non-adhering lymphocytes were washed from the cell culture flask with 
medium. Lymphocytes were used subsequently for the purification of CD4+ T cells via 
magnetic-activated cell separation (MACS).  
3.2.7 Magnetic-activated cell separation of CD4+ T Lymphocytes 
CD4+ T lymphocytes were purified from a mixed lymphocyte population (3.2.6) using 
magnetic-activated cell separation (MACS). Cells can be separated by MACS either by 
positive or negative selection. In a first step, CD25+ T cells were removed by positive 
selection. For that, the PBMC suspension was incubated with a limiting amount (2µl/107 
cells) of bead-coupled anti-CD25 monoclonal antibodies. After a subsequent washing step, 
the cell suspension was loaded onto a column in a magnetic field. The magnetic beads 
retain the CD25+ cells in the column, while the remaining cell types flow through. Outside of 
the magnetic field, CD25+ cells were eluted from the column. In a second step, CD4+CD25- T 
cells were isolated from the CD25+-depleted fraction using the CD4 Isolation kit II and 
additionally depleted from CD25+ cells with 6 µl of anti-CD25 MACS beads per 107 cells. 
 
69  Thomas Mock 3. Methods 
Alternatively, bulk CD4+ T cells were isolated from total PBMCs by positive selection using 
CD4 MicroBeads (Miltyenyi Biotec) according to the manufacturer’s protocol. Briefly, 
PBMCs were resuspended in 80 µl of buffer per 1x107 total cells. 20 µl of CD4 MicroBeads 
conjugated to anti-CD4 monoclonal antibodies were added per 1x107 total cells. The 
suspension was mixed and incubated for 15 minutes at 4°C. Subsequently, cells were 
washed by addition of 2 ml of buffer per 1x107 cells, followed by centrifugation at 300 g for 
10 minutes. Finally, up to 1x108 cells were resuspended in 2 ml of buffer. Magnetic 
separation of bead-labelled CD4+ cells was performed as described before. Isolated T cells 
were rested overnight in X-Vivo 15 medium and diluted to a concentration of 2x106 cells/ml. 
3.3 Cell biological methods 
3.3.1 Transient transfection by electroporation 
Electroporation is a method for the direct transfer of macromolecules (i.e. DNA) into target 
cells by perforating the plasma membrane with a short electric pulse. For transient 
transfection of Jurkat T cells circular DNA plasmids were used ranging from 5 to 15 µg. Per 
electroporation 1 x 107 cells were harvested washed once in PBS and then resuspended in 
400 µl prewarmed RPMI medium without FCS or antibiotics. The cell suspension was mixed 
with the plasmid sample and subsequently transferred into an electroporation cuvette. 
Electroporation was performed with the Gene Pulser System (BioRad), using 950 µF and 
250 V. Then, cells were transferred into 5 ml of prewarmed IMDM medium without 
antibiotics. 24 to 48 hours after electroporation cells were used for subsequent analyses. 
3.3.2 Nucleofection and siRNA-mediated gene silencing 
For siRNA-mediated gene transcript knock down, Jurkat T cells as well as primary human T 
cells were transiently transfected by nucleofection using the Cell Line Nucleofector Kit V and 
the Human T Cell Nucleofector Kit (Amaxa), respectively, according to the manufacturer’s 
instructions. 2x106 Jurkat T cells or 1x107 primary human CD4  T cells were resuspended in 
100 µl kit-specific nucleofection solution containing 1µM siRNA. Subsequently, cells were 
transferred into nucleofection cuvettes. Nucleofection was performed with program X-01 for 
Jurkat T cells or program U-14 for primary human CD4+ T lymphocytes using the Amaxa 
Nucleofector I. After nucleofection, Jurkat T cells were transferred into 6 well plates, 
containing 5 ml of prewarmed IMDM supplemented with FCS, but without antibiotics and 
 
70  Thomas Mock 3. Methods 
cultured for 72 hours before further use. Transfected primary human CD4+ T cells were 
transferred into 3 ml of X-vivo 15 medium in a 12 well plate format and cultured for 48 to 72 
hours before used for further analyses. 
3.3.3 Transfection of HEK293T cells by the Ca3(PO4)2 method 
Cells were grown to 70-80% confluence in 10 cm cell culture dishes. 5-20 µg plasmid DNA 
were mixed with 1 ml 1x HBS and 50 µl 2.5 M CaCl2 were carefully added. After addition of 
CaCl2, mixture were shortly vortexed and incubated for 10 to 15 minutes at RT. 
Subsequently, the mixture was added drop-wise to the cells. To assess transfection 
efficiency, one cell sample was transfected with an expression vector encoding green 
fluorescent protein (GFP). 24 hours after transfection efficiency was determined by 
fluorescence microscopy. After additional 24 hours cells were harvested, lysed and lysates 
used for further analyses. 
3.3.4 Production of recombinant retroviruses 
HEK293FT cells (packaging cells) were seeded with a cell density of 1.5x106 cells/ml in 5 ml 
of DMEM medium in T25 flasks. After reaching a confluence of up to 70%, cells were pre-
treated with 25 µM chloroquine. After 1 hour of incubation with chloroquine, cells were 
transfected with the Ca3(PO4) method, using 600 µl 1x HBS and 30 µl 2.5 M CaCl2. Cells 
were transfected with 6.3 µg TRIPZ shRNAmir expression vector, 4.3 µg of psPAX2  
(encoding for gag, pol, and env proteins) and 2.3 µg of pMD2.G2 (encoding for VSV-G) for 
pseudotyping. 12 hours after transfection the medium was replaced with 4 ml fresh DMEM 
medium and virus production was continued for additional 24 hours.  
3.3.5 Viral transduction of target cells 
Two days post transfection of packaging cells, supernatants were collected and centrifuged 
at 1500 rpm for 5 minutes at 4°C to remove cell debris. Next, cleared supernatants were 
passed though a 0.45 µm filter. 1x105 target cells (Jurkat T cells) were harvested and 
resuspended in 200 µl IMDM or RPMI medium, containing 8 µg/ml polybrene, transferred 
into a 24 well and pre-incubated for 45 minutes at 37°C. 1 ml of viral supernatant was 
added to each well and cells were infected by spin occulation. Therefore, cells were 
centrifuged at 2500 rpm for 2 hours at 30°C. After spin occulation, cells were cultured for 
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additional 12 hours in the presence of the viral supernatant. Subsequently, cells were 
washed three times with fresh IMDM medium, supplemented with 10% FCS and 1 % 
penicillin/streptomycin, finally resuspended in 1 ml of fresh medium and transferred into 24 
well plates. 48 hours after transduction, stably transduced Jurkat T cells were selected by 
puromycin resistance (1 µg/ml). Medium with fresh puromycin was replaced every 48 hours. 
Puromycin was removed when 100% of non-transduced control cells were trypan blue 
positive. 
3.3.6 CFSE labelling of primary human CD4+ T cells 
For CFSE labelling, 50 ml reactions tubes were coated with RPMI/10% FCS (v/v). Primary 
human CD4+ T cells were transferred to pre-coated tubes and harvested by centrifugation at 
1500 rpm at 4°C for 10 minutes. Cells were washed once with 20 to 40 ml PBS, followed by 
centrifugation at 1500 for 10 minutes. Then, cells were resuspended in PBS at a cell density 
of 2x107 cells/ml. CFSE (stock solution: 5 mM) was diluted to a concentration of 0.4 µM in 
PBS. One volume of  CFSE solution was added to one volume of cell suspension (final 
CFSE concentration: 0.2 µM). Cells were incubated on a rotator in the dark at 20°C for  
10 minutes. Then, the reaction was stopped by addition of ice-cold RPMI/10% FCS (v/v) 
and incubated on ice for 5 minutes. Afterwards, cells were washed twice with  
RPMI/10% FCS (v/v) and finally resuspended in X-vivo 15 medium at a density of 3x106 
cells/ml and left untreated overnight. To determine proliferation, cells were distributed in  
96-well round bottom plates at a density of 0.75x105 cells/100 µl per well. Cells were either 
left untreated by addition of 100 µl medium, or stimulated via the TCR using agonistic 
antibodies at a final concentration of 0.2 µg/ml anti-CD3, 0.5 µg/ml anti-CD28 and 2 µg/ml 
GAM in a final volume of 200 µl. CFSE dilution was assessed by flow cytometry (Beckton 
Dickinson) at 4 to 6 days after stimulation. 
3.3.7 Apoptosis analysis 
Apoptotic cell death was examined by DNA fragmentation according to the method of 
Nicolletti (Nicoletti et al., 1991). Cells were collected by centrifugation at 1500 rpm for  
5 minutes, washed with 200 µl PBS and centrifuged again at 1500 rpm for 5 minutes. Then, 
cells were lysed in 200 µl of Nicoletti lysis buffer, containing propidium iodide and stored 
overnight at 4°C in the dark. The propidium iodide stained DNA fragments were quantified 
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by flow cytometry (Becton Dickinson). Specific DNA fragmentation was calculated 
according to the following formula: 
 
 
(% experimental DNA fragmentation – % spontaneous DNA fragmentation) /  
(100 – % spontaneous DNA fragmentation) x 100%. 
3.4 Biochemical and immunological methods 
3.4.1 In vitro stimulation of Jurkat and primary human CD4+ T cells  
Jurkat T cells and primary human T cells were stimulated with agonistic soluble anti-CD3 
(OKT3), anti-CD28 (CD28.2) and goat and mouse monoclonal  antibodies (TCR stimulation), 
using final concentrations between 0.01 to 1.0 µg/ml. Alternatively, cells were stimulated 
with PMA (10ng/ml) and Ionomycin (10 µM) to induce PKC activation and Ca2+ influx, 
mimicking TCR stimulation. Stimulation via TNFR1 was performed using 50 ng/ml 
recombinant TNFα. For biochemical experiments 0.5 to 1x107 cells were harvested by 
centrifugation at 1500 rpm at 4°C, resuspended in 4 ml fresh medium and 5-fold 
concentrated stimulation medium was added. Stimulations in 96-well plates were performed 
in a final volume of 200 µl. 1 to 2x105 Gluc-J16, Jurkat or primary human T cells were 
resuspended in 100 µl fresh medium and 100 µl 2-fold concentrated stimulation medium 
was added. Stimulations were stopped by transferring cells into 15 ml or 1,5 ml reaction 
tubes, depending on the stimulation volume, which were pre-filled with ice-cold PBS. 
Subsequently, cells were centrifuged at 1500 rpm at 4°C for 5 minutes. Then, the 
supernatant was removed, cells were washed with ice-cold PBS and centrifuged at 1500 
rpm at 4°C. The supernatant was drawn off and cells were lysed as described below. 
3.4.2 Cell lysis and protein quantification 
Cells were pelleted by centrifugation, the supernatant was drawn off and cells were washed 
once with ice-cold PBS. Subsequently, cells were pelleted, the supernatant was removed 
and cells were resuspended in 20 µl of ice-cold lysis buffer per 1x106 cells. Lysates were 
incubated on ice for at least 20 minutes. Whole cell lysates were cleared from insoluble cell 
content by centrifugation at 16000 g at 4°C in a table top centrifuge for 15 minutes .  Protein 
concentration of whole cell lysates was determined using the Roti-Quant® Bradford assay 
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according to the manufacturers’ instructions. 0 to 2 µg/ml bovine serum albumin was used 
as a standard, with dilution series done in lysis buffer.  1 µl of sample was mixed with 1 ml 
of Roti-Quant® Bradford reagent and incubated for 5 minutes in the dark. After incubation, 
absorbance at 595 nm was measured in a photometer, and concentrations were determined 
according to the standard curve. Subsequently, lysates were adjusted to equal protein 
levels. For polyacrylamide gel electrophoresis (PAGE), lysates were mixed with an 
appropriate amount of 2x or 5x reducing SDS sample buffer (Laemmli et al., 1970) and 
heated to 95°C for 5 minutes. Alternatively, lysates were subjected to immunoprecipitation 
(see paragraph 3.4.4) 
3.4.3 Preparation of nuclear and cytoplasmic cell extracts  
Nuclear and cytoplasmic extracts were prepared using the NE-PER Nuclear and 
Cytoplasmic Extraction kit (Thermo Scientific) according to the manufacturers instructions. 
After extraction, protein concentration was determined as described previously (see 
paragraph 3.4.2). For storage of nuclear extracts, glycerol ((20% (v/v)) was added and 
samples were stored at -80°C. Cytoplasmic extracts handled like whole cell lysates (see 
paragraph 3.4.2). 
3.4.4 Immunoprecipitation  
For immunoprecipitation (IP) cleared whole cell lysates were adjusted to a volume of 500 µl 
in 1.5 ml Eppendorf tubes. Then, lysates were incubated with a 50% slurry of protein A- 
beads at 4°C on a rotator for 1 hour to pre-clear lysates from unspecifically adsorbing 
proteins. After incubation, samples were centrifuged at 2000 rpm and 4°C in a table top 
centrifuge for 2 minutes. Subsequently, the pre-cleared lysates were transferred to a new 
Eppendorf tube and the desired antibody was added, followed by 1 hour of incubation on a 
rotator at 4°C. After incubation 50 µl of a 50% slurry of protein A-sepharose beads were 
added and samples were incubated for at least 3 hours or overnight. The matrix was 
washed at least 5 times with 1 ml of ice cold lysis buffer to remove unspecifically bound 
proteins. Beads were resuspended in 50 µl of lysis buffer together with 50 µl 2x or 12.5 µl of 
5x reducing sample buffer and heated at 95°C for 5 minutes. Purified proteins were 
detected by SDS-PAGE and immunoblotting (see paragraph 3.4.4 and 3.4.5) 
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3.4.5 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
For analysis, proteins were separated using discontinuous SDS-PAGE (sodium dodecyl 
sulphate – polyacrylamide gel electrophoresis) under reducing conditions (Laemmli et al., 
1970). SDS is an anionic detergent, which denatures proteins and concomitantly confers to 
them a net negative charge. Approximately 1.4 g SDS bind per gram protein and, thus, 
migration of SDS-protein complexes through polyacrylamide gels in an electric field largely 
depends on their molecular mass. For separation of proteins 8-12% polyacrylamide 
separating gels and 5% polyacrylamide stacking gels were used.  
The polymerisation was started by adding 0.1% (v/v) TEMED and 0.1% (v/v) ammonium 
persulphate (APS) and the polymerizing solution was used immediately. The separating gel 
was covered with isopropanol. After 15 minutes the isopropanol was removed by washing 
with water, the gel surface was dried and the stacking gel was added. Electrophoretic 
separation was conducted at a constant current od 25-30 mA/fel for 1.5-2.0 hours. To 
approximate apparent molecular weights of analysed proteins, an appropriate molecular 
weight marker was employed. Following SDS-PAGE, the polyacrylamide gels were 
subjected to immunoblotting (see paragraph 3.4.6).  
3.4.6 Immunoblot analysis 
After SDS-PAGE, separated proteins were analysed by immunoblot (IB) analysis. Therefore, 
proteins were electrophoretically transferred onto a nitrocellulose membrane via Wetblotting 
at 100V (~300 mA) under cooling conditions for 1.5 to 2 hours. In order to analyse different 
proteins at the same time, blots were horizontally cut according to the apparent molecular 
weight, estimated by the utilised marker. Afterwards, membranes were blocked with 
5% (w/v) non-fat dry milk in TBS-T on a rotary shaker at 20°C for 1 hour. After incubation, 
membranes were washed 3 times with TBS-T for 10 minutes each. For detection of specific 
proteins, membranes were incubated with primary antibodies (see paragraph 2.6.1) at 4°C 
overnight. Then, membranes were washed 6 times with TBS-T on a rotary shaker at 20°C, 
10 minutes each. Next, membranes were incubated with required secondary HRP-
conjugated antibodies (see paragraph 2.6.1) at 20°C for 1 hour. Subsequently, membranes 
were washed 3 times with TBS-T for 10 minutes each time. Finally, protein bands were 
detected with ECL substrate solution in a Vilber Lourmat chemiluminescence detection 
system (Software, Chemi-Capt 5000) and bands were quantified using the Bio-1D software.  
For detection of further proteins, the membrane was incubated with stripping buffer to 
denature primary and secondary antibodies, followed by rigid washing of the membrane 
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with TBS-T. Then, the membrane was blocked for 1 hour and the procedure was continued 
as described above. 
3.4.6 In vitro kinase assay  
In vitro kinase assays were performed as described previously (Brenner et al., 2005). 
Endogenous IKK complex was immunoprecipitated with anti-NEMO antibodies. 
Immunoprecipitates were washed 3 to 5 times with lysis buffer, followed by one wash step 
with kinase buffer. Then, beads were resuspended in 100 µl kinase buffer and split in 
equivalent 50 µl aliquots. One part was used to control for protein input, while the other part 
was subjected to in vitro kinase reaction. 5 µg of recombinant GST:IκBα together with 10 
µCi [32P-γ]ATP were added to the reaction mix to serve as a specific substrate of IKK 
kinases. The kinase assay reaction was conducted at 30°C for 30 minutes. Subsequently, 
proteins were electrophoretically separated by SDS-PAGE. Afterwards, the gel was dried 
and subjected to autoradiography. 
3.4.7 Electromobility shift assay (EMSA) 
EMSAs were performed, using the Lightshift® Chemiluminescent EMSA Kit (Thermo 
Scientific) according to the manufacturers’ instructions. The assay makes use of biotinylated 
dsDNA oligonucleotides (see paragraph 2.5.3). To assess binding activity of transcription 
factors, nuclear extracts of stimulated Jurkat or primary human CD4+ T cells were prepared 
(see paragraph 3.4.3), and 0.5 to 1 µl of nuclear extract was added to the reaction mixture.  
3.4.8 Gaussia luciferase reporter assay  
0.5-2x105 GLuc reporter cells were stimulated in 96 well plates for 5 hours. For each 
sample, 20 µl of supernatant was subjected to a Gaussia luciferase assay (p.j.k.) according 
to the manufactures’ instructions. Luciferase activity was measured in 96-well plates using a 
Orion L microplate Luminometer (Berthold Detection Systems) with an integration time of 
3.0 sec. In parallel, cell viability was determined (see 3.4.10) and normalized Gluc activity 
was calculated as the ratio between Gluc activity and cell viability counts. 
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3.4.9 Cell viability assay 
Cell viability was assessed in a 96-well format using the CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega). The assay determines the number of viable cells by measuring 
the intracellular content of ATP. The amount of ATP correlates with the amount of 
metabolically active cells. Cells were resuspended in medium and 50 µl of the cell 
suspension was added to 50 µl of the CellTiter-Glo® reagent (1:1 diluted with medium). 
Then, plates were incubated for 20 minutes at 37°C in the dark. Luminescence was 
measured using an Orion L Microplate Luminometer (Berthold Detection Systems) 
(integration time 1.0 sec). 
3.4.10 Transient reporter assay 
For transient reporter assays 1x107 Jurkat T cells or 2x105 HEK293T cells were co- 
transfected with NF-kB- or AP-1-specific transcriptional reporter plasmids (pGL8xNF-κB- 
fos or p3xAP-1-Luc) and pfos-LacZ as described previously (Arnold et al., 2001). Jurkat T 
cells were co-transfected with 8 µg of reporter plasmid and 1 µg of pfos-LacZ. HEK293T 
cells were co-transfected with 2µg of reporter plasmid and 0.2µg of pfos-LacZ. Transfection 
efficiency was normalized to LacZ expression. 24-48 h post transfection cells were left 
untreated or treated (see paragraph 3.4.1), lysed and luciferase activity was measured using 
the Dual-Light® System (Applied Biosystems) and an Orion L Microplate Luminometer 
(Berthold Detection Systems) according to the manufactures’ instructions. 
3.4.11 Enzyme-linked immunosorbent assay (ELISA) 
To determine cytokine concentrations in the supernatant of stimulated cells, cells were 
stimulated in a 96-well format (see paragraph 3.4.1) overnight. Subsequently, the 
supernatant was collected, and the levels of secreted IL-2, IL-8 and IFNγ were measured 
using enzyme-linked immunosorbent assays (ELISA), according to the manufacturers’ 
instructions. 96-well half area plates were coated with capture antibody (diluted in coating 
buffer, 50 µl per well) overnight at 4°C. After coating, plates were washed 3 times with  
PBS-T and unspecific binding sites were blocked with 100 µl PBS/10% FBS per well for 1 
hour at 20°C. Plates were washed 3 times and 50 µl of sample or standard was added per 
well and incubated for 1 hour at 20°C. After incubation, plates were washed 3 times with 
PBS-T. Subsequently, 50 µl biotinylated detection solution (diluted in PBS/10% FCS, 
1:2000 streptavidin-HRP (Jackson-Immunoresearch)) was added and incubated at 20°C for 
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1 hour. Subsequently, plates were washed 5 times with PBS-T. Finally, 50 µl substrate 
solution (citrate buffer, 0.5mg/ml o-phenylendiamine, 0.1% (v/v) H2O2) were added and 
incubated for an appropriate period of time before the reaction was stopped by addition of 
25 µl 3M H2SO4. For end-point reading, the absorbance signal was measured at 490 nm, 
using the Microplate Reader Model 680 (Biorad). 
3.5 Computational and statistical analysis 
3.5.1 Statistical normalization 
Statistical analysis of the primary RNAi screen and data pre-processing were conducted 
using the cellHTS2 Bioconductor/R software package (in collaboration with D. Nickles, 
DKFZ) (Boutros et al., 2006; Pelz et al., 2010). For each 96-well two reporter signals were 
measured: channel 1 was representative of overall cell viability and cell numbers, whereas 
channel 2 was based on measurement of NF-kB-driven Gluc activity (see also 5.1.5). 
Computational analysis of raw data from each channel revealed in part considerable 
interplate variations as well as systematic intraplate effects (positional effects, such as 
column, row, or edge effects). Therefore, values were statistically normalized using the 
stringent B score algorithm that is suitable to standardize for intraplate and plate-to-plate 
variability (Birmingham et al., 2009; Brideau et al., 2003; Malo et al., 2006). B score 
normalization yielded accurate and similar distributions of median normalized signal 
intensities between replicates and across different plates as assessed by box plot analysis 
(Boutros et al., 2006; data not shown). In addition to statistical normalization, pre- 
processed data from either channel were combined in order to calculate values for NF-kB- 
specific Gluc activity normalized to cell numbers (channel2/channel 1; biological 
normalization). Subsequently, mean Gluc activity of two biological replicates for each siRNA 
transfection was determined. Mean values, in turn, were transformed into the statistical z 
score for hit selection and post-screen analysis.  
3.5.2 Candidate selection by analysis of statistical normality 
For identification of candidate phosphatases (hits) quantified RNAi phenotypes (i.e. mean 
values of normalized NF-kB activity) were scored for statistical significance. To this end, 
normalized measurements were transformed into the statistical z score (Boutros et al., 
2006). Data transformation helps to further minimize data variability and allows for the 
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analysis of statistical normality which is instrumental in defining appropriate thresholds for 
hit selection. Using a quantile-quantile (QQ) plot analysis (Ramadan et. al., 2007) z scores 
assigned to individual phosphatase siRNAs (sample quantiles) were plotted against values 
from a theoretical normal distribution (theoretical quantiles) (Fig. 5.5 A). z score deviations 
from normally (randomly)-distributed values indicated statistically significant RNAi 
phenotypes. For hit selection z scores > +1.5 and < -1.5 were defined as cut-offs values 
(Fig. 5.5 A and B). 
3.5.3 Student’s t-test 
The unpaired Student’s t-test (independent two-sample t-test; unequal sample sizes and 
unequal variance) was used for statistical analysis of data sets, including ELISA, reporter 
gene assays and gene expression analysis. A p value * ≤ 0.05 was considered statistical 
significant. Individual p value thresholds are indicated in figure legends. 
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4. Results 
Signalling to NF-κB upon TCR-triggering and co-receptor engagement is mediated by the 
concerted action of various signalling proteins, including kinases, ubiquitin-editing enzymes, 
scaffold and adaptor proteins. Phosphorylation is the major reversible post-translational 
modification used to facilitate signal transduction and considerable effort has been made to 
identify kinases involved in signal transduction to NF-κB. In contrast, little is known about 
the function of phosphatases as signalling modulators in the NF-κB pathway, despite their 
well established role in regulation of other transcription factors (e.g. NFAT). To evaluate the 
importance of phosphatases on TCR-induced NF-κB activation, we have performed a semi-
large scale RNA-interference (RNAi) screen in Jurkat T cells. The detailed screening 
procedure is published (Brechmann, 2010) and, thus, is only shortly summarised in the 
following paragraph.   
4.1 RNAi screen and data analysis 
For RNAi-screening, a NF-κB reporter cell line (from here on referred to as Gluc-J16), based 
on Jurkat T cells that harbour a NF-κB responsive Gaussia-luciferase (Gluc) reporter gene 
was used (Brechmann , 2010). Gluc contains a natural N-terminal secretion sequence that 
mediates quantitative secretion of native Gluc protein in an active form. Stimulation of Gluc-
J16 cells with agonistic antibodies against CD3 and CD28 or PMA and Ionomycin as well as 
TNFα results in NF-κB-dependent synthesis of Gluc, which is subsequently secreted into 
the surrounding medium (Brechmann, 2010). Therefore, the strength of luciferase activity 
can be measured in the supernatant of stimulated cells and directly reflects the strength of 
NF-κB activity.  
For RNAi-screening, a commercially available small interfering RNA (siRNA) library, targeting 
298 known or predicted phosphatase and phosphatase-associated gene transcripts, was 
used (Brechmann, 2010). Each targeted transcript was covered by three independent siRNA 
oligos, which were transfected independently and in biological duplicates into Gluc-J16 
cells in a 96-well format. In addition, several siRNAs, targeting known NF-κB regulators in 
T cells, such as CYLD (negative regulator) CARMA1 and RelA (positive regulators) and non-
targeting control siRNA oligos were used. 72 hours after transfection, cells were equally split 
and either kept unstimulated or stimulated via the TCR, using agonistic anti-CD3 and anti-
CD28 antibodies and goat-anti-mouse (GAM) crosslinking antibodies (from here on referred 
to as anti-CD3/CD28). After stimulation, luciferase activity was measured in the 
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supernatants. In addition, cell viability was assessed. Data analysis was carried out with the 
cellHTS2 software package (Boutros et al., 2006; Petz et al., 2010). The raw luciferase as 
well as the viability data set was normalized using the iterative B score algorithm, which 
compensates systemic inter- and intraplate variations (Birmingham et al., 2009). After B 
score normalisation, the ratio of processed luciferase and viability values was calculated for 
each individual siRNA transfection to obtain values for NF-κB-specific Gluc-activity, 
normalised to cell viability (Brechmann, 2010). Afterwards, the mean Gluc activity of two 
biological replicates was calculated and transformed into the statistical z score for hit 
selection. The z score specifies the number of standard deviations of a sample from the 
population mean and therefore provides a specific measure for the biological effect of an 
individual siRNA (Birmingham et al., 2009). Positive and negative z scores indicate 
increased or and reduced reporter activity, respectively.  
4.2 RNAi screen identifies protein phosphatase 1, catalytic subuit 
 alpha (PP1α) as a positive regulator of NF-κB signalling in T 
 cells 
Primary RNAi screening identified several tentative candidate phosphatases involved in 
regulation of NF-κB activity upon TCR stimulation. To be further considered as a hit, at least 
two independent oligos per targeted gene had to exceed a z score ≥ 1.5 for negative 
regulators and ≤ -1.5 for positive regulators. Several siRNAs, targeting phosphatases, 
known to be involved in TCR-induced signalling were found to score above the threshold 
criteria. A comprehensive summary of the screening results is given in Brechmann, 2010. 
As shown in Fig. 4.1 A, RelA, CARMA1 and CYLD siRNAs consistently scored above the 
given threshold criteria. In detail, siRNAs targeting the negative regulator CYLD reproducibly 
surpassed a z score of 1.5, indicating enhanced NF-κB-driven activity. In contrast, siRNAs 
targeting the positive regulators CARMA1 or RelA consistently scored below a z score of 
1.5, underscoring the validity of the here applied screening and analysis strategy. 
Albeit the assumption that phosphatases may primarily counteract the activating function of 
kinases and, thus, signalling to NF-κB, the RNAi screen also identified protein phosphatase 
1, catalytic subunit alpha (PP1α) as a positive regulatory phosphatase. Two siRNA oligos, 
targeting PP1α, scored below a z score of -1.5 (siPP1α#1 z score: -2.08; siPP1α#3 z score:  
-2.11), indicating PP1α as a putative positive regulator of NF-κB activity (Fig 4.1 A). To 
validate the primary RNAi screening result, Gluc-J16 cells were transiently transfected with 
the PP1α-specific siRNA oligos, used for primary RNAi screening along with a non-targeting 
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control siRNA and a siRNA targeting RelA (Fig. 4.1 B). 72 hours after transfection, cells were 
stimulated via the TCR and luciferase activity was measured in the supernatant of cells.  
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Figure 4.1 Results of RNAi screen and validation of PP1α as a positive regulator of TCR-
induced NF-κB signalling. (A) Results of RNAi screen, depicting z score distribution of individual 
phosphatase-specific and control siRNAs. The positions of siRNA oligos for PP1α, RelA, CARMA1 
and CYLD are depicted. The Red dashed line indicates the z score threshold of -1.5.  
(B) Validation of primary screening results. Gluc-J16 cells were transfected with non-targeting 
(siContr.), RelA-targeting (siRelA) or three independent PP1α-targeting (siPP1α #1,#2,#3) siRNAs. 
72 hours after transfection, cells were stimulated with 0.5 µg/ml anti-CD3/28 and luciferase 
activity was assessed in the supernatant. In parallel, cell viability was determined using Cell Titer 
Glo©. Luciferase activity was normalised to cell viability. (C) Relative mRNA levels of RelA and 
PP1α were determined by qRT-PCR to control for knock down. Values are normalised to siContr.. 
Results are representative for 3 independent experiments (B and C). Given is the mean +/- SD of 
triplicate stimulation; *, p ≤ 0.05; **, p ≤ 0.005 
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In line with the primary screen, all PP1α-targeting siRNAs (siPP1α #1 – 3) reduced NF-κB-
driven reporter activity by 30 to 40%. As expected, knock down of RelA almost abolished 
luciferase activity (Fig 4.1 A). In addition, knock down efficiency of individual siRNA oligos 
were assessed by qRT-PCR (Fig. 4.1 C). PP1α-specific oligos #1 and #3 reduced PP1CA 
mRNA by 80% or more, while oligo #2 was less efficient (Fig. 4.1 B). Probably, due to its 
lower knock down efficacy oligo #2 may have resulted in a less pronounced phenotype 
during RNAi screening and, thus, did not score under the given criteria (Fig. 4.1 A). 
Importantly, knock down of RelA had no effect on PP1α expression and vice versa  
(Fig. 4.1 C). In summary, transient knock down of PP1α in Gluc-J16 cells confirmed the 
result of the primary RNAi screen.  
4.3 Ectopic expression of PP1α increases stimulus-independent 
 and TCR-dependent NF-κB activity 
Ectopic expression of proteins, for example using HEK293T cells, is a standard procedure 
to characterise protein function in an investigated signalling pathway. HEK293T cells are 
easy to transfect and overexpression of some NF-κB pathway components themselves can 
induce NF-κB activation independent of an additional stimulus. The primary RNAi screen 
and subsequent validation experiments indicated PP1α as a putative positive regulator of 
NF-κB signalling. Therefore, in complementation of these loss-of-function data, PP1α was 
ectopically expressed in HEK293T or in Jurkat T cells to determine its impact on NF-κB 
activation. 
To this end, HEK293T cells were transiently transfected with increasing amounts of an 
expression plasmid, encoding haemagglutinin (HA)-tagged human PP1α or an empty vector 
(Mock) as control (Fig. 4.2 A). NF-κB activity was determined by co-transfecting a NF-κB 
luciferase reporter plasmid. HA-PP1α expression was controlled by immunoblot analysis 
(Fig. 4.2 A, lower panel). After transfection, cells were cultured for 24 hours to allow 
sufficient expression of exogenous HA-PP1α. Subsequently, luciferase activity was 
determined.  
Compared to Mock-transfected cells, expression of HA-PP1α induced reporter activity in a 
dose-dependent manner, indicating that forced PP1α expression can lead to NF-κB 
activation.  
In a second approach, HA-PP1α was ectopically expressed in Jurkat T cells. Therefore, cells 
were transfected with a NF-κB reporter plasmid, together with an empty (Mock) or the HA-
PP1α-encoding expression plasmid (Fig. 4.2 B). 24 hours after transfection, cells were 
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stimulated with increasing concentrations of anti-CD3/CD28 to monitor TCR-induced NF-κB 
activation in response to TCR-triggering. In addition, expression of HA-PP1α was controlled 
by immunoblot analysis  (Fig 4.2 B, lower panel).  
Upon stimulation, HA-PP1α expressing cells showed significantly elevated luciferase activity 
compared to Mock transfected cells (Fig. 4.2 B, upper panel). However, in contrast to 
HEK293T cells, basal NF-κB activity was not induced by exogenous PP1α expression in 
Jurkat T cells. 
In summary, these data further corroborate a role of PP1α in NF-κB activation. Importantly, 
in Jurkat T cells, enhanced NF-κB activity was dependent on stimulation, suggesting that 
PP1α is actively engaged downstream of the TCR or CD28.  
Figure 4.2 Ectopic expression of PP1α augments NF-κB reporter gene activity. HEK293T 
cells (A) or Jurkat T cells (B) were transiently transfected with empty vector (Mock) or expression 
plasmid, encoding haemagglutinin (HA)-tagged human PP1α. To determine NF-κB activity, cells 
were co-transfected with a NF-κB reporter plasmid. 24 hours after transfection, NF-κB activity 
was assessed in whole cell lysates (WCL) of cells. (B) Cells were stimulated via the TCR using 
increasing concentrations of anti-CD3, anti-CD28, as indicated and NF-κB activity was 
determined in WCLs. (A and B) WCLs were subjected to SDS-PAGE followed by immunoblot 
analysis with indicated primary antibodies. Given is the combined mean +/- SD of duplicate 
transfections, each measured in triplicate (A) of three stimulations, each measured in triplicate (B).  
*, p ≤ 0.05; **, p ≤ 0.005; ***, p ≤ 0.0005  
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4.4 Transient knock down of PP1α attenuates secretion of  
 NF-κB-dependent cytokines in T cells 
The preceding loss- and gain-of-function experiments implicated a positive-regulatory role 
of PP1α on NF-κB activation in T cells. However, reporter gene assays are limited in respect 
to explore the physiological function of a protein. In T cells, NF-κB controls transcription of 
various cytokines upon TCR engagement. The genes encoding the T cell cytokine IL-2 and 
the chemokine IL-8 contain several κB-binding sites in their promoter regions that are 
required to drive gene expression. To verify a physiological role of PP1α in T cell-intrinsic 
NF-κB-dependent function, the influence of PP1α knock down on IL-2 and IL-8 cytokine 
secretion was investigated. 
Therefore, Jurkat cells were transiently transfected with non-targeting control or two 
independent PP1α-targeting siRNAs (Fig. 4.3, top panels). To test for technical variation, 
each siRNA oligo was transfected in replicates. 72 hours after transfection, cells were 
stimulated via the TCR and secretion of cytokines was monitored using ELISA. In parallel, 
knock down of PP1α was analysed by immunoblot analysis.  
Transfection of PP1α-specific siRNAs conferred potent protein knock down, which was 
consistent between replicate transfections of the same oligo. As expected, loss of PP1α 
correlated with a significant decrease in IL-8 and IL-2 secretion by 40 to 50% (Fig. 4.3 A 
and B). This phenotype was highly reproducible and did not differ between replicate 
transfections. 
To further extend these findings in non-malignant cells, IL-2 secretion was monitored in 
PP1α-silenced primary human T cells. Therefore, CD4+ T cells were isolated from peripheral 
blood of healthy donors and transiently transfected with two independent PP1α-specific or 
non-targeting control siRNAs. Knock down of PP1α was controlled by qRT-PCR (Fig. 4.3 C, 
right panel). 48 hours after transfection, T cells were stimulated via the TCR and the RNAi-
phenotype was determined by measuring IL-2.  
In line with the phenotype in Jurkat T cells, PP1α knock down in primary T cells correlated 
with a significant decrease in secreted IL-2 compared to control transfected cells  
(Fig. 4.3 C, left panel). Knock down was potently conferred by PP1α-specific oligos, 
resulting in 20% or less residual PP1α mRNA (Fig. 4.3 C, right panel).  
Collectively, these results provide further evidence for a physiological function of PP1α in T 
cells and suggest that regulation of NF-κB activity by PP1α directly affects cytokine 
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secretion. 
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Figure 4.3 Knock down of PP1α attenuates cytokine secretion. (A and B) Jurkat T cells were 
transiently transfected with non- (siContr.) or two independent PP1α-targeting (siPP1α #1, #3) 
siRNAs. 72 hours after transfection, cells were stimulated with 0.5 µg/ml anti-CD3/CD28 for 12 
hours. Subsequently, cytokine levels were measured by ELISA. Knock down of PP1α was 
controlled by subjecting WCLs to SDS-PAGE, followed by immunoblot analysis using primary 
antibodies as indicated. Error bars: +/- SD of three independent stimulations, measured in 
technical replicates (C) Primary human CD4+ T cells were isolated from peripheral blood of healthy 
donors and subsequently transfected with non-targeting control (siContr.) or two independent 
PP1α-targeting (siPP1α #1, #3) siRNAs. 48 after transfection, cells were stimulated with 0.5 µg/ml 
anti-CD3/CD28  for 12 hours and IL-2 levels were measured by ELISA (mean +/- SD of three 
independent stimulations, measured in technical replicates) . Knock down of PP1α was controlled 
by qRT-PCR (right panel) and mRNA levels normalised to siContr. (mean +/- SD of technical 
triplicates).*, p ≤ 0.05; **,  p ≤ 0.005  
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4.5 Transient knock down of PP1α reveals no overt 
 differences  in phosphorylation of NF-κB signalling 
 mediators 
Due to the correlation of RNAi-mediated knock down of PP1α and attenuated NF-κB activity 
as well as decreased cytokine secretion, it is possible that PP1α directly influences signal 
transduction to NF-κB. A central hub within the canonical NF-κB signalling pathway is the 
IKK complex, which mediates phosphorylation-induced degradation of IκB proteins, thereby 
liberating NF-κB dimers to translocate to the nucleus and drive gene transcription. Hence, it 
was sought to determine whether PP1α interferes with activating phosphorylation events 
within the TCR-induced NF-κB signalling pathway.  
Therefore, Jurkat T cells were transiently transfected with non- or PP1α-targeting siRNA.  
72 hours after transfection, cells were stimulated via the TCR for up to 90 minutes. To follow 
the dynamic activation of the NF-κB pathway over time, samples were taken at different 
time points after stimulation (Fig. 4.4). Cells were subsequently lysed and whole cell lysates 
(WCL) were subjected to SDS-PAGE, followed by immunoblot analysis, using phospho-site 
specific antibodies against IKKα/β, IκB and p65. In parallel, to control for pathway 
specificity,  activation of MAPK signalling was monitored by analysis of Erk1/2 and p38 
phosphorylation. Membranes were reprobed with pan-specific antibodies against the 
respective proteins to control for equal loading and to allow an estimation of the strength of 
phosphorylation reactions. 
As depicted in Fig. 4.4, activation loop phosphorylation of IKKα (S180) and IKKβ (S181), 
indicative for IKK activation, peaked after 25 minutes of stimulation and occurred to a 
similar extent in control and PP1α-silenced cells upon TCR-triggering. Accordingly, 
phosphorylation of p65 (S536), critical for the transcription activating function of NF-κB also 
peaked upon 25 minutes of stimulation and was unaffected by PP1α knock down. 
Interestingly, degradation of IκBα was mildly attenuated, while phosphorylation of the 
resynthesized IκBα protein after 90 minutes of stimulation was slightly reduced in PP1α-
silenced cells. However, IκBα resynthesis, which occurs in a NF-κB-dependent manner, was 
not altered. Importantly, phosphorylation of the MAPKs Erk1 and Erk2, as well as p38 was 
not influenced by reduced PP1α levels, indicating that the strength of TCR stimulation was 
comparable between control cells and PP1α-silenced cells. 
As assessed by phospho-immunoblotting, signalling to NF-κB did not seem to be generally 
altered in the absence of PP1α. Yet, a mild influence on IκBα phosphorylation and 
degradation was reproducibly found among independent experiments. However, low cell 
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numbers, and fluctuating cell viability upon transient transfection, hampered phospho-
immunoblot analysis and, thus, required further investigation.  
4.6 Generation of cell lines with inducible PP1α knock down  
So far, validation and initial characterisation of PP1α function was based on transient 
transfections via nucleofection, a commercially available electroporation method under 
optimised buffer conditions. Although knock down and overexpression were quantitatively 
achieved, the number of cells receiving siRNA or DNA constructs within the cell population 
is limited and does not allow for rigid biochemical analysis of signalling pathways. In 
addition, nucleofection can alter cellular behaviour and lowers cell viability, further 
complicating the analyses of PP1α function. To circumvent these obstacles, Jurkat T cell 
lines that harbour a stably integrated non- or PP1α-targeting small hairpin RNA (shRNA) 
expression cassette were generated. To avoid adaptation effects due to long-term silencing 
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Figure 4.4 Transient knock down of PP1α does not reveal overt difference in the 
phosphorylation of NF-κB signalling components.  Jurkat T cells were transiently transfected 
with non- (siContr.) or PP1α-targeting (siPP1α #1) siRNA. 72 hours after transfection, cells were 
stimulated with 0.5 µg/ml anti-CD3/CD28 for the indicated periods of time. Subsequently cells 
were lysed and equal amounts of protein were subjected to SDS-PAGE, followed by immunoblot 
analysis. Phosphorylation of signalling proteins was deteceted by using the phospho-site specific 
primary antibodies as indicated. The membrane was reprobed with antibodies targeted against 
total protein to control for equal loading.  
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of proteins, a Doxycycline (Dox)-inducible shRNA expression system was used. For 
convenience, Dox-induced shRNA expression is accompanied by co-expression of red-
fluorescent protein (RFP), which allows tracking of induced expression by flow cytometry. In 
addition, the lentiviral constructs contain a puromycin resistance cassette, enabling 
shContr.
Day 1Day 0 Day 2 Day 3
shPP1α #47
shPP1α #34
RFP
S
S
C

+ Dox
0
20
40
60
80
100
Day 0 Day 1 Day 2 Day 3
R
FP
 p
o
si
ti
ve
 c
el
ls
 [
%
]
after Doxycycline addition
shContr
shPP1α #47
shPP1α #34
A. 
B. C. 
1 2 3 1 2 3 1 2 3 [days] Dox 
IB: PP1α 
IB: Tubulin 
shContr. shPP1α #47 shPP1α #34 
Figure 4.5 Characterisation of inducible shRNA expression in stably selected Jurkat T cells. 
(A) Indicated cell lines were treated with 2 µg/ml Doxycycline. Induction of RFP expression was 
measured daily using flow cytometry. (B) Percentage of viable, RFP positive cells. (C) Inducible 
PP1α-silencing was controlled by acquiring WCLs of Dox-treated cells daily. Subsequently, equal 
amounts of protein were subjected to SDS-PAGE, followed by immunoblot analysis with indicated 
primary antibodies. Equal loading was controlled by reprobing the membrane with anti-Tubulin 
antibody. 
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selection of cells that stably incorporated the inducible expression cassette into their 
genome. Overall, nine independent shRNA expression constructs and one non-targeting 
control shRNA construct were used for generation of stable Jurkat cell lines. For the 
purpose of this thesis, the characterisation of only three cell lines, one control cell line 
(shContr.) and two shPP1α expressing cell lines (shPP1α #47, and shPP1α #34) are shown 
(Fig. 4.5). For characterisation, stably selected cell lines were treated with Dox and analysed 
for RFP expression by flow cytometry (Fig. 4.5). A single application of Dox resulted in 
robust RFP expression on day one, which increased over time (Fig. 4.5 A) and resulted in 
90% of RFP positive cells after three days (Fig. 4.5 B). Of note, Dox treatment did not 
influence cell viability (data not shown). In parallel, samples of Dox-treated cells were taken 
every 24 hours and expression of PP1α was determined by immunoblot analysis. The 
extend of PP1α protein knock down in shPP1α expressing cell lines occurred in a time-
dependent manner (Fig. 4.5 C) and inversely correlated with RFP positivity. To exclude 
differential TCR stimulation-dependent behaviour, cells were analysed for CD3 and CD28 
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Figure 4.6 Inducible PP1α knock down attenuates secretion of IL-2. (A) Indicated cell lines 
were cultured in the absence (left panel) or presence (right panel) of 2 µg/ml Dox for 72 hours. 
Cells were stimulated with 0.5 µg/ml anti-CD3/CD28 for 12 hours. Subsequently, secretion of IL-2 
was measured by ELISA. Mean +/- SD of three independent stimulations and replicate technical 
measurements is shown.  (B) Induced knock down of PP1α protein was controlled by subjecting 
WCL of cells in (A) to SDS-PAGE, followed by immunoblot analysis using primary antibodies as 
indicated. **, p ≤ 0.005 
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surface expression by flow cytometry (data not shown). CD3 and CD28 surface expression 
did not differ between cell lines and importantly was not altered upon Dox application (data 
not shown). In conclusion, stable cell lines, in which PP1α protein expression can be 
inducibly silenced, were successfully generated.  
To test whether inducible knock down of PP1α would also suppress IL-2 secretion, as seen 
by transient silencing, the two cell lines shPP1α #47 and shPP1α #34 and two cell lines that 
did not decrease PP1α protein levels upon Dox treatment, shContr. and shPP1α #50, were 
analysed by ELISA (Fig. 4.6 A). All cell lines were cultured in the absence or the presence of 
Dox. Three days after Dox application, cells were stimulated via the TCR and IL-2 secretion 
was measured using ELISA. In parallel, PP1α protein levels were assessed by immunoblot 
analysis (Fig. 4.6 B).  
As shown, all cell lines used produced comparable amounts of IL-2 in the absence of Dox, 
indicating that the stable incorporation of the shRNA expression cassette did not alter 
expression of IL-2. In contrast, Dox-induced PP1α silencing suppressed IL-2 secretion by 
40 to 50 % (Fig. 4.6 A, right panel). Importantly, decreased IL-2 levels were confined to cells 
with reduced  PP1α protein expression (Fig. 4.6 B) and did not per se correlate with Dox 
treatment, assigning the phenotype specifically to PP1α function. 
In conclusion, the previous results were confirmed with an independent PP1α loss-of-
function model. Moreover, the used shRNA sequences differ from the previously used 
siRNA sequences, further excluding off-target effects and supporting a specific influence of 
PP1α on TCR-mediated signalling.  
4.7 Knock down of PP1α attenuates IKK activity 
Since transient knock down by siRNA was not applicable to biochemically characterise 
PP1α function within the TCR-induced signalling pathway, the inducible shRNA expression 
system was used for further experiments. Therefore, the phosphorylation status of several 
NF-κB pathway components upon TCR-engagement was analysed. In addition, the kinase 
activity of the endogenous IKK complex was determined by an in vitro kinase assay.  
To this end, PP1α silencing or control shRNA expression was induced, as described above. 
After 72 hours of initial Dox application, cells were stimulated via the TCR over a period of 
90 minutes. The dynamic activation of pathway components was monitored by obtaining 
samples of stimulated cells after defined periods of stimulation. To investigate IKK kinase 
activity, the endogenous IKK complex was immunoprecipitated from WCLs, using anti-
NEMO antibodies. IKK activity was directly measured by applying a fraction of the 
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immunoprecipitates to an in vitro kinase assay using recombinant GST-IκBα as a substrate. 
In parallel, an equivalent portion of immunoprecipitated protein was subjected to SDS-
PAGE to control for equal complex purification by immunoblot analysis. In addition, the 
phosphorylation pattern of various signalling proteins was determined in WCLs. 
As seen in Fig. 4.7 A, PP1α-silencing correlated with a decrease in IKK kinase activity, 
visualised by autoradiography of 32P-IKK and 32P-GST-IκBα. Though, the initial IKKα/β 
autophosphorylation was comparable between PP1α sufficient and deficient cells, in the 
latter autophosphorylation declined more rapidly (Fig. 4.7 A and B). In contrast, 
phosphorylation of IKKα/β as assessed by immunoblot analysis of WCLs was unchanged in 
PP1α-silenced cells (Fig 4.7 A and C), indicating that the activity of IKK-Ks was not affected.  
Overall, the phosphorylation of GST-IκBα was less pronounced in the absence of PP1α (Fig 
4.7 A and B), indicating that IKK kinase activity towards its substrate was decreased. 
Although phosphorylation of IκBα as assessed by phospho-immunoblot analysis seemed 
unaffected (Fig. 4 A), normalisation of phosphorylated to total IκBα protein levels revealed a 
reduction of substrate phosphorylation, again indicating that IKK kinase activity was 
reduced in of PP1α-silenced cells compared to control cells (Fig 4.7 C). In contrast, 
phosphorylation of p65 itself and the MAPKs p38 and Erk1 and Erk2 occurred to an equal 
extent in both cell lines (Fig. 4.7 A, quantification data not shown), implying that the strength 
of TCR stimulation between cell lines was comparable and could not account for the 
observed differences in IKK activity.  
The experiments used to assess PP1α function were either based on endpoint  
measurements after several hours of stimulation or were covering only a time frame of up to 
90 minutes. To gain an extended picture about the influence of PP1α on the NF-κB 
pathway,  long-term kinetics of up to 6 hours were performed. 
To this end, non- or PP1α-targeting shRNA expression was induced as previously 
described. 72 hours after Dox treatment, cells were stimulated via the TCR over a period of 
6 hours, during which lysates of stimulated cells were prepared after different time points of 
stimulation. Subsequently, samples were subjected to SDS-PAGE and the phosphorylation 
status of NF-κB pathway signalling components was determined by phospho-immunoblot 
analysis (Fig. 4.8)  
As shown in Fig. 4.8 A and B, phosphorylation of IKKα/b peaked after 0.5 hours of 
stimulation and was comparable in shContr. and in PP1α-silenced cells (Fig. 4.8 A and B), 
again indicating that the activity of upstream kinases, responsible for IKK phosphorylation, 
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is not likely to be influenced by PP1α. However, phosphorylation of IκBα was again slightly 
decreased by 20 to 30% (Fig. 4.8 A and B), confirming the previous finding. IKK 
phosphorylation was not altered, however kinase activity, measured by phosphorylation of 
IκBα was reduced in PP1α-silenced cells. In contrast, stimulation-dependent IκBα 
degradation and resynthesis occurred to a similar extent in the early phase of TCR-induced 
signalling (up to 2 hours). However, IκBα levels remained decreased at later time points after 
stimulation in PP1α-silenced cells. In line with the preceding experiment, p65 
phosphorylation in the TAD domain was not observed to be influenced by the absence of 
PP1α.  
Collectively, these results demonstrate and verify an influence of PP1α on IKK kinase 
activity, although kinetics and magnitude of IKK activation loop phosphorylation were 
unaffected. The slight changes in phosphorylation and degradation of IκBα require 
additional experimental attention, probably applying more sophisticated techniques not 
applicable at present. In summary, PP1α seems to have only a subtle influence on the early 
cytoplasmic events of signalling to NF-κB.  
Figure 4.7 PP1α alters the kinetics of IKK kinase activity. (A) Indicated cell lines were treated 
with 2 µg/ml Dox to induce non-targeting shRNA expression in control cells (shContr.) or PP1α-
silencing (shPP1α #47). 72 hours later, cells were stimulated with 0.5 µg/ml anti-CD3/CD28 for the 
indicated periods of time. Subsequently, cells were lysed and the IKK complex was 
immunoprecipitated using anti-NEMO antibody. To determine IKK activity, a fraction of the 
immunoprecipitate was subjected to a kinase assay in the presence of [γ-32P]-ATP and 
recombinant GST-IκBα as substrate. An equal portion of immunoprecipitate and WCLs were 
subjected to SDS-PAGE, followed by immunoblot analysis using indicated primary antibodies.  
(B) Quantification of IKK autophosphorylation activity was carried out by quantifiying relative band 
intensities. The 32P-IKK band and total immunoprecipitated IKKβ band intensities of control cells 
at 15 minutes of stimulation was set to 1. 32P-IKK intensities were normalized to total IKKβ 
intensities, to obtain specific values for kinase activity per precipitated protein. Relative amount of 
32P-GST-IκBα was assessed by measuring respective intensities. Intensities in unstimulated cells 
were considered as background and set to 0, whereas the intensitiy in control cells at 15 minutes 
of stimulation was set to 1. (C) Relative quantification of of IKKβ (S177) and IκBα (S32) 
phosphorylation was performed by measuring intensities of the respective immunoblot. Intensities 
of p-IKKβ (S177) at 25 and p-IκBα (S32) at 15 minutes of stimulation in control cells were set to 1. 
Subsequently values were normalized to intensities of total IKKβ and IκBα to obtain values 
indicative for phosphorylation per total protein. Kinase assay, immunoblot analysis and  
quantifications are representative of three independent experiments. 
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4.8 PP1α does not affect TNFα induced signalling to NF-κB 
In macrophages, PP1 has been described as a negative regulator of IKK activity in response 
to TNFα stimulation (Li et al., 2008). Such a role has not been observed in the present study. 
Nevertheless, the idea of an ambiguous signalling function of PP1α downstream of different 
receptor systems in the same cell type is an appealing concept. Therefore, we sought to 
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Figure 4.8 PP1α-silencing decreases IκBα phosphorylation. (A) Indicated cell lines were 
cultured in the presence of 2 µg/ml Dox to induce expression of non-targeting shRNA in control 
cells (shContr.) or PP1α-silencing (shPP1α #47). 72 hours later, cells were stimulated with  
0.5 µg/ml anti-CD3/CD28 for the indicated periods of time. Subsequently, WCL were subjected to 
SDS-PAGE, followed by immunoblot analysis using indicated primary antibodies. (B) 
Quantification of relative IKKβ and IκBα phosphorylation normalized to total protein was 
performed as described in Fig. 4.7. Immunoblot analysis and quantifications are representative of 
3 independent experiments. 
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determine whether PP1α impinges on IKK activity after TNFR stimulation in T cells.   
Knock down of PP1α or non-targeting shRNA expression was induced as described above. 
72 hours later, cells were stimulated via TNFR1 by application of recombinant TNFα over 
various periods of time and activation of NF-κB and MAPK signalling was analysed as 
before.  
As shown in Fig. 4.9, phosphorylation of the investigated signalling proteins collectively 
peaked after 15 minutes of TNFα stimulation and subsequently declining to basal levels. 
Intriguingly, the phosphorylation pattern was unchanged between PP1α-sufficient and   
-silenced cells (Fig. 4.9 A). Also normalisation of phospho-signals to total protein levels did 
not reveal overt differences (Fig. 4.9 B). Moreover, the previously observed decrease in IKK  
kinase activity after TCR engagement, was not apparent after TNFα stimulation (Fig. 4.9 B), 
suggesting that PP1α neither plays a negative nor a positive regulatory role in TNFR-
induced NF-κB signalling in T cells. In line with these data, TNFα-induced NF-κB-dependent 
luciferase reporter acitivity was not altered in PP1α-silenced Gluc-J16 cells (Frey, 2009; data 
not shown), indicating that the phosphatase acts exclusively within the TCR-induced NF-κB 
pathway. 
4.9 PP1α modulates bona fide NF-κB target gene expression  
So far, the here performed experiments were not able to give any indication to the 
mechanism of PP1α function in TCR-induced NF-κB signalling. Although cytokine 
production and NF-κB reporter gene activity were affected in the absence of PP1α, the 
signalling cascade leading to NF-κB activation, despite a small reduction in IKK activity, 
seemed functional. However, these data only provided limited information about the 
transcriptional activity of NF-κB. To gain an extended picture of the kinetics of TCR-induced 
NF-κB-mediated gene expression in PP1α-silenced versus non-silenced cells, NF-κB 
responsive genes were subject of further analyses. 
Figure 4.9 PP1α does not influence TNFα-induced signalling to NF-κB. (A) Indicated cell lines 
were cultured in the presence of 2 µg/ml Dox to induce expression of non-targeting shRNA in 
control cells (shContr.) or PP1α-silencing (shPP1α #47). 72 hours later, cells were stimulated for 
the indicated periods of time with 50 ng/ml recombinant TNFα. Subsequently, WCLs were 
prepared and subjected to SDS-PAGE, followed by immunoblot analysis using indicated primary 
antibodies. (B) For quantification of phosphorylation, band intensities were normalized to 
intensities of total protein, as described before. Intensities in unstimulated cells were set to 1. 
Shown immunoblot analysis and quantifications are representative of 3 independent experiments. 
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PP1α silencing was induced in two cell lines, expressing independent PP1α shRNAs 
(shPP1a #47 and shPP1α #34). In addition, expression of non-targeting shRNA was induced 
in control cells (shContr.). 72 hours later, cells were stimulated via the TCR over various 
periods of time and mRNA levels of several bona fide NF-κB responsive genes, such as  
IL-2,  IL-8, INFγ or IκBα, were determined by qRT-PCR. 
As seen in Fig. 4.10 A, PP1α knock down, resulted in two to three fold lower levels of IL-2 
and IL-8 mRNA after 60 or 90 minutes of stimulation compared to control cells. In contrast, 
INFγ mRNA was equally induced until 60 minutes of stimulation, but reproducibly declined 
in PP1α silenced cells thereafter, while in control cells, mRNA levels further increased. Thus 
PP1α silencing altered the kinetics of INFγ mRNA synthesis, while the overall induction of  
IL-2 and IL-8 mRNA was clearly lower. Interestingly, IκBα expression was only mildly 
affected among independent experiments (Fig. 4.10 A), together with the observation that 
IκBα protein is normally resynthesized after initial degradation in the  
absence of PP1α (Fig. 4.7). 
In summary, expression profiling of the investigated genes demonstrates an impact of PP1α 
on transcriptional activity. Expression of several, but not all bona fide NF-κB target genes 
was shown to be influenced by PP1α. The decreased IL-2 and IL-8 mRNA levels are in line 
with the previous findings. Although transcription initiation is normal for all investigated 
mRNAs, the magnitude of synthesis appears to be controlled by PP1α, indicating that the 
phosphatase might regulate the occupancy or duration of NF-κB at promoter sites.  
Figure 4.10 PP1α influences transcription of bona fide NF-κB target genes. (A) Non-targeting 
and PP1α-targeting shRNA was induced in the indicated cell lines (shContr., shPP1α #47 and #34, 
respectively) by culturing cells in the presence of 2 µg/ml Doxycycline for 72 hours. Subsequently, 
cells were stimulated with 0.5 µg/ml anti-CD3/CD28 and mRNA levels of IL-2, IL-8, INFγ and IκBα 
were determined by qRT-PCR relative to unstimulated cells. (B) Relative PP1α mRNA levels in the 
indicated cell lines were assessed by qRT-PCR. Data are representative of five independent 
experiments. 
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4.10 PP1α regulates DNA binding activity of NF-κB 
The preceding experiment demonstrated a role for PP1α in regulation of NF-κB-mediated 
gene expression, presumably on the level of transcription. Two possible mechanisms may 
account for this phenotype: PP1α either regulates nuclear import of NF-κB dimers or 
modulates the DNA binding activity of the transcription factor. First, the DNA binding activity 
of NF-κB in PP1α-silenced versus non-silenced cells was determined using EMSA. In Jurkat, 
T cells, NF-κB was observed to exhibit high background binding activity in unstimulated 
cells and, thus, experiments were not always conclusive. Hence, primary T cells were used 
to assess the influence of PP1α on DNA binding of NF-κB. 
For this purpose, primary CD4+ T cells were either transfected with control or PP1α-specific 
siRNA. 72 hours after transfection, cells were stimulated via the TCR for the indicated time 
Figure 4.11 PP1α regulates DNA binding activity of NF-κB. Primary human T cells were 
transiently transfected with non-targeting (siContr.) or PP1α-targeting (siPP1α #3) siRNA. 72 hours 
later, cells were stimulated with 0.5 µg/ml anti-CD3/CD28 for the indicated periods of time. 
Subsequently, nuclear extracts were prepared and either subjected to EMSA using dsDNA 
oligonucleotides encompassing the NF-κB binding site in the IL-8 promoter or an EMSA using 
dsDNA oligonucleotides containing the consensus binding site of NF-Y to control for equal protein 
input. Specificity of protein:DNA complexes was controlled by supplying an excess of respective 
unlabelled dsDNA oligonucleotides. In parallel, nuclear extracts were subjected to SDS-PAGE, 
followed by immunoblot analysis. Immunoblots were probed with anti-p65 antibodies to monitor 
stimulus-dependent nuclear translocation of p65 and anti-PARP to control for equal loading. 
Cytosolic fractions of unstimulated cells were subjected to SDS-PAGE, followed by immunoblot 
analysis using indicated primary antibodies to control PP1α knock down (right panel). Results are 
representative of three independent experiments. 
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periods (Fig. 4.11). Subsequently, nuclear extracts of cells were prepared and subjected to 
EMSA, either using NF-κB-specific dsDNA- or NF-Y-specific dsDNA oligonucleotides, to 
control for equal protein input. Specificity of protein:DNA complexes was controlled, by 
adding anti-65 and anti-p50 antibodies to the binding reaction to induce supershifts (data 
not shown) or by applying unlabelled dsDNA probes in excess to compete binding of NF-
κB-  or NF-Y-bound labelled probes. Due to low cell viability after transfection, the analysis 
was limited to three time points after stimulation, which were previously tested to cover the 
peak of NF-κB DNA binding activity after TCR stimulation (data not shown). In addition, 
knock down of PP1α was controlled by immunoblot analysis. 
As seen in Fig. 4.11 (top panel), binding activity of p65:p50 and p50:p50 complexes 
occurred in a stimulus-dependent manner and peaked at 60 minutes of TCR stimulation in 
control-transfected cells. In sharp contrast, knock down of PP1α (siPP1α #3), markedly 
reduced DNA-binding activity of p65:p50 and p50:p50 dimers (Fig. 4.11). In addition, 
nuclear translocation of p65 was analysed, using a portion of nuclear extracts for 
immunoblot analysis. Importantly, nuclear translocation of p65 was unchanged in PP1α-
silenced cells (Fig. 4.11, lower panel). 
Collectively, these data provide evidence that PP1α directly interferes with NF-κB function, 
by regulating its DNA binding activity. Nuclear translocation of p65 was unaffected in PP1α-
silenced cells, indicating that albeit present in the nucleus, p65 is not competent in DNA 
binding in the absence of PP1α. This suggests that a so far unknown modification of p65 or 
a co-factor is regulated by PP1α. 
4.11 Inhibition of PP1 by Tautomycetin attenuates IL-2 secretion 
The presented data show that PP1α regulates NF-κB-mediated gene expression. However, 
this conclusion is primarily based on loss-of-function approaches. To complement these 
data, it was tested, whether the phospholytic activity of PP1α is required. For this purpose, 
Tautomycetin, a phosphatase inhibitor was used, which was shown to selectively inhibit 
PP1 activity (Han et al., 2003). 
Hence, Jurkat or primary human CD4+ T cells were treated with vehicle or increasing 
concentrations of Tautomycetin, ranging from 50 to 250 nM. Cyclosporine A (CsA), a known 
immunosuppressive drug, that counteracts NFAT nuclear translocation by inhibiting 
calcineurin, was used as a positive control. After five hours of pre-incubation with vehicle or 
inhibitors, cells were stimulated via the TCR and IL-2 secretion was measured by ELISA. 
As seen in Fig. 4.12, treatment of Jurkat (A) or primary human T cells (B) with Tautomycetin 
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suppressed IL-2 secretion in a concentration-dependent manner. Although less effective 
than CsA, already 50 nM of Tautomycetin suppressed IL-2 by 30 to 40%, a degree 
comparable to the suppression of IL-2 seen in PP1α-silenced cells. Consistent with knock 
down of PP1α, Tautomycetin did neither affect cell viability nor cytoplasmic signalling to NF-
κB (data not shown). 
Taken together, inhibition of enzymatic activity largely phenocopies the previously 
described effect of PP1α knock down, indicating that catalytic activity is involved in 
regulation of NF-κB signalling by PP1α.  
4.12 Inhibition or knock down of PP1α suppresses proliferation of 
 primary human T cells 
Knock down or inhibition of PP1α suppressed NF-κB-dependent cytokine secretion, like the 
growth factor IL-2, which is required to drive T cell proliferation. Thus, one may speculate 
about a role of PP1α in T cell proliferation. Hence it was tested, whether PP1α-silencing or 
inhibition interferes with TCR-induced proliferation. 
Primary human CD4+ T cells were isolated from peripheral blood of healthy donors and 
transfected with control or PP1α-specific siRNAs. In a second approach, primary T cells 
were treated with various concentrations of Tautomycetin or Cyclosporine A that were 
shown to suppress IL-2 secretion (Fig. 4.12). Proliferation of cells was determined using 
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Figure 4.12 Inhibition of PP1α enzymatic activity attenuates IL-2 production. Jurkat T cells (A) 
or primary human T cells (B) were pre-treated with indicated concentrations of Tautomycetin, 
CyclosporinA (CsA) or vehicle (DMSO) as control for 5 hours. Subsequently, cells were stimulated 
with 0.5 µg/ml anti-CD3/CD28 overnight and levels of secreted IL-2 were measured by ELISA. 
Shown results are representative of five (A) or three (B) independent experiments. (mean +/- SD of 
three independent stimulations and replicate technical measurements); *, p ≤ 0.05; **,  p ≤ 0.005 
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CFSE staining. Therefore, cells were labelled with CFSE 48 hours after transfection.  
24 hours later, cells were stimulated via the TCR and proliferation was assessed on day four 
after stimulation following dilution of CFSE using flow cytometry. As shown in Fig. 4.13 A, 
knock down of PP1α using two independent siRNAs significantly reduced TCR-induced 
proliferation by 40 to 50% compared to control transfected cells. Knock down was 
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(A) Primary human T cells were transiently transfected with control (siContr.) or two independent 
PP1α-specific (siPP1α #1, siPP1α #3) siRNAs. 48 hours after transfection, cells were labelled with 
CFSE. On day three after transfection, labelled cells were stimulated with 0.2 µg/ml anti-CD3,  
0.5 µg/ml anti-CD28 and 2 µg/ml GAM. Subsequently, CFSE dilution was measured by flow 
cytometry on day four after stimulation. Gated on living cells. (B) CFSE-labelled primary T cells 
were stimulated with anti-CD3/CD28 and GAM in the presence of indicated concentrations of 
Tautomycetin (TMC) or CsA or vehicle (DMSO) as co trol for five days. Inhibitors were freshly 
added to the culture medium on day two and four after stimulation. Subsequently, CFSE dilution 
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representative of four independent donors. Numbers in histograms depict the percent of 
proliferating cells in the CFSE dilution gate. (C) Quantification of (B) depicted as percent 
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controlled by qRT-PCR and did result in reduced IL-2 secretion (data not shown). 
Congruently, inhibition of PP1α by Tautomycetin suppressed proliferation in a dose-
dependent manner compared to control treated cells. Consistent with the degree of IL-2 
suppression (Fig. 4.12 B), 100 nM of Tautomycetin suppressed proliferation by ~50% (Fig. 
4.13 B and C). In contrast, 50 nM CsA was sufficient to suppress proliferation by 80%. Of 
note, neither knock down of PP1α nor Tautomycetin exhibited any effect towards cell 
viability, indicating that the reduced rate of proliferation was not caused by cell death. (data 
not shown).  
To test whether the reduced production of IL-2 is causative for the lack of proliferation 
under these conditions, the experiment was repeated in the absence or presence of 
exogenous IL-2 (Fig. 4.14). Tautomycetin reproducibly suppressed proliferation by 50%, 
which was completely rescued by exogenous IL-2. Again, CsA abolished proliferation 
almost completely, but could not be fully rescued by exogenous IL-2.  
In summary, these results indicate that reduced IL-2 production upon inhibition of PP1α is 
causative for the inhibition of proliferation in primary human T cells.  
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Figure 4.14 Tautomycetin-mediated suppression of proliferation is rescued by exogenous 
IL-2. (A) CFSE-labelled primary T cells were stimulated with 0.2 µg/ml anti-CD3, 0.5 µg/ml anti-
CD28 and 2 µg/ml GAM. in the presence of indicated concentrations of Tautomycetin or CsA or 
vehicle (DMSO) as control for five days. In addition, cells were cultured in the presence or 
absence of exogenous IL-2 (100 U/ml) as indicated. Inhibitors were freshly added to the culture 
medium on day two and four after stimulation. Subsequently, CFSE dilution was measured by 
flow cytometry on day five after stimulation. Results are representative of three independent 
donors. (B) Quantification of (A) depicted as percent proliferation (mean +/- SD of three 
independent donors) Significance was calculated to DMSO or DMSO+IL-2 treated cells.  
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4.13 Knock down or inhibition of PP1α sensitizes NF-κB-
 dependent  CTCL cells towards cell death 
The Sézary Syndrome is an aggressive subtype of cutaneous T cell lymphoma (CTCL) and 
is characterised by constitutive proliferation of cells in the blood of patients. Several 
publications have established a direct link between persistent NF-κB activation in Sézary 
cells that is causal for their survival by constantly forcing expression of anti-apoptotic genes 
(Izban et al., 2000; Sors et al., 2006). However, to date, the molecular aetiology and 
abnormalities leading to persistent NF-κB activation are not well understood. However, the 
characterisation of CTCL cell lines reveals a differential dependence on different pathways 
(Brechmann, 2010). Whereas, for example Hut78 cells were shown to exhibit constitutively 
active Ras (Kiessling et al., 2011), HH cells rely on persistent IKK activity (Brechmann, 
2010). While Ras inhibitors are already therapeutically used, systemic application of IKK 
inhibitors, although in clinical trials, might not be feasible. Since it was shown that IKK 
inhibition has unwanted side effects, causing inflammation and breakdown of barrier 
function in the intestinal epithelium (Pasparakis, 2009; Guma et al., 2011), it is of high 
interest to find novel cancer-specific molecular targets that can be therapeutically exploited. 
The present study identified PP1α as a novel positive regulator of NF-κB in T cells. 
Intriguingly, PP1α seems to control the DNA-binding activity of NF-κB in a target gene 
specific manner. It is tempting to speculate that inhibition of PP1α might be a suitable 
therapeutic target in CTCL cells. To test this hypothesis, the influence of PP1α expression 
on CTCL cell survival was investigated. Therefore, two CTCL cell lines, Hut78 and HH, were 
transduced with inducible PP1α-specific shRNA expression constructs as described 
previously. Cells were selected for stable incorporation of the expression cassette into their 
genome and subsequently characterised for RFP positivity after Dox treatment using flow 
cytometry (data not shown). To test for knock down-dependent alterations in cell viability, 
shRNA expression was induced in Hut78, HH and Jurkat T cells. Non-Dox treated cells 
served as controls. Following Dox treatment, samples of cells were acquired on a daily 
basis. A portion of gathered samples was used to control for PP1α protein expression by 
immunoblot analysis. In parallel, cell viability was assessed by propidium iodide staining 
using flow cytometry.  
Viability of Hut78 and Jurkat T cells was unaffected by Dox-mediated PP1α–silencing, but 
HH cells exhibited a strong increase in specific cell death in a time-dependent fashion (Fig. 
4.15 A upper panel). Of note, the induction of the PP1α-specific shRNA expression led to a 
comparable decline of PP1α protein in both cell lines (Fig. 4.15 A lower panel), which 
paralleled increased cell death in HH, but not in Hut78 cells.  
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Next, it was investigated whether inhibition of PP1 activity, rather than silencing, sensitises 
cells towards apoptosis (Fig. 4.15 B). Hence, HH and Hut78 cells were cultured in the 
presence of vehicle or different concentrations of Tautomycetin for up to three days. Cell 
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Figure 4.15 Knock down or inhibition of PP1α sensitizes the NF-κB-addicted CTCL cell line 
HH towards cell death. (A) Indicated cell lines were transduced with lentiviral vectors, containing 
a PP1α-specific Dox-inducible shRNA expression cassette. PP1α-silencing was induced by 
application of 2 µg/ml Dox. Subsequently, specific cell death, compared to untreated cells, was 
determined by propidiume iodide staining daily. WCLs were subjected to SDS-PAGE, followed by 
immunoblot analysis using the indicated primary antibodies, to control for PP1α-silencing (lower 
panel). Reprobing with anti-Actin antibodies verified equal loading. (B) HH (left panel) or Hut78 
(right panel) cells were cultured in the presence of vehicle or indicated concentration of 
Tautomycetin  (TMC) for three days. Viability of cells was determined daily by propidium iodide. 
Specific cell death, compared to untreated cells, was calculated as previously described. 
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viability was assessed on a daily basis by propidium iodide staining using flow cytometry. 
Comparable to PP1α-silencing, HH cells were highly sensitive towards inhibition of PP1α 
activity, resulting in 60 to 70% specific cell death after three days of Tautomycetin treatment 
(Fig. 4.15 B, left panel). In contrast, PP1 inhibition exhibited significantly lower toxicity in 
Hut78 cells, resulting in ~15% to ~20% specific cell death after 3 days of treatment (Fig. 
4.15 b right panel). 
Taken together, these results demonstrate a differential role of PP1α in CTCL cell lines. HH 
cells seem to specifically depend on PP1α activity, indicating the phosphatase as a suitable 
therapeutic target. 
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5. Discussion  
The transcription factor NF-κB is an indispensible regulator of the immune response. It 
mediates lymphocyte activation, proliferation and survival by controlling expression of 
cytokines, growth factors and anti-apoptotic genes (Schulze-Luehrmann and Ghosh, 2006). 
However, several lymphoid malignancies, such as CTCL or ABC-DLBCL, exploit NF-κB 
signalling, resulting in uncontrolled proliferation and expression of anti-apoptotic genes that 
render malignant cells resistant towards apoptosis and insensitive to classical 
chemotherapeutic treatment (Staudt, 2010). Thus, investigation of NF-κB activation as well 
as signal termination is of great interest.  
Engagement of the TCR results in rapid signal transduction to NF-κB, mediated by 
posttranslational modifications of signalling mediators, such as phosphorylation. Many 
studies have concentrated on the identification and characterisation of kinases and their 
substrates, including signalling platforms, like the CBM complex or the IKKs and NF-κB 
subunits. Thus, phosphorylation events cover every step of TCR-induced NF-κB activation 
(see paragraph 1.3.5). However, phosphorylation is reversible and little is known about the 
role of phosphatases in modulating NF-κB activation, although phosphatases have been 
ascribed regulatory functions in several other signalling pathways (Virshup and Shenolikar, 
2010). To date, only few genetic studies demonstrated a selective involvement of 
phosphatases in the NF-κB pathway (see paragraph 1.3.7). However, these studies were 
solely focussing on the TNFR system, using different non-lymphoid epithelial murine and 
human cell lines. Therefore, generalised conclusions, especially with regard to different 
receptor systems and cellular contexts, can not be drawn (Li et al., 2006b; Sun et al., 2009). 
To gain a more comprehensive picture of phosphatases in NF-κB signalling, we employed a 
semi-large scale RNAi screen using Jurkat T cells, allowing to simultaneously study 
signalling downstream of the TCR and the TNFR (Frey 2009, Brechmann, 2010). The genetic 
loss-of-function approach identified several known and unknown candidate phosphatases 
involved in NF-κB signalling (Brechmann, 2010). A subset of candidates selectively scored 
downstream of one of the receptor systems. Accordingly, PP1α was identified as a positive 
regulator of NF-κB specifically downstream of the TCR (see Fig. 4.1, Fig. 4.9) (Frey, 2009; 
Brechmann, 2010). The present study was conducted to validate this finding and 
characterise PP1α and its molecular mechanism with regard to NF-κB activation, T cell 
biology as well as its role as a possible therapeutic target in NF-κB-dependent T cell 
tumors. 
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5.1  RNAi screen identifies PP1α as a positive regulator of NF-κB 
 in T cells 
RNAi-screening has emerged as a powerful tool to identify components of specific cellular 
processes or signalling pathways. Only few RNAi screens were successfully performed in 
lymphocytes. Lymphocytes are largely refractory to liposome-based transfection methods 
and conventional electroporation requires high concentrations of siRNA and is further 
complicated by fluctuating cell viability (Sharma and Rao, 2009). Until now, RNAi screens in 
lymphocytes were primarily based on retroviral transduction of shRNA libraries. Using this 
method, several factors required for proliferation and survival of NF-κB-dependent  
B cell lymphoma cells were identified and characterised (Lenz et al., 2008; Bidère et al., 
2009; Davis et al., 2010; Ngo et al., 2011). Although in the past proven to be successful, 
retroviral approaches entail several pitfalls especially in immune cells: viral infection of target 
cells may directly activate signalling pathways, thereby possibly masking a specific loss-of-
function phenotype. In addition, successfully transduced cells have to be selected via 
antibiotic resistance, potentially leading to selection of unspecifically altered phenotypes 
induced by the technical procedure itself. Due to these obstacles, we favoured transient 
transfection of synthetic siRNA oligos. Although technically challenging, especially in 
suspension cells, we established a Jurkat T cell line, harbouring a stably integrated NF-κB-
dependent reporter gene that allowed specific investigation of genes involved in NF-κB 
signalling. By using a siRNA library, we specifically analysed phosphatases or phosphatase-
associated proteins involved in NF-κB signalling on a large scale (Brechmann, 2010). To our 
knowledge, only one technical report described a siRNA screen in Jurkat T cells utilising 
transient transfection to identify factors involved in CD95-mediated apoptosis (Zumbansen 
et al., 2006). In the present study, we used a commercially available nucleofection method 
for transfection of single siRNA oligos in an arrayed 96 well format. Nucleofection was found 
to be superior over other transfection methods, especially with regard to siRNA delivery, 
knock down efficacy and cell viability (Brechmann, 2010). The validity of the siRNA screen 
was confirmed by the reproducible scoring of positive controls, such as CYLD, CARMA1 or 
p65 (Fig. 4.1 A), which scored with high reproducibility under screening conditions. In 
addition, a number of phosphatases previously associated with NF-κB signalling or T cell 
function scored in our screen (Brechmann, 2010). Moreover, we identified and 
mechanistically characterised the PP4c:PP4R1 phosphatase holoenzyme as a negative 
regulator of IKK activity in T cells (Brechmann, 2010; Brechmann and Mock et al., 
manuscript in preparation), further strengthening the validity of the primary screening and 
analysis strategy. Taken together, these findings prompted us to investigate additional 
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candidate phosphatases. Accordingly, PP1α was identified as a putative positive regulator 
of NF-κB and, thus, was further investigated (Fig. 4.1 A).  
PP1α belongs to the PP1 family of phosphoprotein phosphatases (PPP), which accounts for 
the majority of all phosphatase activity in eukaryotes (Bollen et al., 2010). The human 
genome contains three PP1-encoding genes that encode four PP1 isozymes: PP1α, PP1β 
and the splice variants PP1γ1 and PP1γ2. According to the BioGPS gene expression atlas 
(http://www.biogps.org, GeneAtlas), the four members exhibit a distinct expression pattern 
over different tissues. Interestingly, PP1α is predominantly expressed in cells of the 
hematopoietic system, suggesting a prominent role in immune cells. However, all PP1 
members exhibit rather broad phospholytic activity in vitro and are implicated in almost all 
cellular processes, including mitosis, cytoskeleton organisation, transcription and signal 
transduction. Due to their pleiotropic activity and function, PP1 proteins are assisted by a 
myriad of regulatory proteins that confer substrate specificity, influence cellular localisation 
and control the phospholytic activity of the catalytic subunits (Ceulemans et al., 2002). At 
present, approximately 180 mammalian genes are known to encode direct PP1 interactors, 
but the actual number may be even higher (Bollen et al., 2010; Virshup and Shenolikar, 
2010). PP1 proteins therefore exist in multimeric complexes, containing one catalytic 
subunit and one to two regulatory subunits. The RNAi library used in this study 
encompassed siRNA oligos targeting 20 known PP1 regulatory subunits. However, our data 
analysis and selection criteria did only qualify one PP1 regulatory subunit, called PP1R11, 
for hit selection. In contrast to PP1α though, PP1R11 was found to increase NF-κB activity, 
as well as cytokine secretion upon knock down (Blank, 2011). Therefore, validation and 
characterisation of the positive regulatory role of PP1α in TCR-induced NF-κB signalling 
focussed on the catalytic subunit itself.  
Transient PP1α-silencing suppressed NF-κB reporter activity by 30% to 40%, a phenotype 
congruent with the z scores observed during the initial screen (Fig. 4.1 A). Since expression 
of several cytokines, including IL-2, IL-8 and IFNγ, critically depends on NF-κB function, we 
considered cytokine secretion as a more physiological readout than reporter gene assays. 
Accordingly, we observed a reduction in NF-κB-dependent cytokines, like IL-2 and IL-8, 
ranging from 40% to 60% in transiently PP1α silenced Jurkat T cells (Fig. 4.3). These 
findings were further extended to primary human T cells, suggesting that PP1α indeed plays 
an important role upon TCR engagement. Transient silencing by nucleofection, which 
harbours disadvantages, such as fluctuating cell viability and low cell numbers, limited 
biochemical analysis of signalling events. Hence, Jurkat T cell lines were established in 
which PP1α expression could be inducibly silenced (Fig. 4.5). Induced PP1α silencing 
reproduced the phenotypes observed by transient siRNA transfection. In addition, we could 
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exclude that the observed phenotypes were due to reduced cell viability, since we could not 
observe adverse effects of long term induced PP1α-silencing on cell survival in Jurkat T 
cells (data not shown). Hence, our initial findings could be validated by this independent 
approach (Fig. 4.6). Ectopic expression of PP1α induced NF-κB activity in HEK293T cells in 
the absence of any stimulus (Fig. 4.2 A). In contrast, overexpression of  PP1α in Jurkat T 
cells augmented NF-κB activity only upon TCR-triggering, suggesting that the phosphatase 
is actively engaged downstream of the TCR (Fig. 4.2 B). Further underlining a role of PP1α in 
TCR-induced signal transduction, we found that PP1 phospholytic activity may be 
increased upon TCR engagement using immunoprecipitated PP1α for an in vitro 
phosphatase assay (data not shown). However, these results have to be evaluated with 
caution, since non-specific para-nitrophenylphosphate was used as a substrate. Thus, other 
unspecifically co-purified phosphatases may account for the increased phosphatase activity 
upon TCR stimulation.   
Although one may suspect that due to its pleiotropic function, PP1α knock down may 
disturb several signalling pathways, we only found evidence for a function of PP1α in TCR-
induced NF-κB activation. PP1α-silencing was neither found to affect TNF signalling or 
TNFα induced NF-κB reporter activity nor did we observe an effect on NFAT or AP-1 
activation in T cells (Fig. 4.9 A and B and data not shown).  
Taken together, our RNAi screening and subsequent validation strategy identified and 
confirmed PP1α as a novel positive regulator of NF-κB in T cells. In contrast to the here 
presented data, PP1α has previously been described to negatively regulate IKK activity (Li et 
al., 2008). However, the authors solely focused on the TNFR-induced IKK activation in HeLa 
cells. Moreover, critical experiments concerning interaction and activity were based on 
stably overexpressed proteins in antibiotically-selected HeLa cell lines and were not 
confirmed by more physiological approaches such as knock down or primary cell analysis.  
5.2  The influence of PP1α on NF-κB signalling 
Since PP1α was found to positively regulate NF-κB, we were interested whether PP1α 
directly interferes with signalling to NF-κB upon TCR engagement. Activation of the IKK 
complex is the crucial event within the canonical NF-κB pathway, mediating 
phosphorylation-induced degradation of IκB proteins. In the current study, different 
methods were employed to characterise signal transduction events, crucial for signalling to 
NF-κB activation in non-silenced versus PP1α-silenced cells. Accordingly, IKK kinase 
activity was assessed using in vitro kinase assays and signal propagation was monitored by 
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phospho-immunoblot analysis of critical pathway components, including IKKα, IKKβ, p65 
and IκBα. PP1α-silencing correlated with a decrease in IKK activity towards recombinant 
substrate (Fig. 4.7). Accordingly, phosphorylation of IκBα was mildly decreased (Fig. 4.7). In 
contrast, phosphorylation of p65 at S536 in the transcription activation domain, which was 
also shown to be mediated by IKKβ, displayed no overt abnormalities (Fig. 4.7). Several 
questions arise from these observations: How does PP1α influence IKK activity? And, is the 
observed decrease in IKK activity of functional relevance for NF-κB activation?   
In T cells, IKK activation is dependent on CBM complex-mediated recruitment of the IKK 
complex to the IS, followed by a series of posttranslational modifications of IKKα, IKKβ and 
NEMO that are essential to regulate kinase activity (Vallabhapurapu and Karin, 2009). In line 
with genetic studies, Delhase et al. have defined IKKβ as the dominant kinase component 
within the complex (Delhase et al., 1999), though IKKα may contribute to total IKK activity. 
The authors showed that phosphorylation of two conserved serine residues within the 
activation loop of the kinase domain of IKKα and IKKβ (S176/S180 and S177/S181, 
respectively) is crucial to induce kinase activity. These phosphorylation events were 
suggested to be mediated by transautophosphorylation. Additionally, TAK1 and MEKK3 
were described to act as IKK kinases (Yang et al., 2001b; Shim et al., 2005). However, the 
studies could not provide evidence for a direct involvement in IKK activation loop 
phosphorylation in vivo. Hence, it was recently suggested that initial IKK activation occurs 
through proximity-induced transautophosphorylation, whereas TAK1 and MEKK3 assist to 
prolong IKK activity through a yet to be defined mechanism (Vallabhapurapu and Karin, 
2009). We observed no differences in the peak of IKKα/β autophosphorylation 
(Fig. 4.7 A and B). However, IKKα/β autophosphorylation activity declined more rapidly in 
PP1α-silenced cells compared to control cells, which might be connected to reduced 
activity of the IKK-Ks. Interestingly, one study described a direct interaction between PP1α 
and MEKK3 (Bouwmeester et al., 2004). MEKK3 contains a conserved threonine residue at 
position 294 that when phosphorylated promotes 14-3-3 protein association resulting in 
decreased NF-κB activation upon TNFR and TCR triggering (Matitau and Scheid, 2008).  
Thus, one may speculate that PP1α, through its previously reported interaction with MEKK3, 
controls the IKK function, which may explain the changed kinetics of IKK activity.  In 
contrast to the findings based on in vitro kinase assays, phospho-immunoblot analyses 
revealed no differences in IKKα/β activation loop phosphorylation on all investigated 
phospho-sites in PP1α-silenced cells (Fig. 4.4 and Fig. 4.7). Hence, PP1α may act on IKK 
phosphorylation by itself or through upstream mediators like MEKK3 via another 
mechanism. Accordingly, activation of IKK activity was described to be dependent on two 
separate events (Shambharkar et al., 2007). Although activation loop phosphorylation is 
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required, it is not sufficient to confer kinase activity. In addition, K63-linked ubiquitination of 
NEMO, in a CBM complex-dependent manner, was shown to be mandatory for IKK activity 
upon TCR stimulation. Since the present study focused on changes in phosphorylation of 
pathway components, it cannot be excluded that PP1α influences upstream signalling 
mediators required for ubiquitination of NEMO. Therefore ubiquitination of NEMO in PP1α-
silenced cells should be investigated in the future. Alternatively, other means of regulation 
that have been shown to control IKK activity independent of activation loop phosphorylation 
(Delhase et al., 1999; Huxford and Ghosh, 2009) may account for the observed phenotype 
in PP1α-silenced cells. In this respect, two other regions within the IKKs, the HLH-motif and 
the NBD, are of special importance. The HLH motif directly interacts with the kinase domain 
and mutations within this motif have been shown to decrease IKK activity (Delhase et al., 
1999). It contains several serine residues, which might be subject to regulation by PP1α. The 
NBD, which mediates binding of IKKα/β to NEMO harbors three phosphorylation sites 
(S733, S740 and S750) that control assembly and stability of the IKK complex (Higashimoto 
et al., 2008). However, PP1α-mediated alterations in IKK complex composition or an overall 
decrease of IKK complex per se were not supported by our data (Fig. 4.7 A), excluding an 
influence of PP1α. A prerequisite for a direct regulation of IKKs by PP1α would be a direct 
interaction between these proteins. Indeed, one study has previously shown a direct 
interaction between the IKK complex and PP1α (Li et al., 2008). In contrast to our data, this 
study suggested that PP1α negatively regulates IKK activity, by dephosphorylation of 
IKKα/β. Non-redundant roles of PP1α downstream of different receptor systems and/or 
different cell types might explain these contradicting results. Indeed, we have previously 
identified the PP4R1:PP4c phosphatase holoenzyme to negatively control IKK activation 
loop phosphorylation in T cells (Brechmann, 2010; Brechmann and Mock et al., manuscript 
in preparation), suggesting that different cell types use distinct phosphatases to counteract 
IKK activity. In line with this concept, one study described a positive regulatory role for the 
PP1-related protein PP2A by controlling NEMO function (Kray et al., 2005), although 
evidence exists that PP2A negatively regulates NF-κB signalling upstream of the IKK 
complex (see paragraph 1.3.7). Yet, the study has to be evaluated with caution, since the 
authors used broad range phosphatase inhibitors and methods that could potentially 
indicate a role for any PPP member, including PP1α. We did not observe an association 
between endogenous IKKs and PP1α in Jurkat or primary T cells (data not shown). 
However, using co-expression of IKK components and PP1α in HEK293T cells, we were 
able to co-purify exogenous PP1α preferentially with immunoprecipitated NEMO (data not 
shown). However, this preliminary finding has to be confirmed with endogenous proteins, 
since overexpression may lead to unspecific results. 
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IKK activity is regulated by a large number of posttranslational modifications, conferring 
conformational changes, subcellular localization and enzymatic activity. According to the 
phosphosite database (Hornbeck et al., 2004) IKKα, IKKβ and NEMO contain over 30 
characterized phosphorylation sites, indicating a high degree of regulation. In this study 
though, investigation of phosphorylation sites was hampered by the availability of high-
grade phospho-site-specific antibodies and, thus, the analyses were limited to a subset of 
phosphorylation sites. Therefore, potentially more sensitive and unbiased approaches might 
help to identify PP1α-regulated phosphorylation sites (discussed in paragraph 5.6). Our 
findings imply that PP1α acts in a TCR-dependent manner, either by regulating 
phosphorylation of T cell-specific signalling components or by being actively engaged after 
TCR engagement through an unknown mechanism. However, ectopic expression of PP1α in 
HEK293T cells induced NF-κB activity in the absence of any stimulus, suggesting that PP1α 
substrates are not T cell specific, but PP1α phospholytic activity is regulated in a TCR- or 
CD28-dependent manner. Based on findings of the present study, the possible mechanisms 
of regulation of NF-κB activation by PP1α remain elusive and it appears unlikely that the 
observed mild changes in IKK activity can account for the pronounced effects on cytokine 
secretion. IκBα phosphorylation and degradation were only mildly affected in PP1α-silenced 
cells, while p65 phosphorylation at serine 536 remained unchanged compared to control 
cells. However, PP1α as a catalytic subunit may function in different phosphatase 
holoenzymes at more than one level of the NF-κB activation cascade. Therefore, it is 
plausible that the sum of different effects, including the influence on IKK activity as well as 
other putative molecular alterations in the NF-κB pathway account for the observed 
phenotype. 
5.3  Regulation of NF-κB mediated gene transcription by PP1α 
Although IKK activity as well as IκBα phosphorylation were found to be mildly attenuated, 
subsequent signalling leading to nuclear translocation of p65, at least in scope of the used 
readouts, seemed to be unchanged in PP1α-silenced compared to non-silenced Jurkat T 
cells. In contrast, the presented data clearly demonstrates an influence of PP1α on the 
kinetics and strength of bona fide NF-κB target gene transcription, such as IL-2, IFNγ and 
IL-8 (Fig. 4.10). Surprisingly though, IκBα transcription and resynthesis, which is solely 
dependent on NF-κB activity, was mostly unaffected (see Fig. 4.8 and 4.10). To understand 
this dichotomy, the different regulatory elements of NF-κB target gene selectivity have to be 
taken into consideration. NF-κB is activated by different stimuli, such as TNFα, LPS or 
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antigen receptor-triggering (Sen and Smale, 2010). However, each different stimulus results 
in the activation of distinct sets of NF-κB target genes. In addition, the response in different 
cell types, like lymphocytes, macrophages or epithelial cells, to the same NF-κB activating 
stimulus is different as well (Smale, 2011). Therefore, several layers of regulation confer a 
selective NF-κB response. One mechanism of a selective NF-κB response seems to be the 
regulation of different target genes by distinct homo- and heterodimeric NF-κB species. In 
cells lacking either c-Rel or p65, most NF-κB target genes are expressed normally, 
suggesting highly redundant functions or compensatory mechanisms (Gerondakis et al., 
2006). However, some target genes depend on one particular NF-κB subunit for expression. 
Both, c-Rel and p65 deficient mice (Gerondakis et al., 2006), exhibit immune defects, 
proving that the function of these proteins is not entirely redundant. Microarray analysis 
performed in c-Rel-deficient T cells revealed only few genes that show strong dependence 
on this particular member (Bunting et al., 2007). For example, IL-2 expression was found to 
be attenuated. However, the authors do not exclude that c-Rel function might not be 
limiting for IL-2 expression and that other NF-κB subunits are able to substitute for loss of 
c-Rel. Most cytoplasmic c-Rel is bound by IκBβ, which, like IκBα, is degraded in an IKK-
dependent manner. However, we did not detect a defect in IκBβ degradation in PP1α-
silenced Jurkat T cells (data not shown), suggesting that  PP1α does not selectively interfere 
with c-Rel function. In line with these observations, IL-8 and IFNγ expression that have been 
shown to mainly depend on p65 function and being independent of c-Rel (Kunsch and 
Rosen, 1993; Sica et al., 1997), were suppressed in PP1α-silenced cells (Fig. 4.10), thus 
excluding an selective effect on c-Rel. 
Another fundamental feature of canonical NF-κB activity is its transience. Indeed, relative 
induction of IL-2, IFNγ and IL-8 expression was not affected up to 60 minutes after 
stimulation (Fig. 4.10). Only after 60 (for IL-8) and 90 minutes (for IL-2 and IFNγ), relative  
transcript levels were significantly reduced in PP1α-silenced versus non-silenced cells. Most 
interestingly, IFNγ expression was equally induced in PP1α-deficient and sufficient cells until 
60 minutes of stimulation, but abruptly declined thereafter in the former, while PP1α-
sufficent cells further increased IFNγ transcript levels (Fig. 4.10). In line with these data, 
reduced DNA binding activity of p65:p50 dimers at 60 minutes of stimulation in PP1α-
silenced primary T cells was demonstrated (Fig. 4.11). Taken together, these observations 
suggest that PP1α might regulate the dwell time of NF-κB in the nucleus or its occupancy at 
certain promoter sites. The major pathway to regulate NF-κB nuclear localisation described 
is via nuclear export of IκBα and IκBε-associated NF-κB proteins (Sen and Smale, 2010). 
NF-κB-mediated expression of IκBα and IκBε is rapidly induced upon NF-κB activating 
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stimuli. De novo synthesised IκBs translocate to the nucleus, associate with NF-κB dimers, 
and export the transcription factor to the cytoplasm via NESs present at the N-terminus. In 
addition, IκBα was observed to actively disrupt DNA-bound NF-κB complexes in vitro in a 
cell free system, which may also apply to promoter-bound NF-κB in the nucleus (Zabel and 
Baeuerle, 1990). However, nuclear translocation of p65 was unaffected upon PP1α-silencing 
(Fig. 4.11). Our analyses did not include other NF-κB subunits or IκB proteins and 
immunoblot analysis might be not sensitive enough to detect minor differences in NF-κB 
translocation, when only a subset of target genes is regulated by such a mechanism. One 
approach to address such a question in more detail, would be through monitoring 
nuclear/cytoplasmic shuttling of NF-κB subunits in PP1α-silenced versus non-silenced cells, 
using time-lapse microscopy or high throughput Image-Stream© analysis. In contrast to 
IκBα, IκBβ does not contain a NES and was shown to translocate to the nucleus and 
associate with promoter-bound NF-κB proteins to stabilize DNA-protein interactions at a 
subset of promoters (Suyang et al., 1996; Rao et al., 2010). Accordingly, one may envision 
that PP1α-silencing causes disruption of such stabilised complexes, causing normal nuclear 
export via binding of NES-containing IκB proteins. However, IκBβ stabilised NF-κB-DNA 
complexes have only been shown to form upon prolonged TNFα stimulation and PP1α-
silencing only caused decreased NF-κB acitivity downstream of the TCR, but not of the 
TNFR (Frey, 2009; data not shown).  
Degradation of promoter-bound p65 was reported as another regulatory mechanism to 
control the transient nature of NF-κB-dependent gene expression (Sen and Smale, 2010). 
Several laboratories have shown that an E3-ligase complex in conjunction with the 
ubiquitously expressed negative NF-κB regulator COMMD1 facilitates the proteasome-
mediated degradation of p65 (Maine et al., 2007; Sen and Smale, 2010). In addition, 
methylation of p65 at lysine 314 and 315 by the methyltransferase SET9 has been 
implicated in marking promoter-bound p65 for degradation in an inducible and promoter-
specific manner. SET9 knock down resulted in increased IL-8 expression, but had no effect 
on A20 or IκBα (Yang et al., 2009). Therefore, pre-bound SET9 at a subset of promoters 
might constitute one mechanism by which promoters are marked for down-regulation by 
p65 degradation. Indeed, the activity of SET methyltransferases was shown to be 
counteracted by phosphatases, suggesting a possible point of interference with PP1α. 
Another group of enzymes, the protein inhibitor of STAT (PIAS) proteins were shown to 
control promoter occupancy of NF-κB dimers in a promoter-specific manner. PIAS1 and 
PIAS4 knockout mice are hypersensitive to septic shock and exhibit enhanced DNA-binding 
activity to p65 (Liu et al., 2004; Liu et al., 2005). Interestingly, PIAS1 and PIAS4 regulate 
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expression of distinct NF-κB target genes. Whereas PIAS1 has substantial effects on TNF-
induced IκBα and IL-1β expression, PIAS4 affects expression of the chemokine CXCL1 
(Ruland, 2011). Yet, their exact mode of action is unknown, but involves block of DNA-
binding activity and recruitment of co-repressors. A fraction of IKKα is constitutively 
associated with PIAS1 and can directly phosphorylate PIAS1 after inflammatory activation 
(Liu et al., 2007). This modification induces dissociation of PIAS1 from the kinase and 
stimulates its movement to promoters of NF-κB target genes to mediate transcriptional 
termination. Whether such a mode of regulation also occurs in T cells was not investigated 
so far. However, the finding that PIAS1 knockout mice exhibit normal signal transduction 
and normal nuclear translocation of p65 is similar to our observations in PP1α-silenced cells 
(Fig. 4.7; Fig. 4.11). Therefore, regulation of PIAS activity by PP1α is an appealing idea and 
should be analysed further. 
The above discussed mechanisms give only a snapshot of the regulatory elements that 
contribute to the transient nature of an NF-κB response in the nucleus. The presented data 
strongly suggest a nuclear role of PP1α in regulating NF-κB activity, since cytoplasmic 
signalling events seem not overtly altered. To further analyse the influence of PP1α on 
promoter-specific NF-κB binding activity via PIAS1, SET proteins or other putative 
mechanisms, chromatin immunoprecipitation (ChIP) should be employed to gain an 
extended picture of the dynamics of NF-κB presence at selected promoters.   
5.4  PP1α function is required for normal T cell proliferation 
The presented data shows that knock down of PP1α in primary human CD4+ T cells results 
in a significant reduction of IL-2 secretion. IL-2 is an essential growth factor for T cells 
required for their proliferation. Thus, we were interested whether the suppressed IL-2 
secretion would have any impact on the proliferative capacity of T cells. Indeed, we found 
that knock down of PP1α resulted in a substantial decrease in proliferation of up to ~50%, 
correlating with the degree of IL-2 suppression (Fig. 4.3 C and Fig. 4.13 A). Since transient 
transfection of primary human T cells by nucleofection generally decreased cell viability and 
we also wanted to address whether inhibition of enzymatic activity would suffice for the 
observed phenotype, we explored the use of the PP1 inhibitor tautomycetin. Tautomycetin 
is a natural anti-fungal antibiotic extracted from the bacterium Streptomyces 
spiroverticillatus. Most phosphatase inhibitors, like ocadaic acid, calyculin A, mycrocytins or 
fostriecin exhibit a rather broad spectrum inhibitory activity towards several PPPs, probably 
due to the structural similarity of the catalytic domain of PPPs (Shi, 2009). In contrast, 
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tautomycetin has been defined as a highly specific inhibitor of PP1, suppressing 
phospholytic activity of PP1 proteins 40 fold stronger than that of PP2A or PP2B at low 
concentrations (Mitsuhashi et al., 2008). Application of 50 to 100 nM tautomycetin reduced 
IL-2 secretion by 40 to 50% in Jurkat and in primary human CD4+ T cells, comparable to 
knock down of PP1α (Fig. 4.12). Importantly, tautomycetin exhibited no cytotoxic effects at 
the used concentrations. Therefore, we also assessed whether tautomycetin application 
would suppress T cell proliferation. In line with the degree of suppressed IL-2 secretion, 100 
nM tautomycetin suppressed T cell proliferation by ~50%, again not affecting cell viability 
(Fig. 4.13 B). These data strongly suggest that the suppressed proliferation is directly 
connected to reduced IL-2 production. Indeed, the defect in proliferation by tautomycetin 
treatment was completely rescued by addition of exogenous IL-2 (Fig.  4.14), implying that 
the PP1 inhibition- or knock down-mediated suppression of IL-2 is causal for the 
proliferative defect. CsA, a known immunosuppressive drug targeting calcineurin and 
thereby NFAT function, was used as a control. In contrast to tautomycetin, CsA-mediated 
suppression of proliferation could not be completely rescued by IL-2 addition (Fig. 4.13 B), 
indicating that the inhibitor affects more than one pathway or overlapping pathways to a 
different extent. Accordingly, it has been known that calcineurin inhibition by CsA influences 
signalling to NF-κB (Marienfeld et al., 1997), resulting in lower IKK activity in T cells. Two 
recent publications substantiate this observation, demonstrating that calcineurin activity is 
needed for CBM-complex stability by dephosphorylation of Bcl-10 (Palkowitsch et al., 2011; 
Frischbutter et al., 2011). Hence, while CsA inhibits both NFAT and NF-κB signalling, PP1α 
inhibition or knock down, on the basis of our data, selectively affects NF-κB function, 
explaining why the CsA-mediated suppression of proliferation may not be completely 
rescued by exogenous IL-2. Our suggestion that PP1α selectively interferes with NF-κB 
function is supported by the observation that p65-deficient T cells exhibit reduced, but not 
completely suppressed proliferative capacity (Doi et al., 1997). Tautomycetin has been 
described as a T cell-specific immunosuppressive compound before (Shim et al., 2002; Han 
et al., 2003; Chae et al., 2004). However, most of the studies used concentrations of 
tautomycetin in the micromolar range, which was shown to inhibit other PPP members as 
well (Han et al., 2003). In line with another study that investigated the effects of 
tautomycetin on T cell viability (Shim et al., 2002), we observed increased cell death at these 
concentrations (data not shown), indicating unspecific effects. Interestingly, inhibition of 
PP1α by tautomycetin has also been implicated to suppress IKK activity in HEK293T cells 
(Mitsuhashi et al., 2008). In contrast to our data,  tautomycetin almost completely 
suppressed IKK activity in response to TNFα. However, the different cellular setting 
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combined with the use of very high concentrations of tautomycetin and the lack of genetic 
evidence by knock down of PP1α limits comparisons of this study to ours. 
Taken together, we demonstrate a direct connection between PP1α and IL-2-dependent T 
cell proliferation. Moreover, due to our data, demonstrating an influence of PP1α on NF-κB 
mediated IL-2 gene expression, we suggest that this is directly connected to regulation of 
NF-κB by PP1α. However, more experimental work is required to delineate the role of PP1α 
in T cell physiology.  
5.5  Therapeutic targeting of PP1α in Sézary syndrome  
The concept of “oncogenic addiction” has initially been defined by Weinstein (Weinstein, 
2002) and reflects the observation that cancer cells are dependent on (or “addicted to”) the 
activity of oncogenic factors or pathways for sustained proliferation and survival, by 
counteracting pro- and enhancing expression of anti-apoptotic factors (Weinstein, 2002; 
Hanahan and Weinberg, 2011). However, single oncogenes are not sufficient to drive 
tumorigenesis. Collaboration with other oncogenes or loss of tumor suppressors are 
required. In contrast, single oncogene suppression has been shown to restore the balance 
between pro-and anti-apoptotic factors, which allows a cell to reinstate its physiological 
checkpoint mechanisms, resulting in spontaneous apoptosis of tumor cells (Weinstein, 
2002; Weinstein and Joe, 2008; Hanahan and Weinberg, 2011). Hence, oncogenes or 
oncogenically activated pathways can also be considered as the Achilles heel of cancer 
cells. Several studies have established the oncogenic activation of NF-κB, through a variety 
of oncogenic mutations of pathway components, as a hallmark of several hematologic 
malignancies (reviewed in paragraph 1.4). A shared consequence of these mutations is the 
constitutive activation of IKKs. Accordingly, many IKK inhibitors have been developed and 
proven to exhibit anti-tumorigenic effects in a variety of experimental in vivo models, 
ranging from lymphoma to melanoma (Amschler et al., 2010; Lam et al., 2005). However, at 
present no such drug has been clinically approved. Several hurdles may hamper the 
systemic inhibition of IKKs: (i) long-term and full inhibition of IKKβ would be expected to 
impair innate and adaptive immunity, (ii) since IKKβ was described to counteract IL-1β 
processing and secretion, IKKβ inhibition might cause severe inflammation (Greten et al., 
2007) and (iii) IKK activity has been shown to be essential to maintain epithelial barrier 
function in the small intestine (Pasparakis, 2009; Guma et al., 2011). Therefore, it may be 
more applicable to target disease-specific molecular lesions. Accordingly, frequent 
mutations in the signalling activators CARMA1 and MyD88 have recently been described to 
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drive persistent activity of downstream effectors (like IKKs and IRAK1/4, respectively) in 
ABC-DLBCL cell lines and patient specimens, resulting in constitutive NF-κB activity (Lenz 
et al., 2008; Ngo et al., 2011). Knock down of these oncogenic factors or interference with 
their downstream effectors sensitised cells towards cell death. The identification and 
characterisation of oncogenic mutations and their consequences can therefore open new 
windows of opportunity for therapeutic intervention.  
CTCLs belong to a rather heterogeneous group of skin-associated neoplasms among which 
the leukemic Sézary syndrome (SS) represents the most aggressive subtype (reviewed in 
paragraph 1.4.1), which to date is not curable. Several publications have established a 
direct link between SS cell survival and a dependence on persistent NF-κB activity (Izban et 
al., 2000; Sors et al., 2006; Sors et al., 2008). CTCL cell lines, like HH, SeAx and MyLa as 
well as malignant peripheral blood lymphocytes from SS patients are susceptible to 
inhibition of the NF-κB pathway (Sors et al., 2006; 2008; Kiessling et al., 2009). Hence, 
CTCL cells are defined as oncogenically addicted to NF-κB. However, the molecular 
aetiology of persistent NF-κB activity in SS is largely unknown (Lenz et al. 2008; Ngo et al., 
2011). Our RNAi screening approach identified the PP4c:PP4R1 phosphatase holoenzyme 
as a negative regulator of the IKK complex in T cells (Brechmann, 2010, Brechmann and 
Mock et al., manuscript in preparation). In addition, we found PP4R1 expression to be 
reduced or absent in a subset of CTCL cell lines as well as in SS patient samples. Ectopic 
expression of PP4R1 in the PP4R1-deficient CTCL cell line HH inhibited constitutive IKK 
activity and sensitised cells towards cell death. Therefore, deficiency of PP4R1 might be 
one causative factor that contributes to oncogenic NF-κB addiction in a subgroup of 
CTCLs. However, therapeutic targeting of IKK activity by reintroducing PP4R1 in PP4R1-
deficient cells is hardly applicable. Since PP1α was found as a positive regulator of NF-κB, 
we reasoned that the phosphatase may constitute a suitable therapeutic target for 
treatment of NF-κB-addicted CTCL. Therefore, we analysed the dependence of the CTCL 
lines HH and Hut78 on the expression of PP1α, using our Dox-inducible knock down 
system. Indeed, we found a strong dependence of HH cell survival on PP1α expression (Fig. 
4.15 A). These findings could be further substantiated by the application of the PP1 inhibitor 
tautomycetin, which selectively induced apoptosis in HH, but not Hut78 or Jurkat T cells 
(Fig. 4.15 B and data not shown). Hence, we conclude that PP1α-targeting might be a future 
possibility for treatment of CTCL. Indeed, tautomycetin in addition to its 
immunosuppressive capacity, has been previously shown to exert anti-tumorigenic effects 
(Adler et al., 2009). In addition, systemic application of tautomycetin in a rodent islet 
allograft model for up to 100 days was not exerting specific organ toxicity (Wee et al., 2010). 
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However, substantial experimental work has to be conducted to show whether PP1α 
inhibition is causative for suppression of NF-κB acitivity in CTCL leading to cell death.  
5.6  Outlook 
The present study identified and characterised PP1α as a positive regulator of  
NF-κB signalling after TCR engagement using different experimental readouts. Loss of 
function approaches demonstrated a significant impact on NF-κB-driven cytokine 
production, most likely regulating DNA-binding activity of NF-κB. Moreover, silencing and 
enzymatic inhibition of PP1α was found to inhibit IL-2 dependent proliferation of primary 
human T cells. Furthermore, silencing and enzymatic inhibition of PP1α in HH cells identify 
the phosphatase as a possible therapeutic target in NF-κB-addicted CTCL cells. Although 
these are several lines of evidence for a physiological function of PP1α in T cells, the exact 
molecular mechanism of NF-κB regulation by PP1α remains to be resolved. Analysis of the 
NF-κB signalling pathway yielded little information, apart from a reproducibly observed 
decrease in IKK activity in PP1α-silenced Jurkat T cells. PP1α as a phosphatase is expected 
to modulate dephosphorylation of target proteins. Yet, no overt differences in 
phosphorylation of selected NF-κB pathway components were observed. However, the 
used phospho-immunoblot analysis entails several technical limitations that might hamper 
the identification of changes in the phospho-proteome of PP1α-silenced cells: (i) 
investigation of specific phosphorylated residues in a given protein is highly biased,  
(ii) availability of high quality phopho-site specific antibodies limits analysis to a few known 
phosphorylation sites, (iii) phospho-immunoblot blot analysis might be too insensitive to 
quantitatively detect subtle differences of low abundance phospho-sites. A recent 
proteomics study, which described 696 TCR-responsive phosphorylation sites further 
underlines the limitations of traditional techniques (David K. Han, 2009). Due to these 
obstacles, a more global approach is required to identify PP1α-mediated changes in the 
phospho-proteome of TCR-stimulated cells. Therefore, a highly sensitive proteomic 
screening procedure, based on stable isotope labelling with amino acids in cell culture 
(SILAC) was utilised, but could not be completed during the present study (collaboration 
with Dominic Winter, PhD, Children’s Hospital Boston). SILAC relies on the incorporation of 
amino acids with substituted stable isotopic nuclei (e.g. 2H, 13C, 15N) into the proteome of a 
cell. Thus, cell populations can be cultured in the presence of “light-“ or “middle-“ or 
“heavy-weight” isotopic amino acid analogues. Once the differentially labelled amino acids 
are supplied to cells, they are incorporated in every newly synthesized protein. Hence, after 
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a number of cell divisions, every protein incorporated the differential isotopic  amino acid. 
To identify PP1α-dependent changes in the phospho-proteome of Jurkat T cells, we took 
advantage of the inducible PP1α-silencing system. Therefore, one control cell line 
(shContr.), inducibly expressing non-targeting shRNA, and two cell lines (shPP1α #47.1 and 
shPP1α #47.2) inducibly expressing the same PP1α-targeting-shRNA (as biological 
duplicates) were used. Fig. 5.1 depicts a schematic representation of the experimental 
setup. As indicated, control cells were cultured in the presence of “light-“, while shPP1α 
#47.1 and #47.2 were cultured in the presence of “middle-“ and “heavy-weight” isotopic 
amino acids, respectively,  for a period of 9 days. After 5 days, cells were  supplied with Dox 
to drive non- or PP1α-targeting shRNA expression for 4 days.  On day 9 of metabolic 
labelling, all cells were counted and pooled in a 1:1:1 ratio, enabling stimulation of all cells 
under the same conditions and thus limiting technical variation. Pooled cells were left 
untreated or stimulated via the TCR for 15 or 60 minutes. Further handling of samples and 
analysis is currently carried out as indicated, concentrating on the identification of 
Figure 5.1: SILAC screening apporach for identification of PP1α substrates. Depicted is a 
schematic representation of the SILAC experiment. Indicated cell lines were cultured in the 
presence of light- (yellow filled circles), middle- (red filled circles) or heavy-weight (light violet filled 
circles) isotopic amino acids for a period of nine days. At day five of metabolic labelling, cells were 
supplied with 2 µg/ml doxycycline to induce control shRNA expression or PP1a-silencing in the 
respective cell lines. On day nine of metabolic labelling, equal numbers of cells were pooled in a 
1:1:1 ratio. Subsequently, pooled cells were stimulated with 0.5 µg/ml anti-CD3/CD28 for the 
indicated periods of time. Samples were further processed as indicated. 
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differential occurrence of phospho-peptides. Due to the differential labelling and stimulation 
conditions, changes under basal conditions as well as temporal changes upon stimulation 
can be discriminated. The combined application of PP1α-silencing and quantitative 
phospho-proteomics, therefore, constitutes a powerful tool and will help to delineate the 
mechanism of PP1α function in T cells. Future work should concentrate on the validation 
and characterisation of newly identified PP1α-regulated phospho-sites and their biological 
impact. Based on the results of the present study, we propose that PP1α modulates NF-κB-
mediated gene expression in a promoter-specific manner (Fig. 5.2). Thus, changes in 
phosphorylation of NF-κB pathway components as well as changes regarding nuclear 
proteins, which regulate gene transcription, for instance on an epigenetic level, should be of 
particular interest when analysing results of the SILAC screen. 
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Figure 5.2: Possible mechanisms of PP1α-mediated regulation of NF-κB signalling. A 
possible role for PP1α in regulation of IKK activity is indicated by a dashed line. In addition, PP1α 
was found to control the duration of NF-κB-mediated gene transcription, presumably by 
regulating DNA binding activity of NF-κB in a promoter specific manner. Three possible 
mechanisms may explain these observations: (A) PP1α directly modifies NF-κB subunits on an 
unknown site and thereby stabilises complexes at certain promoter sites. (B) The duration of  
NF-κB-mediated gene expression is negatively controlled by an unknown factor (indicated with 
“?”), which is negatively regulated by PP1α. (C) The occupancy of NF-κB at promoter sites is 
stabilised by an unknown regulator that is positively controlled by PP1α. A-C may involve an 
influence of PP1α on recruitment or interaction of NF-κB with transcriptional co-activators, co-
repressors, histone- or DNA-modifying enzymes. 
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7. Appendix 
7.1  List of abbreviations 
°C  Degree Celsius 
AA  Amino acid  
ABC-DLBCL  Activated B cell-like DLBCL  
ADAP  Adhesion- and degranulation-promoting adapter protein 
Ag  Antigen(s)  
ANK  Ankyrin repeat motif  
AP-1  Activating protein 1  
APC  Antigen presenting cell  
APS  Ammonium persulfate  
ATL  Adult T cell lymphoma/leukemia  
ATP  Adenosine triphosphate  
Bcl  B cell lymphoma  
BCR  B cell antigen receptor  
bp (kb)  Base pair (kilo base pair)  
CARD  Caspase recruitment domain  
Caspase  Cysteine-aspartate specific protease  
CBM complex Carma1-Bcl10-MALT1 complex  
Cbp  Csk-binding protein  
CD  Cluster of differentiation  
CD95L  CD95 ligand  
cDNA  Complementary DNA  
CED  Caspase-8 deficiency  
c-FLIP  Cellular FLICE inhibitory protein  
c-IAP  Cellular inhibitor of apoptosis  
CRAC  Calcium release activated calcium channel  
Csk  Cellular src kinase  
CTCL  Cutaneous T cell lymphoma  
CYLD  Cylindromatosis tumor suppressor  
d  Day  
DAG  Diacylglycerol  
DC  Dendritic cell  
DD  Death domain  
DLBCL  Diffuse large B cell lymphoma 
Dlgh1  Discs large homolog 1  
DMEM  Dulbecco’s Modified Eagle Medium  
DMSO  Dimethyl sulfoxide  
DNA  Desoxyribonucleic acid  
DTT  Dithiothreitol  
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DUB  Deubiquitinating enzyme  
ECL  Enhanced chemiluminescence  
EDTA  Ethylenediaminetetraacetic acid  
EGFP  Enhanced GFP  
ELISA  Enzyme-linked immunosorbent assay  
ER  Endoplasmic reticulum  
ERK  Extracellularsignal-regulatedkinase  
EtOH  Ethanol  
FACS  Fluorescence activated cell sorter  
FCS Fetal calf serum 
FHC Ferritin heavy chain Fig. 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
GCB-DLBCL Germinal center B cell-like DLBCL  
Grb2 Growth factor receptor-bound protein 2 GRP 
GUK Guanylate kinase h 
HTLV-1 Human T-lymphotropic virus type I HTS 
FHC Ferritin heavy chain  
Fig. Figure  
g Gramm  
Gads Grb2-related adaptor downstream of Shc  
GAP GTPase-activating protein 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
GCB-DLBCL Germinal center B cell-like DLBCL  
GEF Guanine-nucleotide-exchange factor  
GFP Green fluorescent protein 
Grb2 Growth factor receptor-bound protein 2  
GRP GDP release protein  
GRR Glycine rich region  
GUK Guanylate kinase  
h Hour  
HLH Helix-loop-helix  
HPK1 Haematopoietic progenitor kinase 1  
HPRT1 Hypoxanthine phosphoribosyl-transferase 1  
HRP Horseradish peroxidase 
HTLV-1 Human T-lymphotropic virus type I  
HTS High throughput screening  
IB Immunoblot(ting)  
IFNγ Interferon gamma 
IgG Immunoglobulin  
IgGH Immunoglobulin heavy chain  
IgGL Immunoglobulin light chain  
IKK IκB kinase 
IL Interleukin  
IMDM Iscove’s modified Eagles medium  
Iono Ionomycin  
IP Immunoprecipitation  
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IP3 Inositol 3,4,5-trisphosphate  
IRES Internal ribosomal entry site  
ITAM Immunoreceptor tyrosine-based activation motif  
Itk IL-2 inducible Tec kinase  
IkB Inhibitor of kB proteins  
JNK/SAPK c-Jun N-terminal kinase/stress-activated protein kinase  
KBD Kinase binding domain  
KD Kinase domain  
kDa Kilo Dalton  
l Liter  
LAT Linker of activated T cells  
LZ Leucine zipper  
mAb Monoclonal antibody  
MACS Magnetic activated cell sorter  
MAGUK Membrane-associated guanylate kinase 
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 1  
MAPK Mitogen-activated protein kinase  
MEF Murine embryonic fibroblast  
MEKK MAPK/ERK Kinase Kinase  
MeOH Methanol 
MF  Mycosis fungoides  
MFI  Mean fluorescence intensity  
MHC  Major histocompatibility complex  
min  Minute(s)  
MLK  Mixed-lineage protein kinase  
MM  Multiple myeloma  
mRNA  Messenger ribonucleic acid  
NBD  Nemo-binding-domain  
NBP  NBDpeptide  
Nck  Non-catalytic region of tyrosine kinase  
NEMO  NF-kB essential modulator  
NES  Nuclear export sequence  
NFAT  Nuclear factor of activated T cells  
NF-κB  Nuclear factor-kappaB  
NIK  NF-kB-inducing kinase  
NK cells  Natural killer cells  
NLS Nuclear translocation sequence  
p  Peptide  
PAGE  Polyacrylamide gel electrophoresis  
PAMP  Pathogen-associated molecular pattern  
PBL  Peripheral blood leukocyte  
PBS  Phosphate buffered saline  
PCR  Polymerase chain reaction  
PDK1  3-Phosphoinositide-dependent kinase 1  
PHA  Phytohemagglutinin  
PI3K  Phosphoinositide-3 kinase  
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PKC  Protein kinase C  
PLCγ1  Phospholipase C gamma 1 
PMA  Phorbol 12-myristate-13-acetate  
PP1CA  Protein phosphatase 1, catalytic subunit alpha  
PP2A  Protein phosphatase 2A  
PP2Ac  Protein phosphatase 2A catalytic subunit  
PP4c  Protein phosphatase 4 catalytic subunit  
PP4R  Protein phosphatase 4 regulatory subunit  
PPP  Phosphoprotein phosphatase  
PRD  PKC-regulated domain  
PRR  Pattern recognition receptor  
PSK  Protein serine/threonine kinase  
PSP  Protein serine/threonine phosphatase  
PSP  Protein serine/threonine phosphatases  
PTEN  Phosphatase and tensin homolog  
PTK  Protein tyrosine kinase  
PTP  Protein tyrosine phosphatase  
PTPN  Protein tyrosine phosphatase, non-receptor type  
PTPR  Protein tyrosine phosphatase, receptor type  
pUb  Poly-ubiquitin  
RHD  Rel homology domain  
RIP1  Receptor-interacting protein 1  
RLU  Relative light unit  
RNA  Ribonucleic acid  
RNAi RNA interference 
ROS Reactive oxygen species  
rpm Rotations per minute  
RT Room temperature  
RT-PCR Reverse transcription PCR  
SDS Sodium dodecyl sulfate  
S Second 
SFK Src family protein tyrosine kinase  
SH Src homology  
SHIP1 SH2 domain-containing inositol phosphatase 1  
SHP1 SH2 domain-containing phosphatase 1  
shRNA Short hairpin RNA  
siRNA Small interfering RNA  
SLP76 SH2-domain-containing leukocyte protein of 76 kd  
SOCE Store-operated calcium entry  
SOS Son of sevenless  
Sts Suppressor of TCR signaling  
Syk Spleen tyrosine kinase  
TAD  Transactivationdomain  
TAK1 TGF-b-activated kinase 1  
T-ALL T cell acute lymphocytic leukaemia  
TCR T cell antigen receptor  
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TEMED N,N,N’,N’-Tetramethyl-ethylenediamine T 
NFR TNF receptor  
TNF-RSC TNFR signaling complex  
TNFα Tumor necrosis factor alpha  
TRADD TNFR1-associated death domain protein  
TRAF TNFR-associated factor  
Tris Tris-[hydroxymethyl]amino-methane  
Ub Ubiquitin  
vs. versus  
wt Wild type  
ZAP-70 Zeta chain-associated kinase of 70 kDa  
ZF Zinc finger 
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